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THESIS ABSTRACT 
The prevention and treatment of cardiovascular disease (CVD), in particular, acute 
coronary syndrome (ACS), constitute a major economic and social burden globally and 
nationally. Furthermore, CVD continues to be the leading cause of death and affects 
patients as well as the healthcare system markedly. Despite the guidelines and policies 
available to reduce this burden, previous studies suggest that evidence-practice gaps in 
CVD care and management still exists; therefore, a greater understanding of inequities 
in healthcare and access to services is needed in order to close these gaps in CVD 
management. The World Health Organization (WHO) has reported that, across the 
globe, there are numerous social factors that are associated with health inequities. 
These inequities reportedly affect outcomes and impose problems for the individuals as 
well as the healthcare system. In Australia, inequity in the delivery of care has been 
documented in various chronic disease areas. Populations for whom inequity has been 
documented include women, those with lower socioeconomic status (SES) and limited 
English proficiency. Overall, there are a few studies, especially in Australia, describing 
how these subpopulations are managed in regard to the prevention and the treatment 
of CVD in primary healthcare, hospital and post-discharge. Therefore, the specific aims 
of this thesis are to [1] determine the effect of gender on the primary prevention of CVD, 
the receipt of CVD risk factor assessment and prescription of guideline-recommended 
medications in Australian primary healthcare; [2] determine the effect of socioeconomic 
status on ACS patients on the receipt of in-hospital care and clinical outcomes, including 
major adverse cardiovascular events or death; [3] determine if English proficiency of 
ACS patients admitted to Australian hospitals has an effect on the receipt of in-hospital 
care and  major adverse cardiovascular events and death in hospital and from 
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admission to follow-up; [4] identify the factors that contribute to household economic 
hardship following an ACS presentation, on the assumption that this may contribute to 
the lack of adherence to the appropriate care at post-discharge.   
 
For this thesis, two systematic reviews will be performed and the specific aims will be 
addressed by analysing three Australian datasets. First, the TORPEDO study (N=53,085) 
which extracted 53,085 patient data at baseline from 40 general practices and 20 
Aboriginal community controlled health services. Second, the CONCORDANCE registry 
which is an ongoing registry which collected over 10,000 patients with suspected or 
confirmed ACS since 2009 from 42 public hospitals nationwide. Third, the SNAPSHOT 
ACS which was an observational audit that collected data on 4,387 patients with 
suspected or confirmed diagnosis of ACS admitted to 286 Australian and NZ hospitals 
between 14-27 May 2012.  
 
For Aim 1, a systematic review was performed to find the pooled effect of gender 
difference in the assessment of CVD risk factors. Further, TORPEDO data were used to 
compare the likelihood of primary prevention of CVD by evaluating the risk factor 
assessment, and further, for those at high-risk of CVD, prescription of medications at 
primary healthcare services between women and men. For Aim 2, the receipt of 
individual guideline-recommended medications in patients with ACS compared 
between the low and the high individual or area-level SES groups was explored through 
a systematic review. Moreover, CONCORDANCE dataset was used to compare in-
hospital care (the receipt of coronary angiogram, revascularisation, a combination of 
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the guideline-recommended medications and referral to cardiac rehabilitation) and 
clinical outcomes (major adverse cardiovascular event (MACE) and death) between four 
socioeconomic groups determined by their area of residence. For Aim 3, SNAPSHOT ACS 
data were used to compare limited English proficient and English proficient patients in 
regards to their in-hospital care, including the length of stay and the receipt of coronary 
angiogram, revascularisation, guideline-recommended medications, referral to cardiac 
rehabilitation smoking cessation advice, dietary advice and physical activity advice, and 
clinical outcomes, including MACE (myocardial infarction/heart failure/stroke) and 
death. For Aim 4, SNAPSHOT ACS health economic data were used to examine the 
factors associated with greater likelihood of experiencing economic hardship following 
their acute presentation. 
 
In terms of results, there was inequitable care for primary prevention of CVD but 
comparable care and clinical outcomes were observed during the acute presentation to 
Australian hospitals. For Aim 1, although the pooled international results showed no 
gender disparity in the assessment of CVD risk, in Australian primary healthcare, 
women were disadvantaged in receiving weaker primary prevention of CVD than men. 
In Australia, women had 12% lower odds of being assessed for CVD risk factors (odds 
ratio (95% confidence interval): 0.88 (0.81, 0.96)). Among patients with CVD or at high 
CVD risk, women aged 35-54 years were less likely to be prescribed the recommended 
medications for CVD management (0.63 (0.52, 0.77)), whereas women aged ≥65 years 
were more likely to be prescribed the medications (1.34 (1.17, 1.54)) compared to their 
male counterparts. For Aim 2 and Aim 3, the pooled international studies presented the 
difference in the prescription of guideline-recommended discharge medications, 
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including beta blocker, statin and angiotensin-converting enzyme (ACE), between the 
lowest and the highest SES groups to patients with ACS in hospital. In Australian 
hospitals, equitable care was provided to patients with ACS despite their SES or English 
proficiency during an acute presentation. The likelihood of receiving coronary 
angiogram, revascularisation, four or more of the five guideline-recommended 
medication and referral to cardiac rehabilitation were similar across the SES groups. 
The group with the lowest SES status were found to have higher odds of MACE, driven 
by the odds of heart failure, however, no significant difference in the odds of short-term 
and long-term death was found between the groups. Similarly, patients’ proficiency in 
English did not affect the length of stay, and receipt of coronary angiogram, 
revascularisation, guideline-recommended medications, referral to cardiac 
rehabilitation and advice on smoking cessation, diet and physical activity. Further, the 
likelihood of short-term and long-term MACE and/or death were comparable. For Aim 
4, post-discharge, more than 50% of patients who survived ACS reported having 
experienced economic hardship. Those who were more likely to experience household 
economic hardship included patients who were younger (18-59 vs ≥80 years: 1.89 
(0.77, 4.63)), with no private health insurance (2.04 (1.37, 3.03)), with pensioner 
concession card (1.80 (1.03, 3.18)) and in low socioeconomic group (lowest vs. highest: 
1.77 (0.91, 3.45)). Gender was not associated with experiencing hardship. 
 
Overall, this thesis suggests that, in Australia, inequities exist in primary healthcare 
regarding the prevention and care of CVD between genders, where women are 
disadvantaged compared to men, but equitable acute care is provided to patients who 
have presented to a hospital due to ACS, regardless of their SES or English proficiency. 
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Post discharge, patients with low SES are more likely to experience economic hardship 
which may lead to further inequity in long-term secondary prevention. Although it is an 
encouraging affirmation that ACS patient care in hospital is not affected by patients’ SES 
or English proficiency, system-wide solutions are needed to resolve the issue of inequity 
in primary prevention of CVD and reduce the economic burden of managing ACS to, 
therefore, reduce the risk of a secondary event.  
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CHAPTER ONE  
Introduction and Thesis Aims 
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BURDEN OF CARDIOVASCULAR DISEASE  
Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels (1). 
The principal types of CVD include coronary heart disease (CHD) and stroke (2). These 
diseases are generally caused by accumulated fat, cholesterol and other substances in 
the inner lining of the arteries, reducing or blocking the blood supply to the heart or to 
the brain (3). Acute coronary syndrome (ACS) is a subset of CHD. It can be a high-risk 
and severe condition where reduced or blocked blood supply damages or destroys 
heart tissue and possibly cause death (4). ACS consists of acute myocardial infarction 
(AMI), which includes ST-elevation myocardial infarction (STEMI) and non-ST-elevation 
myocardial infarction (NSTEMI), and unstable angina (UA) (4). STEMI is the most 
severe condition, usually caused by complete occlusion of at least one of the three major 
coronary arteries; NSTEMI refers to the condition where a major coronary artery is 
partially occluded or a minor artery is completely occluded; and UA is where there is 
disruption to coronary blood supply with heart muscle damage that may be reversible 
(Figure 1) (5, 6).  
 
CVD is the leading cause of death globally and constitutes severe issues for individuals 
and the healthcare systems (1). In 2012, the World Health Organization (WHO) 
estimated 17.5 million deaths due to CVD, which accounted for 31% of all deaths 
worldwide. 7.4 million people died of CHD, and 6.7 million people died of stroke, 
explaining 13% and 12% of the cause of death, respectively (7). In Australia, in 2015, 
about 45,400 deaths were due to CVD, which represented 29% of all Australian deaths 
(8). ACS contributes to more than 20% of CVD deaths in Australia, and the number of 
deaths is predicted to increase from about 10,000 in 2010 to about 13,700 by 2020 (9). 
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The number of hospitalisations due to ACS is also increasing. Between 1993-94 and 
2007-08, the number of hospitalisation increased by 79.5% for AMI and 33.1% for UA, 
resulting in 56,000 and 39,000 hospitalisations for AMI and UA, respectively in 2007-
2008 (10). Moreover, the number of repeat ACS events is high, where 26,000 
hospitalisations were due to a secondary event in 2010 alone (9). 
 
Being the leading cause of death, the cost of CVD is also the highest among any other 
disease groups in Australia (11). In 2008-09, 12% of all healthcare expenditure in 
Australia, estimated to be $7.6 billion, was associated with CVD (11). Of CVD, CHD had 
the highest burden of cost of over $2 billion (11). Specifically for ACS, the health care 
system cost was estimated to be $1.9 billion in 2010, further, and indirect cost was 
estimated to be $3.2 billion, which includes the cost of reduced labour market 
participation and premature mortality (productivity loss), carer cost due to reduced 
productivity and leisure time and the loss in economic efficiency due to additional 
public healthcare expenditure (9). The economic burden does not only affect the 
healthcare system but also the patients and their households. Recent research in other 
chronic disease areas has shown that patients and their households experience financial 
hardship in managing the disease, even with the support of Medicare (12-15). Financial 
hardship was experienced in 57% of the patients with chronic kidney disease, 61% of 
the patients with stroke and 78% of the patients with chronic obstructive pulmonary 
disease (12-14). As the population ages, and life expectancy and the number of CVD and 
ACS events increase, the social and economic burden associated with these diseases is of 
growing concern and the demand for effective primary and secondary prevention is 
intensifying. 
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Figure 1. Atherosclerotic plaque formation leading to acute coronary syndrome  
From: Carol Mattson Porth. Pathophysiology Concepts of Altered Health States. Seventh 
Edition. Philadelphia Lippincott Williams & Wilkins. 2005. Copyright © 2013, Wolters 
Kluwer Health. Reproduced with permission (16). 
 
CVD RISK FACTORS  
There are non-modifiable and modifiable risk factors for CVD. Non-modifiable risk factors 
include older age, male gender and family history of CVD (17). The risk of heart disease 
appears about a decade earlier for men than women, but the risk increases after 
menopause for women (18-21). Although non-modifiable risks cannot be managed, people 
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with these risks are advised to screen for modifiable risk factors regularly. Modifiable risk 
factors include behavioural and biomedical risk factors. Behavioural risk factors are 
tobacco use, overweight/obesity (body mass index ≥25 kg/m2), physical inactivity, 
unhealthy diet and alcohol consumption. Whereas, biomedical risk factors are high blood 
pressure (≥140/90 mm Hg), high cholesterol (total cholesterol ≥6.2 mmol/l) and diabetes 
(fasting plasma glucose ≥7.0 mmol/l) (1, 18, 22). Extensive effort has been and is still being 
invested into research and evidence-based guidelines that assist clinicians to help their 
patients control their CVD risk factors and prevent and manage CVD. 
 
EVIDENCE-BASED PREVENTION AND MANAGEMENT 
There are national and international recommended guidelines for the treatment, the 
management and the prevention of CVD based on decades of research (17, 23-31). 
These guidelines were developed based on up-to-date research and through 
consultation with the multidisciplinary expert working group, key health professionals, 
government policy makers, professional bodies and consumers, and are reviewed and 
updated every few years (17, 27, 30). These evidence-based recommendations can be 
categorised in terms of primary prevention at primary healthcare, in-hospital 
management and post-discharge secondary prevention.  
 
Primary prevention 
CVD can be prevented prior to an event through assessing the risk factors listed above with 
a general practitioner (GP) and calculating an absolute cardiovascular risk using a risk 
score (17, 23, 24). There are a number of risk scores available including the Framingham 
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Risk Equation and the Systematic Coronary Risk Evaluation (SCORE) (32-36). Australian 
guidelines recommend that patients with clinically determined high-risk (diabetes and 
aged>60 years; diabetes with microalbuminuria; or moderate or severe CKD) are provided 
with aggressive blood pressure, lipid lowering therapies together with intensive lifestyle 
advice. Adults aged ≥45 years and Aboriginal and Torres Strait Islanders aged ≥35 years 
not known to have CVD or are not at clinically determined high-risk are recommended to 
receive absolute CVD risk assessment using the Framingham Risk Equation every two 
years (17, 23). Those who are found to be at high-risk of CVD with absolute CVD risk of 
>15% over the next 5 years, should be provided with risk factor modifying medications and 
lifestyle advice as described above (23).  
 
Lifestyle advice includes smoking cessation for smokers; dietary changes to consume diet 
rich in vegetables and fruit, low in salt and trans and saturated fat; increased physical 
activity to at least 30 minutes of moderate intensity physical activity, weight control for 
those who are overweight or obese and reduced alcohol consumption (17, 24). Those at 
high-risk of CVD, and further, have symptoms such as chest, shoulder, arm and jaw pain, 
shortness of breath, nausea, vomiting and sweating, are advised to be assessed for ACS 
(27). According to the latest ACS guidelines, patients with such symptoms are 
recommended to receive electrocardiography (ECG), stress test and troponin testing at a 
primary care or the emergency department (27). Also, if a patient with suspected ACS 
presents to a primary care physician, the patient should be referred to the emergency 
department as soon as possible and be risk assessed using the Suspected ACS Assessment 
Protocol to be accurately diagnosed as ACS. 
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In-hospital management of ACS  
Similarly to the American Heart Association and European Society of Cardiology 
guidelines, in Australia, early risk assessment following the diagnosis of ACS is 
recommended to obtain an overall estimate of patient’s prognosis (27-31). This can 
guide clinicians to make more accurate clinical decisions in providing recommended 
care and prevent overestimation or underestimation of the risks (37). The use of either 
of two validated risk scores for re-MI or mortality, which are Global Registry of Acute 
Cardiac Events (GRACE) risk score and Thrombolysis In Myocardial Infarction (TIMI) 
risk scores, is recommended in combination with bleeding risk scores such as the 
CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse 
outcomes with Early implementation of the ACC/AHA guidelines) and ACUITY (Acute 
Catheterization and Urgent Intervention Triage strategy) bleeding risk score (38-41).  
 
In-hospital management varies depending on patients’ condition and comorbidities, 
however, for patients diagnosed with STEMI, acute reperfusion or invasive management 
is recommended (27-29, 31, 42). If timely, primary percutaneous coronary intervention 
(PCI) is not available (within 90 minutes of first medical contact), thrombolysis is 
advised to be used while being transferred to a hospital with resources to perform 
primary PCI. Patients with NSTEMI or UA at high or very high-risk are recommended to 
be assessed with coronary angiography and treated with PCI or coronary artery bypass 
graft (CABG) where appropriate. In terms of pharmacotherapy, acute anti-ischaemic 
therapies, antiplatelet therapies, and anticoagulant therapies are recommended to be 
used during the admission as needed. 
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Secondary prevention 
For survivors of CVD, lifestyle modification and adherence to medication are strongly 
recommended (22, 43, 44). Patients are advised to completely stop smoking and avoid 
exposure to second-hand smoke; reduce the amount of alcohol consumption to no more 
than two standard drinks per day; consume healthier diet including increased amount 
of fruits, vegetables and wholegrain foods, and reduced dairy products, processed food 
and salt intake; increase regular exercise to at least 30 minutes daily; and manage 
weight to maintain a normal body mass index (18.5 to 24.5 kg/m2). Blood pressure, 
cholesterol and diabetes should be managed. Adherence to antiplatelet therapies 
(aspirin, clopidogrel, prasugrel or ticagrelor), anticoagulant therapies, angiotensin-
converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), beta 
blockers and statins are recommended as needed. Patients are advised to attend cardiac 
rehabilitation or secondary prevention programs to gain support in lifestyle 
modification, appropriate exercises, health education and counselling. Those at risk of, 
or with, depression are recommended to screen for depression and receive medical 
management. Further, other recommendations include annual influenza vaccinations, 
hormone replacement therapy and oral contraception in women of child-bearing age.  
 
CURRENT AUSTRALIAN EVIDENCE-PRACTICE GAPS 
Despite these guidelines, evidence provided by the National Heart Foundation has 
shown that the optimal care has not been provided to a large proportion of the 
population. Modifiable risk factors can be easily tested at a primary healthcare and 
controlled in the prevention of CVD, however, there are a significant number of people 
with uncontrolled risk factors in Australia. In 2011-12, a third of Australian adults had 
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high blood pressure, and of those, more than two-thirds did not take medication to 
control the blood pressure (45). A third of Australian adults had high cholesterol, and 
78% of these patients were uncontrolled. Fifty-five percent of the population were 
overweight or obese, yet 58% of the population were sedentary or had low levels of 
physical activity (45). Also, only 48% of regular attendees of general practice received 
appropriate CVD risk screening (46).  
 
The evidence-practice gaps in the provision of care in Australian hospitals still exist. 
Recent comprehensive cross-sectional audits have suggested that guideline-
recommended medications were not used as frequently as recommended in patients 
with ACS in hospital (47, 48). Patients in smaller hospitals were even less likely to 
receive the recommended medications than those in the principal referral hospitals 
(principal referral hospital: 69% vs. small hospital: 51%) (48). In terms of invasive 
management, such as PCI or CABG, it was performed on only half of the patients with 
high-risk NSTEMI/UA (47, 49). Although patients with STEMI were more likely to 
receive evidence-based therapy, only about 70% of them received reperfusion and only 
23% received within the recommended time, which includes thrombolysis within 30 
minutes or primary PCI within 90 minutes of presentation (49, 50). 
 
Post discharge, the rate of medication prescription after an acute coronary event was 
also relatively low (aspirin: 87%, other antiplatelet: 63%, beta blocker: 71%, ACE/ARB: 
65% and statin/other lipid-lowering therapy: 85%) (51). The rates of cardiac 
rehabilitation referral and lifestyle modification advice were also low. Only 46% of the 
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patients who survived an ACS event received a cardiac rehabilitation referral, 43% 
received physical activity advice, 36% received dietary modification advice and 70% of 
smokers received smoking cessation advice (51). Even though the national and 
international guidelines recommend the receipt of medications, lifestyle advice and 
referral to cardiac rehabilitation, only 27% of Australian survivors of ACS received the 
optimal care for secondary prevention in 2012 (51). Overall, current studies suggest 
that there are significant evidence-practice gaps but there has been little research 
investigating whether certain patient characteristics or social situation impact on 
whether they receive guideline-recommended care. 
 
POTENTIAL HEALTH INEQUITIES IN DISEASE MANAGEMENT 
The WHO has defined health inequities as avoidable inequalities in health, including the 
risk of illness and the prevention or the treatment of illness, between groups of people 
within countries and between countries due to inequalities within and between 
societies (52). The WHO has also reported that health inequities continue to exist today 
due to social factors including gender, socioeconomic status (SES) and ethnicity 
(including language proficiency) (53). Evidence from previous studies has supported 
this statement and shown that there are gaps in treatment and outcomes between 
genders, people of varying SES and those who are proficient and not proficient in a 
certain language with CVD/ACS. 
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Gender 
CVD is the major cause of death for both women and men worldwide (54) and in 
Australia (55). As in the United States (US) and the United Kingdom (UK), in Australia, 
the number of cardiovascular death is greater in women than men (22,493 vs. 21,109 in 
2013) (8, 56). Yet, possibly because CVD was thought to be a ‘man’s disease’, there is 
substantial evidence that gender disparities in treatment still exist in CVD. It was also 
reported that women are less likely to be tested for CHD due to the lack of discussion 
between physicians and female patients regarding the risk (57). Women were less likely 
to be recommended for cardiac catheterisation, stress testing or to see a cardiologist in 
the emergency department (ED), and further, in hospital, women were less likely to be 
recommended for further testing (58). Women also received counselling or education 
about CHD less often than men in hospital and at 30-day follow-up (58). Studies from 
the UK and Spain have found that women were less likely to be assessed for CHD risk 
factors in primary care and receive treatments such as recommended medications (59-
61). Despite the evidence showing inequity in assessment and management of CVD in 
other countries, in Australia, research on the implications of gender difference in the 
primary and secondary prevention of CVD is limited, especially in primary care. It is 
uncertain whether women receive equal primary prevention compared to men in being 
screened for CVD risk factors and prescription of the guideline-recommended 
medications. 
 
Socioeconomic status 
SES is a descriptive term for the position of persons in society, based on a combination 
of occupational, economic, and educational criteria (62). It is well known that people in 
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low SES groups are more likely to experience significant health inequities in many 
health areas including CVD and CHD (63, 64). In 2011-12, prevalence of CVD was 9% 
higher for patients in the lowest than the highest SES group (26% vs. 17%) (64), and the 
prevalence of CHD was more than twice as high for those in the lowest SES group 
compared to those in the highest SES group (5% vs. 2%) (64). It was also found that 
socioeconomic disadvantage is associated with lower odds of receiving coronary 
angiography and higher odds of mortality due to CVD and CHD (63, 65). Although the 
effect of SES has been explored in the past, whether health inequities due to SES 
continues to remain today in providing treatments to patients with CVD/CHD and the 
rate of CVD-related events is uncertain. 
 
Language barriers 
Communication between physicians (plus clinical and other healthcare staff) and 
patients is important in managing and preventing disease. Effective communication in 
providing the current risk of the patients and the benefits of adhering to medical 
therapies were proven to help decrease outcomes (66). Previous studies indicate that 
language barrier causes disparities in medication prescription, the length of stay, 
cardiac rehabilitation attendance and mortality (67-69). Australia is a multicultural 
country, where it was reported in the 2016 census that 33% were born overseas (70). 
In greater capital cities, 28% of the people spoke a language other than English at home, 
and of those, 4.8% of people were not proficient in English. Compared to 2011, 150,948 
more people in 2016 spoke English not well or not at all (71). Despite the growth of 
multilingualism and the evidence of variations in procedures and outcomes, this 
research on Australian patients using contemporary data is limited. 
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In Australia, various strategies are in place to minimise inequities and provide a high 
standard of care to all, including evidence-based guidelines for CVD and ACS and 
Medicare benefits. Although evidence-practice gaps were evident in studies with the 
general Australian population, it is unclear what, if any, level of inequities in care exist 
between people of various gender, SES and English proficiency. Therefore, the 
exploration of inequities in the healthcare system is needed. 
 
SUMMARY 
CVD, including ACS, is the leading cause of death and disease burden globally. However, 
despite international and Australian guidelines, less than half of Australians receive CVD 
risk assessment in primary healthcare, and only one-quarter of patients admitted to 
hospital with ACS receive a combination of appropriate medicines, lifestyle advice and 
referral to rehabilitation at the point of discharge. Further, adherence to lifestyle 
modification and recommended medicines post-discharge is suboptimal at less than 
50%. While we have an overall understanding of current evidence-practice gaps, there 
are only limited studies that have reported the impact of inequities such as gender, SES 
and language spoken on management.  
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THESIS AIMS 
The overall aim of my doctoral research is to identify whether health inequities exist in 
patients with CVD/ACS in primary healthcare and hospital systems and short-term and 
long-term outcomes, and determine how the disease affected subgroups of ACS patients 
in regard to their household economic hardship after discharge. Specific research 
objectives are to: 
1. Determine if gender affects the receipt of CVD risk factor measurements, and of 
patients with high CVD risk, prescription of guideline-recommended medications 
in Australian primary healthcare. 
 
2. Determine whether SES affects the receipt of in-hospital care and the odds of 
outcomes for ACS patients. 
 
3. Determine the effect of English proficiency on in-hospital care and post-hospital 
outcomes amongst patients with ACS. 
 
4. Determine the economic burden on survivors of ACS in the 18 months after 
admission via examination of; i) illness-related catastrophic expenditure 
(assessed as out-of-pocket expenditure) and ii) economic hardship (assessed as 
an inability to make necessary household payments or requiring assistance to 
meet such costs). 
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CHAPTER TWO 
Overview of Data Sources Used for Studies Contained in This Thesis 
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This chapter details the three data sources used for analyses in this thesis in order to 
address the aims. The data sources include baseline data of one of the largest Australian 
primary healthcare clinical trials, TORPEDO, and two large-scale Australian ACS 
registries, CONCORDANCE and SNAPSHOT ACS, were used to answer the aims. All three 
datasets are observational data, which enables researchers to observe and assess 
various subgroups of patients in real life situations. Also, as the aims of this thesis are to 
compare the receipt of guideline-recommended care by social and demographic profile 
of patients, the observational data are most suitable. In combination, access to these 
large contemporary datasets will enable me to explore health care delivery inequalities. 
 
TORPEDO 
Treatment of Cardiovascular Risk using Electronic Decision Support (TORPEDO) study 
was a cluster randomised controlled trial to test whether a computer-guided quality 
improvement intervention improved CVD risk management when compared with usual 
care (1). This study was funded by the National Health and Medical Research Council 
(NHMRC) of Australia and the New South Wales Department of Health. Although the 
data was extracted for a cluster randomised  trial, only the observational baseline data 
were used in this thesis. Australian general practices and Aboriginal Community 
Controlled Health Services (ACCHSs) were eligible to participate if there was exclusive 
use of an electronic health record that was compliant with study software to record risk 
factor information, pathology test results and prescribe medications. Patients were 
eligible for inclusion if patients were regular attendees of an eligible GP or ACCHS, 
where they have had three visits in the last two years and one visit in the last six 
months, and aged ≥ 35 years, if they are Aboriginal or Torres Strait Islander, and aged ≥ 
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45 years, if not. Baseline data on 53,085 patients from 40 GPs and 20 ACCHSs across 
New South Wales and Queensland were extracted between September 2011 and May 
2012. Consent waiver was granted, given that data collection was based on de-identified 
extracts from the electronic health record system.  
 
The aim of the cluster randomised controlled trial was to determine whether the 
‘HealthTracker’, an electronic decision support tool designed to help primary healthcare 
professionals implement guideline recommendations, and clinical workforce training 
improved CVD risk management compared with usual care (1). It was a unique study 
where a third of the participating practices were ACCHS. This work was recognised 
through the receipt of the 2014 Cardiac Society of Australia and New Zealand Ralph 
Reader Young Investigator Prize, which was rewarded to Associate Professor David 
Peiris, the Principal Investigator of the TORPEDO study. Thus far, five manuscripts have 
been published from this study and several more are in preparation for publication. The 
ethics approvals are contained in Appendix 3. 
 
CONCORDANCE 
The Cooperative National Registry of Acute Coronary Care, Guideline Adherence and 
Clinical Events (CONCORDANCE) is an ongoing cohort study that provides continuous 
real-time reporting on the clinical characteristics, management and outcomes of 
hospitalised ACS patients to clinicians, hospital administrators, sponsors/interested 
stakeholders and government (2). Since 2009, the first 10 consecutive eligible patients 
admitted to one of the 41 participating Australian public hospitals per month were 
recruited. The eligibility criteria are patients aged 18 years or older, who presented to a 
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hospital with symptoms of an ACS together with significant electrocardiographic 
changes, elevated cardiac enzyme levels, or newly documented CHD. Patient data 
including demographic, admission detail, medical history, initial assessment, 
reperfusion, medications, in-hospital events, final diagnosis and discharge detail were 
obtained from the medical records. These data are used to create online real-time key 
performance indicator reports which measure the effectiveness of care (for example, 
time to reperfusion and appropriate medical therapy provided). Using these reports, 
individual hospitals are benchmarked against aggregate measures, but not against other 
individual hospitals. To date, the CONCORDANCE study has recruited about 11,600 
patients across the country. The participants were followed-up at 6-months via phone 
or mail survey, and as of July 2017, 8738 (81% of those who survived to discharge) 
patients have completed 6-month follow-up. From 2009 to 2013, patients were 
followed-up at two years post-discharge, but due to the large number of patients who 
were lost to follow-up, the participating hospitals transitioned from performing two-
year follow-up to one-year between 2014 and 2015. At follow-up, data regarding 
readmissions, medication use, lifestyle factors and quality of life assessment were 
collected. Opt-out consent method was used and consent waiver was approved for 
patients who died or were too ill to provide consent. The case report forms and ethics 
approvals are contained in Appendix 2. 
 
CONCORDANCE is the largest and the longest running Australian ACS registry, which 
provides insight into the standard practice. Therefore, the data would be suitable to 
examine the possible inequities that may exist in the provision of care in real life 
situation. The data contributed to making evidence-based ACS guidelines. This work has 
30 
 
resulted in the publication of nine manuscript and additional five manuscripts under 
review. More than 20 specific studies that were based on CONCORDANCE data were 
presented at national and international conferences, including European Society of 
Cardiology (2013 and 2014), American College of Cardiology (2014), World Congress of 
Cardiology (2014) and Cardiac Society of Australia and New Zealand (2012-2016).  
 
SNAPSHOT ACS 
SNAPSHOT ACS was the first bi-national audit of the treatment journey of ACS patients 
across Australia and New Zealand (3). This audit was developed as a collaborative 
quality improvement initiative between the Cardiac Society of Australia and New 
Zealand, the Heart Foundation of Australia, the Australian Commission on Safety and 
Quality in Health Care, the George Institute for Global Health, and health networks or 
state governments in New South Wales, Queensland, Victoria, South Australia and 
Western Australia. It was designed by a bi-national academic network of clinicians and 
researchers and managed by a steering committee with key stakeholder representation. 
All hospitals, including public, private, rural or metropolitan, that were identified 
through public records and health networks to receive patients with suspected ACS 
were approached to participate. In total, 525 hospitals were approached, and of 478 
hospitals that gained ethics approval, patients with suspected ACS were admitted to 286 
hospitals during the two-week audit period (14th - 27th May 2012). Of the 478 hospitals, 
438 completed a site survey which described the local resources.  
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Data from 4,387 (New South Wales/Australian Capital Territory: 1,138; Queensland: 
695; Victoria: 722; Western Australia: 352; South Australia: 360; Northern 
Territory/Tasmania: 114; and New Zealand: 1,006) consecutive patients admitted to 
286 hospitals were collected. Patients over 18 years of age and admitted overnight for 
suspected or confirmed ACS between 14th and 27th May 2012 were eligible for 
inclusion in the audit. In Australia, ethics approval for opt-out consent was used, and in 
NZ, a process of national ethical review was undertaken and a consent waiver was 
approved for NZ participants. Data on patient demographic, medical history, cardiac 
risk factors, hospital admission, initial assessment, hospital transfer, reperfusion, 
medications, in-hospital events, final diagnosis, referral to cardiac rehabilitation, 
lifestyle advice and hospital discharge were collected from the medical records. The 
case report forms and ethics approvals are contained in Appendix 1. 
 
For the Australian cohort, prior to the 18-month follow up, National Death Index data 
were linked to identify the deceased. Three thousand and ninety-five participants who 
were found to be alive at 18-months post-discharge were followed-up by mail or phone 
surveys on events. Of those, 1920 responded to the survey and data on their 
rehospitalisation, lifestyle, medication use and quality of life were collected. For the 
New Zealand cohort, the rehospitalisation, lifestyle factors and medication data from 
the Ministry of Health were linked. Additional data on household economic status were 
collected from the participants in New South Wales and Queensland (n = 702). These 
included personal and family information, education, employment and household 
financial situation after the cardiac event. 
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Despite the short, two-week audit period, the ACS hospitalisations reported in 
SNAPSHOT ACS was found to be reflective of the national pattern of ACS admissions 
recorded by the Australian Institute of Health and Welfare (4). This dataset provides a 
summary of the standard clinical practice in majority of the Australian and New Zealand 
hospitals, which would provide reliable evidence in determining whether health 
inequities exist in disease management. As a result of this monumental initiative, the 
primary paper won the Medical Journal of Australia/MDA National Research Award for 
the best research article published in the Medical Journal of Australia in 2013. To date, 
15 published papers have arisen from this audit.  
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CHAPTER THREE 
Systematic review of the gender differences in primary and secondary 
prevention of cardiovascular disease 
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PREFACE TO THE CHAPTER 
This chapter presents a systematic review and meta-analysis of the international 
literature that compares the assessment of CVD risk between women and men in 
primary healthcare. It addresses the first part of Aim 1 of this thesis but in the global 
perspective. This review titled, Sex comparison in the assessment of cardiovascular risk in 
primary healthcare: Systematic review and meta-analysis, has been submitted to 
Circulation: Cardiovascular Quality and Outcomes.  
 
Despite the guideline recommendations to provide equal and optimal care for all in 
primary healthcare, the gender difference in CVD risk screening may exist partly due to 
physician’s lower perceived risk of CVD in women. Through the systematic review, 
comparable CVD risk assessment was observed between the genders around the world, 
a considerably low rate of assessment was identified in both women and men and 
limited research on the gender difference of the risk screening was found. This chapter 
recommends further research in disparities related to gender in risk assessment and 
other diagnostic testings of CVD and continued effort to find strategies to increase the 
rate of CVD risk assessment in primary healthcare.   
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Sex differences in the assessment of cardiovascular risk in 
primary healthcare: a systematic review and meta-analysis 
 
ABSTRACT 
Objective: To determine whether sex differences exist in the assessment of 
cardiovascular disease (CVD) risk scores and risk factors in primary healthcare. 
Methods: PubMed and EMBASE were systematically searched on 31st January 2017. 
Clinical trials and observational studies were included if they reported on the 
assessment of CVD risk score, blood pressure (BP), cholesterol, or smoking status in 
primary healthcare, stratified by sex. Meta-analyses were performed, using random 
effects models, to determine differences between sexes, separately for adjusted and 
unadjusted data. 
Results: Of 14,928 studies found in the search, 22 studies (including 4,754,782 
patients) were included in the meta-analysis for quantitative assessment. Overall, CVD 
risk assessment rate was similar in women and men (CVD risk score: 30.7% vs. 35.2% 
[difference (95% CI): -4.5 (-5.1, -3.9)]; BP: 91.3% vs. 88.5% [2.8 (2.5, 3.0)]; cholesterol: 
69.9% vs. 71.0% [-1.1 (-1.5, -0.8)]; and smoking: 85.9% vs. 86.7% [-0.8 (-1.1, -0.5)]). The 
pooled adjusted likelihood of having CVD risk score, BP and cholesterol assessments 
were comparable between women and men; OR (95% CI): 0.87 (0.70, 1.07); 1.41 (0.89, 
2.25); and 1.15 (0.82, 1.60), respectively. However, women were 32% less likely to be 
assessed for smoking (0.68 (0.47, 1.00)). There was substantial heterogeneity between 
studies and the risk of publication bias was moderate. 
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Conclusion: Despite guideline recommendations, assessment of CVD risk score in 
primary healthcare was low in both sexes. Women were less likely to be assessed for 
their smoking status than men, whereas no sex discrepancies were found for BP and 
cholesterol assessments.  
  
INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death globally for both women and 
men (1). In 2015, the World Health Organization (WHO) estimated that 17.7 million, or 
31%, of all deaths were due to CVD, of which 8.8 million were due to coronary heart 
disease and 6.2 million were due to stroke (1, 2). An estimated 80-90% of premature 
CVDs are preventable by controlling modifiable risk factors such as high blood pressure 
(BP), high cholesterol, diabetes, in addition to not smoking, maintaining a healthy diet, 
and regular physical activity (3, 4). Therapeutic interventions are recommended in 
those at high 10-year risk for CVD.  
 
To identify high-risk individuals and target therapeutic interventions in individuals 
without prior CVD, CVD guidelines in primary healthcare recommend regular 
assessment of an individual’s risk of CVD within the next 10 years. Guidelines 
recommend that this risk should be estimated using prediction models, including the 
Pooled Cohorts Equation in the United States, Systemic Coronary Risk Estimation 
(SCORE) in Europe, QRISK2 in England and Wales, and absolute CVD risk assessment 
using the Framingham Risk Equation in Australia, that includes assessment of 
traditional CVD risk factors including age, sex, smoking, blood pressure, and lipids (5-8). 
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CVD risk scores help physicians to make more appropriate clinical decisions and 
increases awareness of their own risk among patients (9). Current cardiovascular 
guidelines generally recommend that clinical decisions for preventive care should be 
based upon an individual’s risk of getting a CVD, for example, within the next 10 years 
(6, 7).  
 
Traditionally, there has been a misconception that CVD is a male dominated disease. 
Ample evidence now shows that CVD affects women as much as, if not more, than men 
(1, 10, 11). However, perhaps due to the traditional misconception, doctors in 
emergency departments are significantly less likely to identify coronary artery disease 
as a cause of chest pain and to recommend diagnostic tests to women than men (12, 13). 
Likewise, in primary healthcare, physicians are more likely under-estimate the risk in 
women, compared to men with a similar risk profile (14). Guidelines, however, 
recommend the assessment of CVD risk in both women and men. 
 
We conducted a systematic review with meta-analysis to assess whether CVD risk score 
assessment, or that of individual risk factors, are equally provided to women and men in 
primary healthcare service.  
 
METHODS 
This study is registered in the International prospective register of systematic reviews 
(PROSPERO) Registry (Registration number: CRD42017068423). The Preferred 
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Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were 
used (15). 
 
Search strategy 
MEDLINE and EMBASE databases were systematically searched on 31st January 2017 
using search terms regarding sex, primary care and assessment of CVD risk scores or 
individual CVD risk factors (total cholesterol, high-density lipoprotein cholesterol, 
systolic BP, and smoking status) (Appendix 1). The studies found were imported into a 
reference management system (Endnote X7) and duplicates were removed.  
 
Study selection criteria 
Randomised controlled trials and observational studies conducted in a routine primary 
healthcare setting including adult women and men were included. Studies needed to 
report the sex-specific number or rate, or the odds ratio (OR) comparing the sexes, for 
the assessment of a CVD risk score or individual CVD risk factors. While our primary 
interest was CVD screening among the general population, we also included studies of 
patients with diabetes or hypertension due to their high CVD risk. Single-sex studies, 
studies with less than 1000 participants, and studies conducted in a population with 
prior CVD were excluded. Only the studies with 1000 or more participants were 
included to reduce the between-study heterogeneity. There was no restriction on 
language. Where duplicate reports of the same study were found, the most recent study 
was included. Reference lists of the included studies were screened to find possibly 
relevant studies. If only the abstract was available, the data were not included, however, 
41 
 
if the full manuscript was published during the screening period, the study data 
included in the manuscript were used. 
 
The screening of studies was split between two reviewers (KH and EM), each of whom 
extracted data. To harmonise the methods of screening, both reviewers independently 
screened the title and abstract of a randomly selected 1000 studies and their 
acceptance/rejection decisions were compared. Discrepancies were discussed and 
solved with other authors. 
 
Data extraction 
Data were independently extracted by KH and EM and entered into a purpose-built 
database. The extracted data included the study details (authors’ names, aim, study 
design, study population, year of recruitment, and country/region of recruitment), CVD 
risk factors assessed, and the reported number, rate or the odds ratio (OR) of the 
assessment of CVD risk score or risk factors, by sex.  
 
Assessment of risk of bias 
A modified Newcastle-Ottawa Quality Assessment Scale for cohort studies was applied 
to assess bias 16. According to that scale, the categories assessed were Selection (three 
items), Comparability (one item) and Outcome (one item). Studies were awarded one 
star for each item of assessment within the Selection and Outcome categories, and a 
maximum of two stars for the item in Comparability category. 
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Outcomes 
The primary outcome was the assessment of a validated CVD risk score or a 
combination of multiple risk factors. If a study reported on the assessment of more than 
one risk score, then the more widely used risk score was extracted. For example, 
Delpech et al. reported the use of SCORE and French scales, and as SCORE is the CVD 
risk assessment scale recommended by the European guidelines, we extracted SCORE 
only (6, 17). Secondary outcomes were summary measures of systolic BP, cholesterol 
(total cholesterol and/or high-density lipoprotein cholesterol) and smoking status. 
Eligible studies without sufficient data for meta-analyses were included in the 
qualitative analyses. 
 
Statistical analysis 
The included studies reported, for both sexes either unadjusted results, as the number 
of people included and the rate of assessment of CVD risk scores/risk factors; and/or 
adjusted results, as ORs and 95% confidence intervals (CIs). Where only unadjusted 
results were reported, the women to men prevalence ratio (PR) and the corresponding 
95% CI was estimated from the rate and the sample size. For studies that reported 
stratified results, such by age group, PRs and the 95% CIs in each stratum were 
summarised using a fixed effect model to obtain one PR and corresponding 95% CI per 
study. One study included patients of all ages, with the reported outcomes stratified by 
age. To limit the results to those for adults, we summarised the information from age 
groups ≥18 years only (18). Random effects meta-analyses with inverse variance 
weighting were performed separately for the unadjusted results and the adjusted 
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results to obtain the pooled estimates of PR and OR (with 95% CIs), respectively. Where 
more than two studies were pooled together, I2 was used to quantify heterogeneity, and 
Cochran’s Q test was used to test for heterogeneity (p<0.1 was considered statistically 
significant for the Q test). Publication bias was assessed using funnel plots and tested 
using Egger’s test. All analyses were performed using Stata version 13.1 (Stata 
Corporation, Texas, USA). 
 
RESULTS 
Of 14,928 studies identified from the initial search, 494 full-text studies were screened. 
In total, 27 studies met the eligibility criteria, and 22 reported sufficient data to be 
included in the meta-analyses for quantitative assessment (Figure 1). Characteristics of 
the studies are shown in Table 1. Three studies reported data exclusively on diabetic 
patients (18-20) and two studies reported on hypertensive patients (21, 22). All but one 
was observational studies; the other involved baseline data from a randomised clinical 
trial (23). The majority of the studies were from Europe (18 of 27), with nine conducted 
within the United Kingdom. Overall, data from 4,754,782 (51% women) patients were 
included in the meta-analyses.  
 
CVD risk score 
Five studies, including 99,443 patients, reported the sex-specific rate of assessment of a 
CVD risk score (27, 29, 34, 35, 40). CVD risk score was assessed in 30.7% women and 
35.2% men (difference (95% CI): -4.5 (-5.1, -3.9)). The pooled unadjusted results 
suggested that women were 13% less likely to have a CVD risk score recorded than 
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men: PR 0.87 (95% CI: 0.78, 0.96). The pooled adjusted OR was identical to the 
unadjusted PR, but was not statistically significantly different from unity: OR 0.87 (0.70, 
1.07) (Figure 2). There was substantial heterogeneity between studies (I2Unadjusted= 
95.6% [p<0.001] and I2Adjusted= 89.2% [p<0.001]). 
 
Blood pressure assessment 
Twelve studies, with data from 3,996,688 patients, reported on BP assessment (18, 19, 
23, 26, 27, 31-34, 36, 38, 42). BP was assessed in 91.3% of women and 88.5% of men 
(difference (95% CI): 2.8 (2.5, 3.0)). The pooled unadjusted PR showed that women 
were 10% more likely to be screened for BP than men; PR 1.10 (1.07, 1.13). The pooled 
adjusted OR was directionally similar but found no statistical difference between 
women and men: OR 1.41 (0.89, 2.25) (Figure 3). There was considerable heterogeneity 
between studies (I2Unadjusted= 99.9% (p<0.001) and I2Adjusted= 96.8% (p<0.001)). 
 
Cholesterol assessment 
Fourteen studies, including 4,580,468 patients, reported on the sex-specific assessment 
of cholesterol (18-22, 26-28, 32-34, 38, 41, 42). Cholesterol levels were assessed in 
69.9% of women and 71.0% of men (difference (95% CI): 1.1 (-1.5, -0.8)), with no 
evidence for a sex difference in either the unadjusted or adjusted results: PR 1.01 (0.95, 
1.07) and OR 1.15 (0.82, 1.60), respectively (Figure 4). There was significant 
heterogeneity between the studies (I2Unadjusted= 99.9% (p<0.001) and I2Adjusted= 99.4% 
(p<0.001)).  
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Smoking status 
The assessment of smoking status, by sex, was reported in 14 studies including 
4,007,550 patients (18-20, 22, 26, 27, 30-34, 38, 39, 42); 85.9% of women and 86.7% of 
men (difference (95% CI): -0.8 (-1.1, -0.5)) were assessed for smoking status. The 
pooled unadjusted PR suggested that the assessment of smoking status was comparable 
between women and men: PR 0.99 (0.97, 1.02). However, the pooled adjusted OR 
provided evidence of lower assessment rates in women than men by 32%: OR 0.68 
(0.47, 1.00); p=0.049) (Figure 5). There was, again, substantial heterogeneity between 
studies (I2Unadjusted= 99.9% (p<0.001) and I2Adjusted= 94.0% (p<0.001)). 
 
Qualitative assessment 
Of the 27 studies, five did not report sufficient data to be included in the meta-analysis. 
BP assessment rate was compared in two of the studies, which showed that women 
were more likely to receive BP assessment than men (25, 43). Women were more often 
assessed for cholesterol by about 10% (24, 25, 37, 43). Moreover, Van der Weijden et al. 
found that cholesterol assessment varied by age and was lower in women than men 
aged 18-64 years (41 vs. 59%), whereas, assessment was higher in women than men 
aged ≥65 years (67 vs. 33%) (44). Two studies reported that smoking status was less 
likely to be assessed in women than men, although the differences were small (25, 43). 
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Risk of bias 
The risk of bias was moderate and the information on cohort selection, data collection, 
comparability of cohort and assessment of outcomes were clearly reported in most 
studies (Table 2). All studies included a representative sample and ascertained 
exposures and outcomes from primary healthcare data extractions. However, as most of 
these studies did not primarily aim to determine the difference in assessment of CVD 
risk factors between women and men, only 10 of the 27 studies were adjusted for 
covariates, two of which adjusted for a single factor. Moreover, there was no indication 
of publication bias (CVD risk score: p=0.625; BP: p=0.824; cholesterol: p=0.892; and 
smoking status: p=0.192). 
 
DISCUSSION 
This systematic review with meta-analysis including 27 studies and 4,754,782 patients 
compared the likelihood of CVD risk score and risk factor assessment among women 
and men in primary care. CVD risk assessment was conducted in only about a third of all 
patients, without differences between women and men. Assessments for BP and 
cholesterol were comparable between the sexes, but there was some indication that 
smoking status was less likely to be assessed in women than men.  
Current cardiovascular guidelines widely recommend the use of CVD risk assessment 
scores to guide clinical decision making in both men and women. While the lifetime risk 
of CVD is similar in women and men, the 10-year risk of CVD is generally substantially 
lower in women than men up until old age, which may lead to discrepancies in the 
utilization of CVD risk assessment scores (45). Data from a survey among 500 
47 
 
physicians in the US demonstrated that the likelihood of CVD risk assessment was 
driven by actual risk level (14). Moreover, sex differences in the use of preventive 
therapy were largely explained by physician’s lower perceived risk of CVD, despite 
similar calculated risk for women versus men. In contrast, although we found that 
women were 13% less likely than men to have their CVD risk score assessed, these 
results were not statistically significant in the adjusted analyses. Nevertheless, 
assessment of CVD risk score was low in both men and women, suggesting that 
improving physician assessment of CVD risk score may be an important educational 
target to improve the quality of CVD preventive care and lower morbidity and mortality 
from CVD for both men and women.  
 
Although CVD risk score assessment is the current paradigm in guiding treatment 
decisions in the primary prevention of CVD, their effect on clinical outcomes is 
uncertain. A recent Cochrane review suggested that CVD risk scores had limited effects 
on CVD events, but may slightly reduce CVD risk factor levels and may increase 
preventive medication prescribing in individuals at high-risk, without evidence of harm 
(46). However, multiple limitations and substantial study heterogeneity hampered 
definitive conclusions and new approaches may be needed to implement and evaluate 
CVD risk scores in primary CVD prevention. Computerized clinical support tools are a 
promising strategy to improve healthcare quality. Several electronic decision support 
tools have been developed to assist primary healthcare physicians deliver equitable and 
guideline-recommended care (47, 48). A large cluster-randomised trial in Australia 
demonstrated that a computerised decision support system, combined with audit and 
feedback strategies, improved the assessment of CVD risk score, but did not increase 
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medication prescription (47). Digital applications are also increasingly available for 
patients to monitor their own risk of CVD, which may help to improve lifestyle 
behaviours and physician-patient communication (49, 50). Further studies are required 
to evaluate the effects of such digital interventions on the management of CVD risk 
score in both men and women 
 
This study provided some evidence for lower rates of smoking assessment in women 
than men. Globally, smoking is five times more prevalent in men than women, which 
may explain this discrepancy (51). However, the prevalence of smoking is largely 
similar between men and women in high-income countries, where all the studies were 
based. A meta-analysis found that smoking has 25% greater effect on the risk of 
coronary heart disease amongst women than men (52). Therefore, it is important that 
women receive screening and advice regarding smoking to at least the same extent as 
men. 
 
Sex-specific findings should be reported more routinely. In this comprehensive review, 
only 27 studies reported the sex difference in the assessment of CVD risk, of which only 
five reported the difference in the assessment of CVD risk score. Further, 18 of the 27 
studies were based in Europe, and of these, nine studies were based in the United 
Kingdom. Further research is needed to explore the difference between women and 
men from various parts of the world. 
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The limitations of this study are inherent to its design and include variation between 
studies in study design, study duration, and the degree of adjustment for covariables; 
only nine of the 22 studies were adjusted for one or more factors. Moreover, despite our 
broad search, only 22 studies met the inclusion criteria and could be included in the 
meta-analyses. Sex-specific results for CVD risk assessment were generally not reported 
even when both women and men were included in the study.  
 
CONCLUSION 
Equitable CVD risk score assessment was provided to women and men, however, the 
assessment rate for both sexes was low. Although marginal evidence of a sex difference 
was found in the assessment of smoking status, where women were 32% less likely to 
be assessed, both sexes received comparable assessment of BP and cholesterol. Further 
studies and continuous effort are needed to find effective strategies to increase the rate 
of CVD risk score assessment and continue to provide equal assessment to both women 
and men.  
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TABLES 
Table 1. Description of studies included in the systematic review 
First author, year Country Year of 
data 
collection 
Analysed 
sample size 
(% of 
women) 
Age in years Cohort Reported 
assessment 
of risk 
factors or 
risk scores 
Type of 
reported 
outcome  
Adjusted for Included 
in meta-
analysis 
Bartholomeeusen et 
al., 2008 
Belgium 1994-2003 139,148 
(NR) 
≥25 General patients Cholesterol Number 
and/or % 
Unadjusted No 
Broomfield et al., 
2008 
Canada 2003-04 1,539 (57%) ≥65 General patients BP Number 
and/or % 
and adjusted 
OR 
Practice clustering  Yes 
Brugulat et al., 1998 Spain 1990-95 3,000 (NR) ≥15 General patients BP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted No 
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Dalton et al., 2011 United 
Kingdom 
2003-09  21,510 
(47%) 
35-74 General patients 
without CVD or 
diabetes 
BP, 
cholesterol 
and smoking 
status 
Number 
and/or % for 
all three risk 
factors, and 
adjusted OR 
for BP and 
cholesterol 
only 
Patient level: Ethnicity, 
age, sex and SES 
quintile  
Practice level: No. of 
FTE GPs, practice 
register size, practice 
register per FTE GP and 
indices of SES quintile 
of practice population 
Interaction term: Age 
and sex 
Yes 
Delpech et al., 2016 France 2005-09 2,124 (59%) 40-74 General patients BP, 
cholesterol, 
smoking 
status and 
CVD risk 
score 
Number 
and/or % 
and adjusted 
OR 
Patient variables: age, 
no. of consultations 
annually, duration of 
physician–patient 
relationship (years) 
and educational and 
SES level 
Physician variables: 
age, office location, 
Yes 
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mean duration of 
consultations (minutes) 
and mean no. of 
consultations weekly 
Exeter et al., 2015 New Zealand 2006-11 627,907 
(54%) 
≥25 General patients 
without CVD or 
diabetes. 
Cholesterol Number 
and/or % 
and 
unadjusted 
and adjusted 
OR 
Sex, age, ethnicity and 
SES. 
Yes 
Gu et al., 2013 New Zealand 2007-12  10,863 
(54%) 
≥20 General Pacific 
Islander 
patients, but not 
indigenous. 
CVD risk 
score 
Number 
and/or % 
Unadjusted Yes 
Hamilton et al., 2016 England 2006-08 41,239 
(55%) 
≥15 General patients 
without 
coronary heart 
disease, stroke 
or transient 
ischaemic attack, 
hypertension, 
Smoking 
status 
Number 
and/or % 
Unadjusted Yes 
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diabetes, chronic 
obstructive 
pulmonary 
disease, asthma, 
schizophrenia, 
bipolar affective 
disorder or other 
psychoses. 
Hendricks et al., 
2015 
Netherlands 1997-2013 No overall 
number but 
by year* 
<75  Diabetic patients SBP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Hetlevik et al., 1997 Norway 1993-94 2,468 (57%) All ages Hypertensive 
patients 
Cholesterol Number 
and/or % 
Unadjusted Yes 
Hippisley-Cox et al., 
2004 
England NR (data 
extracted 
1999) 
29,492 
(52%) 
≥35 General patients  SBP and 
smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Hippisley-Cox et al., 
2008a 
United 
Kingdom 
1995-2007 1072800 
(51%) 
35-74 General patients 
without 
diabetes, CVD or 
SBP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted Yes 
64 
 
statin 
prescription 
Hippisley-Cox et al., 
2008b 
England and 
Wales 
1993-2008 2,285,815 
(50%) 
35-74 General patients 
without CVD or 
statin 
prescription 
SBP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Hyun et al., 2017 Australia 2009-12 53,085 
(58%) 
Aboriginal: 
≥35 
Non-
aboriginal: 
≥45 
General patients SBP, 
cholesterol, 
smoking 
status and 
CVD risk 
score 
Number 
and/or % 
and 
unadjusted 
and adjusted 
OR 
Age, sex, Aboriginal 
status, diabetes, 
overweight/obese, 
high BP, high total 
cholesterol, low HDL 
cholesterol, smoking 
status and practice 
clustering 
Yes 
Journath et al., 2008 Sweden 2002-05 6,537 (52%) N/R Treated 
hypertensive 
patients 
Cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Lang et al., 2016 United 
Kingdom 
2007-09 7,987 (52%) 50-74 General patients 
without CVD 
CVD risk 
score 
Adjusted OR 
only 
Age, SES, practice SES, 
smoking status and 
practice clustering 
Yes 
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Laverty et al., 2010 United 
Kingdom 
2006-07 36,407 
(47%) 
≥40 General patients 
without CVD 
BP Number 
and/or %  
Age, sex, SES, 
ethnicity and practice 
clustering 
Yes 
Lugomirski et al., 
2013 
Canada 1999-2005 10,968,715 ≥20 General patients Cholesterol Number 
and/or % 
Unadjusted No 
Peiris et al., 2009 Australia 2005-08 1,165 (59%) ≥18 General 
Indigenous 
patients 
BP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Petri et al., 2006 England 2002-03 5,980 (44%) ≥35 Diabetic patients BP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Rafi et al., 2015 England NR 21,403 
(52%) 
≥18 General patients Smoking 
status 
Number 
and/or % 
Unadjusted Yes 
Rafter et al., 2005 New Zealand 2000 25,384 
(44%) 
Men ≥45; 
women ≥55 
General patients  CVD risk 
score 
Number 
and/or % 
Unadjusted Yes 
Rafter et al., 2008 New Zealand 2001-03 1,680 (49%) Men ≥35; 
women ≥45 
General patients Cholesterol Number 
and/or % 
Unadjusted Yes 
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Rosell-Murphy et al., 
2015 
Spain 2006-08 373,203 
(NR) 
≥16 General patients BP, 
cholesterol 
and smoking 
status 
Adjusted OR Patient level: age, 
number of visits, no. of 
health problems, 
dyslipidaemia, obesity, 
tobacco use and at-risk 
drinker 
GP level: sex of GP, 
average no. of patients 
with health problems 
and % of assigned 
patients visited  
Primary healthcare 
level: region, rurality, 
average coverage and 
average % of patients 
aged ≥65 
Yes 
Seculi et al., 2003 Spain 1995-2000 5,875 (NR) ≥15 General patients BP, 
cholesterol 
and smoking 
status 
Number 
and/or % 
Unadjusted No 
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Van der Weijden et 
al., 1996 
Netherlands 1990-92 3,577 (54%) ≥18 General patients Cholesterol Number 
and/or % 
Unadjusted No 
Wong et al., 2012 China 2008-09 1,970 (55%) N/R Type 2 diabetic 
patients 
Cholesterol 
and smoking 
status 
Adjusted OR Duration of diabetes Yes 
 
NR: not reported; BP: blood pressure; OR: odds ratio; CVD: cardiovascular disease; No.: number; FTE: full-time equivalent; GP: general 
practitioner; SES: socioeconomic status; and HDL: high-density lipoprotein. 
*See Appendix 2 
68 
 
Table 2. Risk of bias 
First author, year Selection 
(out of 3) 
Comparability 
(out of 2) 
Outcome 
(out of 1) 
Broomfield et al., 2008 *** * * 
Dalton et al., 2011 *** ** * 
Delpech et al., 2016 *** ** * 
Exeter et al., 2015 *** ** * 
Gu et al., 2013 ***  * 
Hamilton et al., 2016 ***  * 
Hendricks et al., 2015 ***  * 
Hetlevik et al., 1997 ***  * 
Hippisley-Cox et al., 2004 ***  * 
Hippisley-Cox et al., 2008a ***  * 
Hippisley-Cox et al., 2008b ***  * 
Hyun et al., 2017 *** ** * 
Journath et al., 2008 ***  * 
Lang et al., 2016 *** ** * 
Laverty et al., 2010 *** ** * 
Peiris et al., 2009 ***  * 
Petri et al., 2006 ***  * 
Rafi et al., 2013 ***  * 
Rafter et al., 2005 ***  * 
Rafter et al., 2008 ***  * 
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Rosell-Murphy et al., 2015 *** ** * 
Wong et al., 2012 *** * * 
Bartholomeeusen et al., 2008 ***  * 
Brugulat et al., 1998 ***  * 
Lugomirski et al., 2013 ***  * 
Seculi et al., 2003 ***  * 
van der Weijden et al., 1996 ***  * 
 
Newcastle-Ottawa quality assessment scale 
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FIGURES 
Figure 1. Flowchart of study selection 
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Figure 2. Meta-analysis of the adjusted effect of sex (women vs. men) on 
cardiovascular risk score assessment 
 
1 Patient level: age, no. of consultations annually, duration of physician–patient 
relationship (years) and educational and SES level. Physician level: age, office location, 
mean duration of consultations (minutes) and mean no. of consultations weekly. 
2 Age, sex, Aboriginal status, diabetes, overweight/obese, high BP, high total cholesterol, 
low HDL cholesterol, smoking status and practice clustering. 
3 Age, SES, practice SES, smoking status and practice clustering. 
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Figure 3. Meta-analysis of the adjusted effect of sex (women vs. men) on blood 
pressure assessment 
 
1 Practice clustering. 
2 Patient level: age, no. of consultations annually, duration of physician–patient 
relationship (years) and educational and SES level. Physician level: age, office location, 
mean duration of consultations (minutes) and mean no. of consultations weekly. 
3 Patient level: age, number of visits, no. of health problems, dyslipidaemia, obesity, 
tobacco use and at-risk drinker. GP level: sex of GP, average no. of patients with health 
problems and % of assigned patients visited. Primary healthcare level: region, rurality, 
average coverage and average % of patients aged ≥65. 
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4 Patient level: Ethnicity, age, sex and SES quintile. Practice level: No. of FTE GPs, 
practice register size, practice register per FTE GP and indices of SES quintile of practice 
population. Interaction term: Age and sex. 
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Figure 4. Meta-analysis of the adjusted effect of sex (women vs. men) on 
cholesterol assessment 
 
1 Duration of diabetes. 
2 Patient level: age, no. of consultations annually, duration of physician–patient 
relationship (years) and educational and SES level. Physician level: age, office location, 
mean duration of consultations (minutes) and mean no. of consultations weekly. 
3 Age, sex, ethnicity and SES. 
4 Patient level: Ethnicity, age, sex and SES quintile. Practice level: No. of FTE GPs, 
practice register size, practice register per FTE GP and indices of SES quintile of practice 
population. Interaction term: Age and sex. 
5 Patient level: age, number of visits, no. of health problems, dyslipidaemia, obesity, 
tobacco use and at-risk drinker. GP level: sex of GP, average no. of patients with health 
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problems and % of assigned patients visited. Primary healthcare level: region, rurality, 
average coverage and average % of patients aged ≥65. 
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Figure 5. Meta-analysis of the adjusted effect of sex (women vs. men) on smoking 
status assessment 
 
1 Duration of diabetes. 
2 Patient level: age, no. of consultations annually, duration of physician–patient 
relationship (years) and educational and SES level. Physician level: age, office location, 
mean duration of consultations (minutes) and mean no. of consultations weekly. 
3 Patient level: age, number of visits, no. of health problems, dyslipidaemia, obesity, 
tobacco use and at-risk drinker. GP level: sex of GP, average no. of patients with health 
problems and % of assigned patients visited. Primary healthcare level: region, rurality, 
average coverage and average % of patients aged ≥65. 
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APPENDICES 
Appendix 1. Search terms 
PubMed 
1. cardiovascular diseases [MeSH] 
2. cardiovascular [tiab] 
3. CVD [tiab] 
4. Angina [tiab] 
5. myocardial infarction [tiab] 
6. coronary heart disease [tiab] 
7. coronary artery disease [tiab] 
8. acute coronary syndrome [tiab] 
9. ischemic heart disease [tiab] 
10. ischaemic heart disease [tiab] 
11. heart failure [tiab] 
12. peripheral vascular disease [tiab] 
13. heart infarction [tiab] 
14. stroke [tiab] 
15. cerebrovascular accident [tiab] 
16. peripheral artery disease [tiab] 
17. MI [tiab] 
18. cerebrovascular disorders [Mesh] 
19. cerebrovascular disease* [tiab] 
20. Cholesterol [MeSH] 
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21. cholesterol [tiab] 
22. systolic blood pressure [MeSH] 
23. systolic blood pressure [tiab] 
24. systolic BP [tiab] 
25. smoking [MeSH] 
26. smoking [tiab] 
27. smoker [tiab] 
28. tobacco [tiab] 
29. cigarette [tiab] 
30. cigar [tiab] 
31. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 
17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 
32. cardiovascular score [tiab] 
33. cardiovascular risk score [tiab] 
34. ASSIGN score [tiab] 
35. Qrisk [tiab] 
36. Systematic COronary Risk Evaluation [tiab] 
37. Framingham score [tiab] 
38. Framingham risk [tiab] 
39. Framingham index [tiab] 
40. pooled cohort equation [tiab] 
41. 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 
42. 31 or 41 
43. Primary Health Care [MeSH] 
44. Primary service [tiab] 
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45. GP [tiab] 
46. Primary Health Care [tiab] 
47. primary healthcare [tiab] 
48. primary medical care [tiab] 
49. general practitioner [tiab] 
50. general practice [tiab] 
51. family doctor [tiab] 
52. family practitioner [tiab] 
53. family physician [tiab] 
54. 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 
55. primary prevention [MeSH] 
56. primary prevention [tiab] 
57. 55 or 56 
58. 54 or 57 
59. male [MeSH] 
60. male [tiab] 
61. men [tiab] 
62. man [tiab] 
63. 59 or 60 or 61 or 62 
64. female [MeSH] 
65. female [tiab] 
66. women [tiab] 
67. woman [tiab] 
68. 64 or 65 or 66 or 67 
69. 63 and 68 
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70. sex [MeSH] 
71. sex [tiab] 
72. gender [tiab] 
73. 69 or 70 or 71 or 72 
74. Risk factors [MeSH] 
75. Risk factors [tiab] 
76. risk assessment [MeSH] 
77. risk assessment [tiab] 
78. absolute risk [tiab] 
79. health screen[tiab]  
80. health screening[tiab]  
81. health measurement[tiab]  
82. health assessment[tiab] 
83. Health care Disparity [Mesh] 
84. Health care Disparity [tiab] 
85. Health care Disparities [tiab] 
86. 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85  
87. 42 and 58 and 73 and 86 
88. animal/ 
89. human/ 
90. 88 not 89 
91. case report/ 
92. 87 not 90 
93. 92 not 91 
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EMBASE 
1. exp cardiovascular disease/  
2. cardiovascular*.tw.  
3. CVD*.tw.  
4. Angina.tw. 
5. myocardial infarction.tw 
6. coronary heart disease*.tw 
7. coronary artery disease*.tw. 
8. acute coronary syndrome*.tw. 
9. isch?emic heart disease*.tw 
10. MI.tw 
11. heart failure.tw. 
12. peripheral vascular disease*.tw 
13. heart infarction*.tw 
14. stroke.tw 
15. cerebrovascular accident*.tw 
16. peripheral artery disease*.tw 
17. cerebrovascular disease*.tw 
18. cholesterol blood level/ 
19. exp cholesterol blood level/ 
20. exp high density lipoprotein cholesterol/ 
21. exp systolic blood pressure/ 
22. high density lipoprotein cholesterol.tw. 
23. HDL cholesterol.tw. 
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24. total cholesterol.tw. 
25. systolic blood pressure.tw. 
26. systolic BP.tw. 
27. smoking/ 
28. smoking habit/ 
29. smoking status.tw 
30. (smoking adj (status or habit)).tw. 
31. smoker.tw. 
32. ((cigarette or tobacco or cigar) adj use?).tw 
33. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 
17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 
31 or 32 
34.  exp cardiovascular risk/ 
35. (cardiovascular adj2 score).tw. 
36. (assign adj score).tw. 
37. QRisk.tw. 
38. Systematic COronary Risk Evaluation.tw. 
39. (Framingham adj4 (score or risk or index)).tw. 
40. pooled cohort equation.tw 
41. 34 or 35 or 36 or 37 or 38 or 39 or 40 
42. 33 or 41 
43. (primary adj3 care*).tw. 
44. Primary service*.tw. 
45. GP.tw. 
46. General practic*.tw. 
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47. Primary health?care.tw. 
48. exp primary medical care/ 
49. exp general practitioner/ 
50. exp general practice/ 
51. (family adj (doctor or practitioner or physician)).tw. 
52. 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 
53. exp primary prevention/ 
54. (primary adj2 prevention).tw. 
55. 53 or 54 
56. 52 or 55 
57. ale/ 
58. (men or man or male).tw 
59. 57 or 58 
60. female/ 
61. (woman or women or female).tw 
62. 60 or 61 
63. 59 and 62 
64. gender/ 
65. sex/ 
66. (Gender* or sex*).tw 
67. 63 or 64 or 65 or 66 
68. exp risk factor/ 
69. exp risk assessment/ 
70. (risk adj5 (assess* or measur* or screen*)).tw. 
71. (absolute adj5 risk*).tw.  
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72. (health adj3 (assess* or measur* or screen)).tw. 
73. exp health care disparity/ 
74. (health?care adj3 disparit*).tw. 
75. 68 or 69 or 70 or 71 or 72 or 73 or 74 
76. 42 and 56 and 67 and 75 
77. animal/ 
78. human/ 
79. 77 not 78 
80. case report/ 
81. 76 not 79 
82. 81 not 80 
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Appendix 2. Number of screened women and men in the studies included in the 
meta-analysis by outcome. 
First author, year N (%) of screened women N (%) of screened men 
Broomfield et al., 2008 BP: 743 (84) BP: 555 (84) 
Dalton et al., 2011 BP: 9,282 (92); 
TC: 6,313 (62); 
Smoke: 9,910 (98) 
BP: 9,124 (80); 
TC: 5,916 (52); 
Smoke: 10,683 (94) 
Delpech et al., 2016 BP: 1,022 (82); 
TC: 520 (42); 
Smoke: 568 (46); 
CVD RS: 237 (19) 
BP: 792 (78); 
TC: 473 (47); 
Smoke: 580 (57); 
CVD RS: 260 (26) 
Exeter et al., 2015 TC: 223,507 (65) TC: 192,485 (67) 
Gu et al., 2013 CVD RS: 1,698 (29) CVD RS: 1,797 (36) 
Hamilton et al., 2016 Smoke: 12,500 (56) Smoke: 12,708 (68) 
Hendricks et al., 2015 1998: 
HDL: 630 (70); 
BP: 781 (87); 
Smoke: 497 (55) 
1998: 
HDL: 627 (71); 
BP: 745 (84); 
Smoke: 517 (58) 
 2000: 
HDL: 389 (97); 
BP: 574 (98); 
Smoke: 398 (100) 
2000: 
HDL: 374 (96); 
BP: 542 (99); 
Smoke: 391 (100) 
 2002: 
HDL: 574 (95); 
BP: 590 (97); 
Smoke: 605 (100) 
2002: 
HDL: 542 (93); 
BP: 561 (96); 
Smoke: 584 (100) 
 2004: 
HDL: 1,803 (83); 
2004: 
HDL: 1,893 (83); 
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BP: 2,021 (93); 
Smoke: 1,960 (90) 
BP: 2,135 (93); 
Smoke: 2,057 (90) 
 2006: 
HDL: 5,390 (87); 
BP: 5,817 (94); 
Smoke: 5,557 (90) 
2006: 
HDL: 5,702 (86); 
BP: 6,220 (94); 
Smoke: 5,968 (90) 
 2008: 
HDL: 9,111 (96); 
BP: 9,358 (99); 
Smoke: 9,282 (98) 
2008: 
HDL: 9,947 (96); 
BP: 10,206 (98); 
Smoke: 10,123 (98) 
 2010: 
HDL: 13,851 (98); 
BP: 14,107 (99); 
Smoke: 13,894 (98) 
2010: 
HDL: 15,807 (98); 
BP: 16,017 (99); 
Smoke: 15,791 (98) 
 2013: 
HDL: 18,664 (96); 
BP: 18,937 (97); 
Smoke: 18,859 (97) 
2013: 
HDL: 21,985 (95); 
BP: 22,378 (97); 
Smoke: 22,216 (96) 
Hetlevik et al., 1997 TC: 409 (29) TC: 390 (37) 
Hippisley-Cox et al., 2004 BP: 13,832 (90); 
Smoke: 9,747 (63) 
BP: 11,123 (79); 
Smoke: 7,918 (56) 
Hippisley-Cox et al., 2008a BP: 511,423 (94); 
TC: 221,869 (41); 
HDL: 159,690 (29); 
Smoke: 508,680 (94) 
BP: 457,217 (86); 
TC: 213,793 (40) 
HDL: 151,782 (29); 
Smoke: 460,616 (87) 
Hippisley-Cox et al., 2008b BP: 1,056,902 (92); 
TC: 476,040 (41); 
Smoke: 1,047,768 (91) 
BP: 960,907 (85); 
TC: 372,153 (33); 
Smoke: 970,260 (85) 
Journath et al., 2008 TC: 2,660 (78); TC: 2,658 (85); 
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Smoke: 2,830 (83) Smoke: 2,689 (86) 
Lang et al., 2016 NR NR 
Laverty et al., 2010 BP: 7,803 (45) BP: 5,533 (29) 
Peiris et al., 2009 BP: 642 (93); 
TC: 410 (59); 
HDL: 334 (48); 
Smoke: 483 (70) 
BP: 409 (87); 
TC: 275 (58); 
HDL: 222 (47); 
Smoke: 349 (74) 
Petri et al., 2006 35-44: 
BP: 168 (94); 
TC: 133 (74); 
Smoke: 167 (93) 
35-44: 
BP: 251 (92); 
TC: 202 (74); 
Smoke: 256 (94) 
 45-54: 
BP: 233 (97); 
TC: 199 (83); 
Smoke: 231 (96) 
45-54: 
BP: 503 (97); 
TC: 448 (87); 
Smoke: 491 (95) 
 55-64: 
BP: 496 (99); 
TC: 448 (89); 
Smoke: 486 (97) 
55-64: 
BP: 763 (98); 
TC: 690 (89); 
Smoke: 750 (96) 
 65-74: 
BP: 698 (99); 
TC: 630 (89); 
Smoke: 674 (96) 
65-74: 
BP: 889 (99); 
TC: 811 (91); 
Smoke: 863 (96) 
 75-84: 
BP: 574 (97); 
TC: 459 (77); 
Smoke: 546 (92) 
75-84: 
BP: 556 (98); 
TC: 466 (82); 
Smoke: 534 (94) 
 ≥85: 
BP: 223 (91); 
≥85: 
BP: 113 (95); 
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TC: 139 (57); 
Smoke: 198 (81) 
TC: 85 (71); 
Smoke: 105 (88) 
Rafi et al., 2015 Smoke: 11,040 (99) Smoke: 9,742 (95) 
Rafter et al., 2005 CVD RS: 3,753 (34) CVD RS: 4,681 (33) 
Rafter et al., 2008 TC: 496 (60) TC: 552 (69) 
Rosell-Murphy et al., 2015 NR NR 
Wong et al., 2012 NR NR 
 
BP: blood pressure; TC: total cholesterol; CVD RS: cardiovascular risk score; HDL: high-
density lipoprotein; and NR: not reported.  
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Appendix 3. Funnel of standard error by log prevalence ratio for publication bias 
assessment. 
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CHAPTER FOUR 
The effect of gender on the CVD risk factor measurements, and of 
patients with high CVD risk, prescription of guideline-recommended 
medications in Australian primary healthcare 
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PREFACE TO THE CHAPTER 
This chapter also addresses Aim 1, but with a focus on the care provided in Australian 
primary healthcare. It examines whether the gender difference exists in the receipt of 
primary CVD prevention through the assessment of CVD risk factors, and prescription of 
appropriate medications using data from the TORPEDO study. The ethics approval for 
this study is provided in Appendix 3. This chapter consists of a manuscript titled: 
Gender Inequalities in Cardiovascular Disease Prevention and Management in Australian 
Primary Health Care: Results from the TORPEDO Study.  
 
The issue of limited evidence on gender comparison in the receipt of CVD prevention 
and care in primary care also exists in Australia. Unlike Chapter 3, in which positive 
findings of equitable CVD risk assessment provided to women and men in primary 
healthcare were found, in Australia, women were less likely to be risk assessed than 
men. Moreover, younger women were substantially less likely to receive guideline-
recommended medication prescription to control CVD risk factors, whereas, older 
women were considerably more likely to receive the medication prescription compared 
to their male counterparts. This chapter calls for system-wide solutions to these 
inequities. 
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ORIGINAL ARTICLE
Gender inequalities in cardiovascular risk factor
assessment and management in primary healthcare
Karice K Hyun,1 Julie Redfern,1 Anushka Patel,1 David Peiris,1 David Brieger,2
David Sullivan,3 Mark Harris,4 Tim Usherwood,1,5 Stephen MacMahon,1,6
Marilyn Lyford,1,7 Mark Woodward1,6
ABSTRACT
Objectives To quantify contemporary differences in
cardiovascular disease (CVD) risk factor assessment and
management between women and men in Australian
primary healthcare services.
Methods Records of routinely attending patients were
sampled from 60 Australian primary healthcare services
in 2012 for the Treatment of Cardiovascular Risk using
Electronic Decision Support study. Multivariable logistic
regression models were used to compare the rate of
CVD risk factor assessment and recommended
medication prescriptions, by gender.
Results Of 53 085 patients, 58% were female.
Adjusting for demographic and clinical characteristics,
women were less likely to have sufﬁcient risk factors
measured for CVD risk assessment (OR (95% CI): 0.88
(0.81 to 0.96)). Among 13 294 patients (47% women)
in the CVD/high CVD risk subgroup, the adjusted odds
of prescription of guideline-recommended medications
were greater for women than men: 1.12 (1.01 to 1.23).
However, there was heterogeneity by age (p <0.001),
women in the CVD/high CVD risk subgroup aged
35–54 years were less likely to be prescribed the
medications (0.63 (0.52 to 0.77)), and women in the
CVD/high CVD risk subgroup aged ≥65 years were more
likely to be prescribed the medications (1.34 (1.17 to
1.54)) than their male counterparts.
Conclusions Women attending primary healthcare
services in Australia were less likely than men to have
risk factors measured and recorded such that absolute
CVD risk can be assessed. For those with, or at high risk
of, CVD, the prescription of appropriate preventive
medications was more frequent in older women, but less
frequent in younger women, compared with their male
counterparts.
Trial registration number 12611000478910,
Pre-results.
INTRODUCTION
Despite decreasing mortality rates due to cardiovas-
cular disease (CVD) in many countries, it remains
the leading cause of death worldwide for both
women and men.1 2 Previously, CVD was assumed
to be more prevalent in men and therefore women
tended to be less intensively treated.3 To close the
treatment gap between women and men, the
improvement of cardiovascular health in women has
been promoted through health initiatives and
research.4 5 Yet, in Australia, as in the United States
and the UK,6 7 women have a higher number of
cardiovascular deaths per year than men (23 755 vs
21 867 deaths in 2012),1 largely because they live
longer. Women with diabetes have over 40% greater
excess risk of coronary heart disease (CHD)8 and
nearly 30% higher relative risk for stroke compared
with men with diabetes.9 More research is needed to
uncover the reasons for these female disadvantages.
One possibility is that women are less often recog-
nised as being prone to CVD than men and are thus
less likely to receive a timely diagnosis and to receive
appropriate treatment after a positive diagnosis.
There is evidence that risk assessments and medi-
cation adherence have a positive impact on out-
comes.10 11 Studies from countries outside Australia
have found that women with CHD are less likely than
men to undergo risk factor assessments in primary
healthcare.12 13 Some studies have also shown that
women with CHD are less likely to receive recom-
mended medications than men,13 14 although other
studies have shown no gender differences.15
While differences in CVD assessment and man-
agement between women and men have been
observed in other countries, the extent to which
this may be an issue in Australian primary health-
care is unknown. We aimed to determine whether
measurement of CVD risk factors and guidelines
recommended medication prescriptions varied
between women and men in a large Australian
primary healthcare cohort.
METHODS
Study design and data
Baseline data from the Treatment of
Cardiovascular Risk using Electronic Decision
Support (TORPEDO) study were used for analysis.
TORPEDO was a cluster randomised trial to test
whether a computer-guided quality improvement
intervention improved CVD risk management
when compared with usual care. Full details of the
study and the primary results of the trial have been
published.16 Although the data were extracted for a
cluster randomised trial, only the baseline data were
used in this observational study. Brieﬂy, Australian
general practices (GPs) and Aboriginal Community
Controlled Health Services (ACCHSs) were eligible
to participate if there was exclusive use of an elec-
tronic health record that was compliant with study
software to record risk factor information, path-
ology test results and prescribe medications.
The total TORPEDO cohort included Aboriginal
and Torres Strait Islander people aged ≥35 years
To cite: Hyun KK,  
Redfern J, Patel A, et al.  
Heart 2017;103:500–506.
1The George Institute for Global 
Health, Sydney Medical School, 
University of Sydney, Sydney, 
Australia
2Department of Cardiology, 
Concord Hospital, University of 
Sydney, Sydney, Australia
3Department of Chemical 
Pathology, Royal Prince Alfred 
Hospital, Sydney, Australia
4Centre for Primary Health Care 
and Equity, University of New 
South Wales, Sydney, Australia
5Sydney Medical School 
Westmead, University of Sydney, 
Sydney, Australia
6The George Institute for Global 
Health, University of Oxford, 
Oxford, UK
7WA Centre for Rural Health, 
University of Western Australia, 
Perth, Australia
Correspondence to
Karice K Hyun, The George 
Institute for Global Health, 
Sydney Medical School, 
University of Sydney, Level 10, 
King George V Building, 83-117 
Missenden Rd, Camperdown, 
NSW 2050, Australia;  
khyun@georgeinstitute.org.au
Received 23 June 2016
Revised 14 November 2016
Accepted 17 November 2016
Published Online First 
28 February 2017
Healthcare delivery, economics and global health
500 Hyun KK, et al. Heart 2017;103:500–506. doi:10.1136/heartjnl-2016-310216
group.bmj.com on May 14, 2017 - Published by http://heart.bmj.com/Downloaded from 
and others aged ≥45 years (no upper age limit) from 40 GPs and
20 ACCHSs across New South Wales and Queensland. These
age criteria were based on Australian guideline recommendations
for conducting a CVD risk assessment.10 To be eligible for inclu-
sion, patients had to be regular attendees of the service. The def-
inition of a regular attendee was based on Australian GP
standards and includes at least three attendances in the previous
24 months and at least one attendance in the previous 6 months.
The average cluster size was 750 patients and 30% of the
patients were at high CVD risk. CVD was deﬁned as a recorded
diagnosis of CHD, ischaemic stroke or peripheral vascular
disease. High CVD risk was deﬁned in a manner consistent with
the deﬁnition in Australian guidelines where patients with any of
the following are considered high risk of CVD: diabetes mellitus
and age >60 years, diabetes mellitus and albuminuria, chronic
kidney disease (stage 3B or worse) or extreme individual risk
factor elevations: systolic blood pressure (SBP) ≥180 mm Hg,
diastolic BP ≥110 mm Hg, total cholesterol >7.5 mmol
(290 mg/dL) or a calculated 5-year CVD risk of >15% (based
on the Framingham Risk equation).10 17
Deidentiﬁed data were extracted between September 2011
and May 2012 for all patients who met these criteria. Data
extraction was performed using a validated extraction tool at
randomisation.18 The study was approved by the University of
Sydney Human Research Ethics Committee and the Aboriginal
Health and Medical Research Council of New South Wales
Human Research Ethics Committee. Individual consent waiver
was granted, given that data collection was based on deidentiﬁed
extracts from the electronic health record system.
Outcomes
Two outcomes were analysed. First, for patients in the total
cohort, we analysed the rate of having recorded risk factor infor-
mation sufﬁcient for guideline-recommended absolute CVD risk
assessment. Second, in the CVD/high CVD risk subgroup, we
analysed the rate of optimal guideline-recommended preventive
medication prescriptions. Based on the components of the
Framingham risk score, sufﬁcient assessment of risk factors for
CVD risk assessment was deﬁned as having recorded smoking
status at least once, SBP in the previous 12 months, total choles-
terol and high-density lipoprotein (HDL) cholesterol in the pre-
vious 24 months.17 Optimal prescriptions of recommended
medication were deﬁned as a current prescription for at least one
BP-lowering drug and a statin for people at high risk without
established CVD, or at least one BP-lowering drug, a statin and
an antiplatelet agent (unless contraindicated by oral anticoagu-
lant use) for people with a recorded diagnosis of CVD.10
Statistical analyses
Missing data were not imputed for these analyses. Assessment of
individual risk factors and prescription of individual medica-
tions were deﬁned as having a record; if the value was missing,
this was considered as having had no assessment or prescription.
Baseline characteristics and prescription of medications to
women and men were compared using χ2 tests for categorical
variables and t-tests for continuous variables. Assessment of
individual risk factors was compared between gender and age
groups using χ2 tests. The deﬁnition for sufﬁcient assessment of
CVD risk factors was as follows: having recorded smoking
status at least once, SBP in the previous 12 months, total choles-
terol and HDL cholesterol in the previous 24 months.17
Although body mass index (BMI) and fasting glucose are not
included in the Framingham risk score, and therefore not
included in the deﬁnition for sufﬁcient assessment of CVD risk
factors, since they are also important risk factors for CVD, we
analysed these variables also. Multiple-adjusted generalised esti-
mating equation (to account for the clustering by healthcare
provider) logistic regression models with an exchangeable
working correlation matrix were used for each of the outcomes
to estimate the ORs and the corresponding 95% CIs for women
versus men. For both outcomes, independent predictors
included in the models were as follows: gender (women vs
men), age groups (35–54 years, 55–64 years, ≥65 years),
Aboriginal/Torres Strait Islander status, diabetes status, over-
weight/obese (BMI ≥25 kg/m2 vs not), high BP (SBP
≥140 mmHg/diastolic BP ≥90 mm Hg vs not), high total
Table 1 Baseline comparison by gender
Total cohort CVD/high CVD risk subgroup
Variable
Women
30 601 (58%)
n (%)
Men
22 484 (42%)
n (%)
Overall
53 085
n (%) p Value
Women
6202 (47%)
n (%)
Men
7092 (53%)
n (%)
Overall
13 294
n (%) p Value
Age, mean (SD) 61 (13.3) 60 (12.4) 61 (12.9) <0.001 70 (13.1) 68 (12.0) 69 (12. 6) <0.001
Aboriginal and/or Torres Strait Islander 5411 (17.7) 4012 (17.8) 9423 (17.8) 0.63 1632 (26.3) 1412 (19.9) 3044 (22.9) <0.001
Recorded diagnosis of diabetes 4392 (14.4) 4181 (18.6) 8573 (16.1) <0.001 3264 (52.6) 3240 (45.7) 6504 (48.9) <0.001
Systolic blood pressure, mean (SD) 128 (17.4) 131 (16.3) 130 (17.0) <0.001 135 (20.7) 135 (18.6) 135 (19.6) 0.99
Total cholesterol, mean (SD) 5.1 (1.1) 4.8 (1.1) 5.0 (1.1) <0.001 4.9 (1.5) 4.5 (1.3) 4.6 (1.4) <0.001
High-density lipoprotein cholesterol, mean (SD) 1.5 (0.4) 1.2 (0.3) 1.4 (0.4) <0.001 1.4 (0.4) 1.2 (0.3) 1.3 (0.4) <0.001
Current smoker 4817 (19.2) 4252 (22.2) 9069 (20.5) <0.001 1054 (20.0) 1455 (22.9) 2509 (21.5) <0.001
BP-lowering prescription 13 502 (44.1) 10 968 (48.8) 24 470 (46.1) <0.001 4975 (80.2) 5538 (78.1) 10 513 (79.1) <0.001
Statin/other lipid-lowering prescription 9575 (31.3) 8755 (38.9) 18 330 (34.5) <0.001 4184 (67.5) 4903 (69.1) 9087 (68.4) 0.04
Oral anticoagulant prescription 889 (2.9) 948 (4.2) 1837 (3.5) <0.001 469 (7.6) 563 (7.9) 1032 (7.8) 0.42
Antiplatelet prescription 6014 (19.7) 6003 (26.7) 12 017 (22.6) <0.001 3312 (53.4) 4071 (57.4) 7383 (55.5) <0.001
All essential CVD risk factors measured* 12 669 (41.4) 10 323 (45.9) 22 992 (43.3) <0.001 – – – –
Recommended medications prescribed† – – – – 2909 (46.9) 3405 (48.0) 6314 (47.5) 0.20
n (%) if not otherwise stated.
*Defined as having recorded smoking status at least once, systolic BP in the previous 12 months, total cholesterol and high-density lipoprotein cholesterol in the previous 24 months.
†Defined as prescription for at least one BP-lowering drugs and a statin for people at high risk without established CVD, or at least one BP-lowering drugs, a statin and an antiplatelet
agent (unless contraindicated by oral anticoagulant use) for people with a recorded diagnosis of CVD.
BP, blood pressure; CVD, cardiovascular disease.
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cholesterol (total cholesterol ≥5.5 mmol vs not), low HDL chol-
esterol (HDL cholesterol ≤1 mmol vs not) and smoking status
(current smokers vs ex/never smokers). Moreover, the ORs and
the corresponding 95% CIs for women versus men were
derived for individual CVD risk factor assessments separately
using the same model, but excluding covariates that are related
to the outcomes. For example, if the odds of smoking assess-
ment were being analysed, smoking status was excluded from
the list of covariates. Similarly, the ORs and the corresponding
95% CIs for women versus men were derived for individual
recommended medication prescriptions. The model predicting
the measurement and recording of CVD risk factors was per-
formed for the total cohort, while the analysis predicting the
receipt of appropriate CVD medications was restricted to those
in the CVD/high CVD risk subgroup. For each outcome, prede-
ﬁned subgroup analyses were performed by adding an inter-
action term between gender and the CVD risk factors (age
groups, indigenous status, overweight/obese, high BP, high total
cholesterol, low HDL cholesterol and current smoker status) to
the multiple-adjusted logistic regression model. The covariates
and the restrictions for the analyses of each outcome remained
the same as above. The subgroup analyses for Aboriginal/Torres
Strait Islander status were performed for those who were 45 or
older only to keep the age groups consistent. Furthermore, the
interaction between gender and age groups for the two out-
comes was also explored by Aboriginal/Torres Strait Islander
status, using the same model. To explore the interaction
between gender and age groups on prescription of each class of
medication (BP medication, statin and antiplatelet), multiple-
adjusted generalised estimating equation logistic regression
models were used. The covariates for these analyses were as
listed above. Interaction was addressed by ﬁtting age group as a
continuous variable to produce a test for trend.
Data were analysed using SAS V.9.4 (SAS Institute, Cary,
North Carolina, USA).
RESULTS
Data on 53 085 patients were extracted from 60 services at
baseline; 30 601 (58%) patients were women. Of the total
cohort, 13 294 (25%) were in the CVD/high CVD risk sub-
group (6621 patients with prevalent CVD and 6673 at high
CVD risk), 47% (n=6202) of whom were women.
Gender differences in the overall cohort
The mean age was 61 years for women and 60 years for men.
Women had lower rates of recorded diabetes and of being a
current smoker. Women also had a lower mean SBP and a
higher mean total cholesterol (table 1).
Overall, only 43.3% of patients had all necessary CVD risk
factors recorded for absolute risk assessment. Compared with
men, women were less likely to have the CVD risk factors
recorded (41.4% vs 45.9%, p<0.001). Women were signiﬁcantly
less likely to have smoking status, SBP, total cholesterol, HDL
cholesterol and BMI recorded compared with men (table 2).
Also, when the rates of risk factor assessment were compared
within age groups, where there were signiﬁcant differences
between women and men, women were consistently less likely to
have their risk measured than men (table 2).
After adjustment, the odds of women having all necessary risk
factors recorded for an absolute risk assessment was 12% lower
compared with men (OR (95% CI): 0.88 (0.81 to 0.96))
(ﬁgure 1). Taking the individual risk factors separately, the odds
of having smoking status recorded was 22% lower (0.78
(0.66–0.91)), SBP recorded was 12% lower (0.88 (0.81–0.96))
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and cholesterol (total and/or HDL cholesterol) recorded was 8%
lower (0.92 (0.86–0.98)) in women than men. The only signiﬁ-
cant subgroup heterogeneity observed was in relation to total
cholesterol (pinteraction=0.02); however, no gender difference was
observed among individuals with high total cholesterol (ﬁgure
1). As well as a lack of evidence for heterogeneity in the total
cohort, no heterogeneity was found between age groups for both
Aboriginal/Torres Strait Islanders and others (pinteraction=0.49
and 0.69, respectively). For age groups 35–54, 55–64 and 65 and
older, the ORs (95% CIs) for all Aboriginal/Torres Strait Island
people were 0.75 (0.63 to 0.89), 0.72 (0.51 to 1.02) and 1.05
(0.64 to 1.72), and the corresponding results for others were
0.92 (0.81 to 1.05), 0.87 (0.76 to 0.99) and 0.94 (0.83 to 1.05).
Gender differences in patients in the CVD/high CVD risk
subgroup
Of the 13 294 patients found to be in the CVD/high CVD risk
subgroup, the mean age of women was 70 years and of men was
68 years (table 1). The proportion of women and men who
were prescribed recommended medications were similar (46.9%
vs 48.0%, p=0.20) but low overall, where only 47.5% of the
patients in the CVD/high CVD risk subgroup received the pre-
scriptions. When prescription of each class of medication was
compared, women were less likely to be prescribed statin and
antiplatelet, but slightly more likely to be prescribed
BP-lowering medication compared with men (table 3). Women
in the youngest (35–54 years) age group were substantially less
likely to be prescribed BP-lowering medication, statin and anti-
platelet than men in the same age group (table 3).
After adjusting for covariates, the odds of women receiving
recommended medication were greater by 12% than for men
(OR (95% CI): 1.12 (1.01 to 1.23)) (ﬁgure 2). Signiﬁcant het-
erogeneity was found between age groups (p for interaction
<0.001), where younger women were substantially less likely to
be prescribed recommended medications by 37% (0.63 (0.52 to
0.77)) and older women were 34% more likely to be prescribed
medications (1.34 (1.17 to 1.54)) compared with men (ﬁgure
2). Moreover, both Aboriginal/Torres Strait Island people and
Figure 1 Multiple-adjusted female to
male ORs and 95% CIs for the
assessment of cardiovascular risk
factors. HDL, high-density lipoprotein.
Indigenous: Aboriginal and/or Torres
Strait Islander; overweight/obese: body
mass index ≥25 kg/m2; high blood
pressure: systolic blood pressure
≥140 mm Hg and diastolic blood
pressure ≥90 mm Hg; high total
cholesterol: total cholesterol
≥5.5 mmol and low HDL cholesterol:
HDL cholesterol ≤1 mmol. Each
variable in the ﬁgure is adjusted for all
the others.
Table 3 Prescription of individual classes of medications to patients in the CVD/high CVD risk subgroup by gender and age group
Total CVD/high CVD risk subgroup 35–54 years 55–64 years ≥65 years
Variable
Women
6202
(47%) n
(%)
Men
7091
(53%)
n (%) p Value
Women
874
(44%)
n (%)
Men
1107
(56%)
n (%) p Value
Women
1417
(43%)
n (%)
Men
1887
(57%)
n (%) p Value
Women
3911
(49%)
n (%)
Men
4097
(51%)
n (%) p Value
Blood pressure
medication
4975 (80.2) 5538 (78.1) 0.003 578 (66.1) 789 (71.3) 0.01 1090 (76.9) 1426 (75.6) 0.37 3307 (84.6) 3323 (81.1) <0.001
Statin 4088 (65.9) 4820 (68.0) 0.01 505 (57.8) 749 (67.7) <0.001 986 (69.6) 1293 (68.5) 0.51 2597 (66.4) 2778 (67.8) 0.18
Antiplatelet 3312 (53.4) 4071 (57.4) <0.001 411 (47.0) 618 (55.8) <0.001 701 (49.5) 1034 (54.8) 0.002 2200 (56.3) 2419 (59.0) 0.01
Anticoagulant 469 (7.6) 563 (7.9) 0.42 27 (3.1) 30 (2.7) 0.62 49 (3.5) 76 (4.0) 0.40 393 (10.0) 457 (11.2) 0.11
CVD, cardiovascular disease.
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others showed lower odds of being prescribed recommended
medication in younger women than younger men. For age
groups 35–54, 55–64 and 65 and older, the ORs (95% CIs) for
all Aboriginal/Torres Strait Island people were 0.65 (0.53 to
0.80), 1.30 (1.00 to 1.69) and 1.23 (0.93 to 1.62) (pinteraction-
=0.01), and the corresponding results for others were 0.60
(0.37 to 0.96), 0.91 (0.76 to 1.09) and 1.36 (1.18 to 1.57)
(pinteraction=0.004), respectively.
When examining individual classes of medication, women
aged 35–54 years were less likely to be prescribed BP medica-
tion, statin and antiplatelet than their male peers (0.69 (0.54 to
0.87), 0.65 (0.49 to 0.87) and 0.73 (0.56 to 0.96) respectively)
(ﬁgure 3). Furthermore, a positive trend of the odds of women
receiving each medication compared with men by age group
was observed for three of the four medication classes. Most
especially, women in the youngest age group were less likely to
be prescribed BP-lowering medication and statin, whereas
women in the oldest age group were more likely to be pre-
scribed BP-lowering medication and statin compared with their
male counterparts. Overall, prescription of recommended medi-
cations to overweight/obese women and men were comparable;
however, of those who were not overweight/obese, women had
Figure 2 Multiple-adjusted female to
male ORs and 95% CIs for
guideline-recommended medication
prescription among the patients in the
cardiovascular disease/high
cardiovascular risk subgroup. HDL,
high-density lipoprotein.Indigenous:
Aboriginal and/or Torres Strait Islander;
overweight/obese: body mass index
≥25 kg/m2; high blood pressure:
systolic blood pressure ≥140 mm Hg
and diastolic blood pressure
≥90 mm Hg; high total cholesterol:
total cholesterol ≥5.5 mmol; and low
HDL cholesterol: HDL cholesterol
≤1 mmol. Each variable in the ﬁgure is
adjusted for all the others.
Figure 3 Multiple-adjusted female to
male ORs and 95% CIs for the
prescription of blood pressure-lowering
medication, statin, antiplatelet and
anticoagulant therapy among the
patients in the cardiovascular disease/
high cardiovascular risk subgroup, by
age group. Each variable in the
ﬁgure is adjusted for age groups,
Aboriginal/Torres Strait Islander status,
diabetes status, overweight/obese, high
blood pressure, high total cholesterol,
low high-density lipoprotein cholesterol
and smoking status.
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36% higher odds of being prescribed recommended medications
than men (pinteraction=0.02) (ﬁgure 2).
DISCUSSION
This study provides contemporary gender comparisons of CVD
risk assessment and management provided by a sample of
primary healthcare services in Australia. Our results show that
overall proportion of patients who were assessed and treated
were notably low, and women were less likely to have CVD risk
factors measured than men. Although there was no evidence of
heterogeneity by age in risk factor measurement between the
genders, there was such heterogeneity in treatment for patients
in the CVD/high CVD risk subgroup. Our ﬁnding suggested
that older women in the CVD/high CVD risk subgroup overall
had greater odds of being prescribed recommended medications
than men, while the converse was true for their younger
counterparts.
Despite guidelines, including those of The Royal Australian
College of General Practitioners and the National Vascular
Disease Prevention Alliance, regarding screening for CVD risk
factors,10 19 20 inequality in CVD prevention through assessing
risk factors remains between women and men. Our results are
similar to those from a study from the UK where the likelihood
of assessing smoking status, cholesterol, BP and BMI was 35%
higher in men than in women.13 Another UK study has found
that men tended to have higher rates of comprehensive risk
factor assessment than women (22% vs 20%), although this dif-
ference was not statistically signiﬁcant.12 This gap may occur
due to barriers at individual, social and system levels.21 At indi-
vidual and social levels, physicians may not be aware or familiar
with the updated guidelines, or physicians and women may
have the old misconception of CVD being a man’s disease.22
Furthermore, the misconception of senior physicians may have
been passed on to the younger generation of physicians; there-
fore, where there are ﬁnancial disincentives and time and
resource constraints, women have been disadvantaged in receiv-
ing appropriate CVD risk factor assessment.
There are a number of study limitations that are noteworthy.
First, the services recruited for the TORPEDO study did not
represent a random sample of primary healthcare services in
Australia. All of the GPs were located in urban areas of New
South Wales and Queensland, whereas about 30% of Australian
GPs are in rural or remote areas. Furthermore, several services
were teaching GPs and this may reﬂect a stronger commitment
to improving healthcare quality compared with non-teaching
practices. It is possible, therefore, that the gaps in care practices
encountered in this study may potentially be even larger in the
broader primary healthcare sector. Second, the study population
for the TORPEDO study was restricted to regular attendees of
the primary healthcare service. Regular attendees are commonly
used in the denominator for quality improvement indicators
and for the purposes of the randomised trial it was important to
deﬁne a relatively stable population to test the effect of the
intervention. However, this means that we are unable to
extrapolate the ﬁndings to infrequent attenders who may exhibit
different demographic, health and healthcare seeking character-
istics. Third, we were unable to capture contraindications to
recommended medications (eg, pregnancy, high bleeding risk
and allergies or medication intolerances). This could explain a
small proportion of the treatment gaps encountered.
To overcome the misconceptions and barriers that may
prevent gender equality in assessment and management of
CVD, some doctors, researchers and organisations from across
the world have made signiﬁcant efforts to promote women’s
CVD health. Studies regarding CVD management for women in
the past decade have informed educational campaigns for
greater attention to women’s cardiovascular health.23
Programmes such as Go Red for Women and The Women’s
Room are examples of these initiatives.4 5 Despite such initia-
tives, our study found that younger women with CVD/high risk
of CVD between the ages of 35 and 54 were signiﬁcantly less
often prescribed recommended medications than younger men
with CVD/high risk of CVD. This is consistent with previous
studies reported from other countries.13 24 In contrast, older
women with CVD/high risk of CVD were more likely to be pre-
scribed than older men with CVD/high risk of CVD, suggesting
possible presence of age stereotypes in medical management of
CVD. This indicates that strategies and incentives are needed at
the system level, together with education of physicians and
public about this inequality at the individual and social level, to
minimise the treatment gap between women and men. For
example, academic programmes such as those of NPS
MedicineWise can promote better understanding and improved
prescribing of medications;25 health quality identiﬁcation system
such as gender-speciﬁc quality indicators may be incorporated
into quality improvement programmes to support better assess-
ment and treatment of patients and targeted funding model
such as speciﬁc Medicare Beneﬁts Schedule reimbursement for
patients with CVD/high risk of CVD can provide ﬁnancial
incentives for physicians.
CONCLUSION
Despite guidelines recommending that risk factors should be
assessed and managed in both sexes, inequalities remain.
Women are not receiving equitable testing in Australian primary
healthcare and, while women in general receive appropriate
medications more often than do men, younger women with
CVD/high risk of CVD are disadvantaged in terms of receipt of
essential treatments to prevent CVD events. System-wide solu-
tions to these inequalities and the increase of the overall rates of
assessment and management of CVD are needed.
Key messages
What is already known on this subject?
Risk assessment and medication adherence have a positive
impact on preventing and managing cardiovascular disease
(CVD); however, differences in CVD assessment and
management between women and men have been observed in
countries such as the UK.
What might this study add?
In Australian primary healthcare services, women were less
likely to be assessed for CVD risk factors at primary healthcare
services. Of those at high risk of CVD, younger women
(35–54 years) were less likely to be prescribed guideline-
recommended medications than younger men (35–54 years),
whereas older women (≥65 years) were more likely to be
prescribed guideline-recommended medications than their
counterparts.
How might this impact on clinical practice?
System-level strategies are needed to improve the provision of
CVD assessment and treatment to minimise the gap between
women and men.
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PREFACE TO THE CHAPTER 
The manuscript that forms this chapter is titled: The effect of socioeconomic 
disadvantage on prescription of guideline-recommended medications for patients with 
acute coronary syndrome: systematic review and meta-analysis. This chapter consists of a 
systematic review and meta-analysis on the difference in the prescription of guideline-
recommended ACS medications at discharge between the lowest and the highest 
individual or area-level SES groups. It attends to the global perspective of Aim 2 of the 
thesis. 
 
The WHO reports that patients in low SES may be subjected to health inequity, but 
varied results regarding the effect of care received in hospital exist (1). This review 
identified that discrepancies across SES groups exist in the prescription of discharge 
medications at discharge, where patients in the lowest SES group are less likely to be 
prescribed for beta blocker and statin but more likely to be prescribed for ACE than 
those in the highest SES group. This chapter recommends further investigation to find 
factors that lead to this inequity. 
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The effect of socioeconomic disadvantage
on prescription of guideline-recommended
medications for patients with acute
coronary syndrome: systematic review and
meta-analysis
Karice K. Hyun1,2,6*, David Brieger3, Mark Woodward2,4, Sarah Richtering5 and Julie Redfern2
Abstract
Background: There are varying data on whether socioeconomic status (SES) affects the treatment in patients
with acute coronary syndrome (ACS). Our aim was to obtain a reliable estimate of the effect of SES on
discharge prescription of medications following an ACS through systematic review and meta-analysis.
Methods: Medline, EMBASE and Global Health were searched systematically on 6th April 2016. Studies
were eligible if the participants had ACS and reported the rate/odds of guideline-recommended ACS
medications prescription (aspirin, antiplatelet, beta blocker, angiotensin co-enzyme inhibitors (ACEi)/
angiotensin receptor blockers (ARB) and statin) at discharge stratified by SES. A meta-analysis was
performed to pool the estimates, comparing the prescription ratio (PR) between the lowest and the
highest SES groups.
Results: Of 252 articles found from the search, seven met the eligibility criteria and it included 41,462
(20,986 from the lowest SES group) patients. We found that the individual/neighbourhood level SES did
not affect the prescription of aspirin (PR (95% CI): 0.97 (0.91, 1.03)), but for beta blocker and statin, the
lowest SES group were disadvantaged (0.84 (0.73, 0.94), 0.80 (0.62, 0.98), respectively). In contrast, ACEi
were prescribed more often to the lowest individual/neighbourhood level SES group than the highest
(1.13 (1.05, 1.22)). Although the risk of bias was low, there was considerable heterogeneity between the
studies.
Conclusions: Despite the recommendations to close the treatment gap, the rate of prescription of
guideline-recommended medications in managing ACS is significantly different between patients with the
lowest and the highest groups. A solution is needed to provide equitable care across the SES groups.
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Introduction
Acute coronary syndrome (ACS) is a high-risk form of
coronary atherosclerosis, consisting of myocardial in-
farction (MI) and unstable angina (UA). About 1.4
million people are hospitalised with a diagnosis of
ACS every year in the United States [1]; in Australia,
more than 95,000 are hospitalised each year with a re-
admission rate within 6 months of about 20% [2, 3].
To reduce the risk of recurrence or death, recom-
mended treatment guidelines for optimal treatment
are in place [4–7]. An important part of these guide-
lines is the prescription of recommended medications
at discharge from hospital. The recommended
medications include aspirin and antiplatelet, which
prevent blood to clot; beta blocker and angiotensin
co-enzyme inhibitor (ACEi)/angiotensin receptor
blocker (ARB), which are blood pressure lowering
medications; and statin/lipid lowering therapy, which
are cholesterol lowering medications [8, 9]. These
evidence-based medications have been proven to
reduce the risk of mortality and major adverse cardio-
vascular events, with further risk reduction when used
in combination, and are recommended to be taken
long-term [4–7, 10, 11]. However, studies suggest that
there are social subgroups that receive optimal treat-
ment less often [12–16].
World Health Organisation (WHO) reports that so-
cial factors such as socioeconomic status (SES) can
influence patients’ treatment of illness as well as
health [17]. Previous studies found that patients with
low SES have significantly higher risk of an outcome
or death due to a chronic disease, including chronic
obstructive pulmonary disease outcomes, cardiovascu-
lar disease [18–20]. Similar results were found for
ACS, where the lowest SES group had the highest
rates of MI and death due to coronary heart disease
[21]. When it seems appropriate for those with ACS
and low SES to be treated more rigorously compared
to those with high SES, some studies have reported
that patients in the lowest SES group were disadvan-
taged in receiving some guideline recommended
discharge medication prescriptions [12–16]. However,
there were also evidence suggesting that patients
receive comparable rate of prescription across the
SES groups [13–15, 22, 23].
Therefore, to better understand whether the treatment
gap exists between the SES groups in patients with ACS,
we aimed to synthesise results from studies that reported
on the effect of SES on discharge prescription of medica-
tions for patients with ACS.
Methods
Pre-specified methods for this systematic review were
registered in the International prospective register of
systematic reviews (PROSPERO) Registry (registration
no.: CRD 42016048503). Studies were eligible for
review if the participants were patients with a
diagnosis of ACS, stratified by patients’ SES and the
studies reported the rate or the odds of any of the
prescription of guideline-recommended ACS medica-
tions (aspirin, antiplatelet, ACEi/ARB, beta blocker
and/or statin/lipid-lowering therapy) at hospital
discharge. Due to the nature of the question, only
observational studies were included. There were no
language or date restrictions. The Preferred Reporting
Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines were used to report this system-
atic review [24].
Search strategy/data extraction
The search strategy was conducted after consultation
with librarians. The databases searched for this review
were MEDLINE (1946 - 6th April 2016), EMBASE
(1974 - 6th April 2016) and Global Health (1973 -
6th April 2016), via Ovid. Search terms related to
ACS, SES (employment, occupation, income and
education) and recommended medications (aspirin,
other antiplatelet, beta blocker, ACE/ARB, and statin/
lipid-lowering therapy) were used (Appendix 1) to
find all studies that compared the prescription of
recommended medication for ACS patients by SES.
Additional articles were obtained through manual
search of reference lists. Duplicates were removed
using a reference management system (Endnote X7)
and manual assessment. All remaining studies were
screened initially by reading the titles and abstracts,
and then, the relevant studies were selected and the
full texts of the studies were read to determine if they
met the inclusion criteria. The literature search was
completed by one author (KH) and validated by a
second author (SR). These two authors performed
study selection independently, and any disagreement
was resolved through discussion.
Data were extracted by one author (KH) and check
by a second author (SR) for accuracy. Adjusted or
unadjusted prevalence ratios and rates of medication
prescription by SES groups were extracted. Other
extracted data included study details (authors’ name,
aim, year of recruitment, country of recruitment),
ACS diagnosis (MI or ACS), the definition of SES,
the number of SES groups compared, prescribed
medications.
Risk of bias
The Newcastle-Ottawa Scale was used to assess the
risk of bias of the observational studies for the review
and the meta-analyses [25]. The assessment was
performed independently by two authors (KH, SR).
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The components assessed were Selection (four items
of assessment), Comparability (one item) and
Outcome (three items), where a study can be awarded
a maximum of one star for each item of assessment
within the Selection and Outcome components, and a
maximum of two starts for Comparability.
Outcomes
Outcomes of interest were the prescription of recom-
mended medications for ACS management, which were
aspirin, other antiplatelet, beta blocker, ACEi/ARB, and
statin/other lipid-lowering medications, separately and
combined. Varying definitions of SES were accepted if
the measure of SES was credible and categorised.
Regardless of the number of SES categories reported,
only the lowest and the highest groups were compared
for this review. The reason for this was that the studies
included in this review reported between two and four
SES groups, where three of the seven studies only
reported two SES groups. For the four studies that re-
ported on more than two groups of SES, the prescription
rate across all SES groups have been included in the
Appendix (Appendix 2).
For studies that compared the prescription of
medication using more than one definition of SES,
the most frequently used measure of SES among
the other studies was selected to reduce the
diversity of the SES definitions when pooling the
studies.
Statistical analysis
A priori, the outcome for this study was defined as
the pooled prescription ratio comparing the lowest
(most deprived) and highest (least deprived) individ-
ual/neighbourhood level SES groups of those groups
reported in each study. Sensitivity analyses was per-
formed by including the results from comparing be-
tween country level SES. For the studies that reported
the rate of recommended medication prescription
only, the prescription ratio (PR) and corresponding
95% confidence interval (CI) for the prescription of
recommended medication between the lowest and the
highest SES groups were estimated from the rate of
prescription and the sample size, for each study using
the following formulae:
Prescription ratio ¼ p1
p2
Where p1 = proportion of patients in the lowest SES
group with a prescription of medication; and.
p2 = proportion of patients in the highest SES group
with a prescription of medication.
95%confidence interval ¼ e ln P^Rð Þ1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1−x1ð Þ=x1
n1
þ n2−x2ð Þ=x2n2
q
Where n1 = total patients in the lowest SES group.
n2 = total patients in the highest SES group.
x1 = number of patients in the lowest SES group with
a prescription of medication.
x2 = number of patients in the highest SES group with
a prescription of medication.
Meta-analysis was performed using the random
effects model to pool the estimates. For medications
that had been examined in more than two studies, I2
was used to quantify heterogeneity, and Cochran’s Q
test to test the heterogeneity (p-value of <0.1 will be
considered statistically significant for the Q test).
Publication bias was tested using the funnel plot and
Egger’s test.
Results
Of 252 articles found from the initial search, 14
articles were assessed in full-text and seven articles
met the eligibility criteria to be included in the sys-
tematic review (Fig. 1). The measures of SES in-
cluded income, education, deprivation score and
country income level (Table 1). Characteristics of the
seven articles are shown in Table 1. Two of the
studies analysed different medications from one
dataset [12, 22]. One study focused on international
variations, and countries were compared according
to SES; in this instance, the outcomes for the
country with the low/middle SES was compared to
that with the high as stratified in the original article
[18]. Four studies focused on population subgroups
within regions and compared neighbourhoods within
these regions [12, 14, 22, 23]. Two studies reported
patient level SES [13, 16]. In total, the seven articles
included ACS 41,462 patients in the lowest and
highest SES groups together, of which 20,986 were
from the lowest group. Of the total, 392 patients
were stratified by country level income, and 127 of
those were from the lowest income countries [15].
In regards to the outcomes reported, five articles ex-
amined the prescription of aspirin [12–15, 23], five
articles on beta blocker [12–15, 23], three articles on
ACE [12, 13, 15], three articles on lipid lowering
therapy [15, 16, 22] and two articles on combination
of medications [12, 15].
Aspirin prescription
The four studies that reported the aspirin prescrip-
tion at discharge by the individual/neighbourhood
level SES groups included 36,427 (18,386 in the
lowest SES group) patients [12–14, 23]. Overall,
there was no significant difference in the likelihood
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of prescription between the lowest and the highest
SES groups (PR (95% CI): 0.97 (0.91, 1.03)) (Fig. 2),
however, considerable heterogeneity was observed
(I2 = 96%, p = 0.0001). The PR (95% CI) between
the country level SES was 1.01 (0.98, 1.05) [15].
The sensitivity analysis, which pooled the results
comparing the individual/neighbourhood and the
country level SES, also showed no difference in the
receipt of aspirin between the SES groups (0.98
(0.93, 1.03)).
Beta blocker prescription
The lowest SES group were less likely to receive
the prescription of beta blocker at discharge than
the highest SES group. Beta blocker was explored
in the same four studies comparing the individual/
neighbourhood level SES that reported the prescrip-
tion of aspirin [12–14, 23]. The pooled PR for the
prescription of beta blocker at discharge was 0.84
(95% CI: 0.73, 0.94) (Fig. 3) but the I2 statistic was
91%, indicating substantial heterogeneity between
the studies (p = 0.0001). The PR (95% CI) compar-
ing the lowest and the highest country level SES
was 0.93 (0.85, 1.02) [15]. The pooled PR was
similar even after including the country level SES
(0.86 (0.76, 0.95)).
Lipid-lowering therapy prescription
The total number of patients included in the two
studies that compared between the individual/neigh-
bourhood level SES and reported lipid lowering ther-
apy prescription at discharge was 4049, and of these,
2183 were in the lowest SES group [16, 22]. Both pa-
pers showed that patients in the lowest SES group
were less likely to receive the prescription compared
to the highest group, and the pooled PR was 0.80
(95% CI: 0.62, 0.98). The PR (95% CI) between the
country level SES was 0.85 (0.77, 0.94) [15]. The sen-
sitivity analysis also showed that patients in the low-
est SES group were less likely to receive the
prescription of lipid lowering medication compared to
those in the highest SES group (0.82 (0.72, 0.92)).
ACEi prescription
ACEi prescription at discharge was reported in two stud-
ies (9859 patients, and 5032 patients from the lowest SES)
[12, 13]. In contrast to the other medications, the lowest
SES group were more likely to receive the prescription of
Fig. 1 Flowchart of study selection. ACS: acute coronary syndrome; ACEi: angiotensin co-enzyme inhibitors
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ACEi than the highest SES group (PR (95% CI): 1.13 (1.05,
1.22)). Similar results were found when the country level
SES groups were compared, but the PR was greater be-
tween the lowest and the highest SES groups (1.36 (1.21,
1.52)) [15]. Therefore, the PR from the sensitivity analysis
was moderately greater (1.21 (1.05, 1.38)).
Composite medications
Two studies compared the prescription of composite
medications. One study compared the neighbourhood
level SES and defined composite medications as the pre-
scription of two or more of aspirin, beta blocker and
ACEi [12], and the other study compared the country
level SES and defined it as the prescription of aspirin,
clopidogrel, statin and beta blocker [15]. The two studies
found discordant results: the first study found no differ-
ence in the prescription of medications by SES whereas
the second study reported that patients in the lowest
SES group have 70% lower odds of receiving the pre-
scription of medications compared to the highest SES
group (odds ratio (95% CI): 0.3 (0.2, 0.6)).
Risk of bias
Overall, the risk of bias was low. Most articles clearly re-
ported the cohort selection, data collection, comparabil-
ity of cohorts and assessment of outcome (Table 2). All
studies obtained exposures from either medical records
or a structured interview, and all studies, except one, re-
ported to have collected the outcome data from the
medical records. However, five of the seven articles did
not adjust for confounders because finding the associ-
ation between the SES groups and prescription of rec-
ommended ACS medications were not the primary aim
of their study, increasing the risk of bias. Two criteria in
the Outcome section regarding the follow-up were ir-
relevant for the objective of the current study, therefore,
were not included in the assessment (Table 2). Also,
there was no indication of publication bias (aspirin:
p = 0.910; beta-blocker: p = 0.468; statin: p = 0.393; and
ACEi: p = 0.827).
Two criteria regarding the follow-up were irrelevant
for the objective of the current study, therefore, were
not included in the assessment (denoted as “-”).
Fig. 3 Meta-analysis of the effect of socioeconomic status (lowest vs. highest) on prescription of beta blocker. CI: confidence interval
Fig. 2 Meta-analysis of the effect of socioeconomic status (lowest vs. highest) on prescription of aspirin. CI: confidence interval
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Discussion
The current systematic review has assessed and analysed
seven articles that compared the likelihood of prescription
of guideline-recommended medications (aspirin, beta
blocker, lipid-lowering therapy and ACEi) to ACS patients
between the SES groups at hospital discharge. We found
that individual/neighbourhood level SES had an effect on
the prescription of beta blocker, statin and ACEi, but
not aspirin. Beta blocker and statin were 16% and
20% less likely, respectively, to be prescribed to the
lowest SES group than to the highest SES group. In
contrast, ACEi was 13% more likely to be prescribed
to patients in the lowest SES group compared to
those in the highest SES group. The study that com-
pared between the country level SES showed similar
results, where the lowest SES group were less often
prescribed beta blocker and lipid lowering therapy
but more often prescribed ACEi than the highest
SES group [15].
The opposing effect of SES on two blood pressure
lowering medications (ACEi and beta blocker) was an
interesting finding given that both medications are
indicated for patients with hypertension and heart
failure. It is widely known that ACS risk factors,
including hypertension, heart failure and diabetes, are
more prevalent in patients with low SES [26, 27],
which was also found in the studies included in this
review. Although ACEi and beta blocker are both
similarly effective in controlling blood pressure [28],
ACEi is recommended for patients with hypertension,
diabetes and kidney disease, whereas, the use of beta
blockers has been discouraged in patients with dia-
betes due to the masking of hypoglycaemic symptoms
[29]. The increased prevalence of comorbidities in
lower SES groups may be one of the reasons why
ACEi was more often prescribed to the lowest than
the highest SES group.
Three of the seven studies included in this review
have explored the effect of a second socioeconomic
measure, which also showed that patients with lower
SES tended to receive prescriptions to recommended
medication less often compared to those with higher
SES. Gerber et al. reported a significant proportional
difference in the percentage prescribed beta blockers
between those with <12 years (32%) and ≥12 years
(38%) of education [13]. However, the prescriptions
of aspirin and ACEi were comparable (80% vs. 83%
and 22% vs. 20%, respectively). After adjustment,
Foraker et al. found that patients with Medicaid
(predominantly those with low income) were less
likely to receive aspirin (OR (95% CI): 0.92 (0.87,
0.98)) and composite medications (0.94 (0.88, 1.00)),
although the prescription of composite medications
were marginally significant with the upper CI on
1.00 [12]. The likelihood of being prescribed beta
blocker and ACEi were not statistically significant.
Kawecka-Jaszcz et al. explored the effect of employ-
ment on the prescription of lipid-lowering therapy,
and found that the proportion of those who were
prescribed lipid-lowering medication was lower by
8% for the unemployed than for the employed, how-
ever, the difference was not significant (39% vs. 47%;
p > 0.05) [16]. Although the percent difference be-
tween the SES groups varied slightly between the so-
cioeconomic measure used in the meta-analyses and
the second socioeconomic measure, the results were
comparable between different measures of SES. Re-
gardless of the type of the SES, the rate of aspirin,
beta blocker and lipid-lowering therapy prescriptions
were lower for patients in the lowest SES group,
whereas, the rate of ACEi prescription was higher
for patients in the highest SES group.
ACS, being a disease with a high incidence of recurrent
adverse clinical events, has recommended guidelines and
clinical pathways in place to help clinicians provide op-
timal treatment to every patient. However, despite these
inclusive recommendations, applicable to all patients, it
is unclear as to why variation in the prescription of
guideline-recommended medications between the SES
groups is often found in studies. Reasons might include
physicians’ clinical management that varies to accom-
modate patients’ financial status to lessen their burden,
as was reported to have been done in primary care [30].
Further investigation would be needed to find factors
that cause the discrepancy in the prescription of recom-
mended medication at discharge to be able to find ways
to provide equitable care for all patients and prevent a
secondary event.
There were limitations to this review. First, the
reviewed studies used observational data, which may
be subject to reporting bias. Second, we could only
compare between the lowest and the highest SES
groups in the meta-analysis as some studies reported
only two SES groups, therefore could not use
complete data from all studies. Third, the studies being
Table 2 Risk of bias
First author, year Selection
(out of 5)
Comparability
(out of 2)
Outcome
(out of 1)
Barakat et al., 2001 [23] **** * - -
Foraker et al., 2010 [12] **** ** * - -
Gerber et al., 2008 [13] **** * * - -
Kawecka-Jaszcz et al., 2003 [16] **** * * - -
Kitzmiller et al., 2013 [22] **** ** * - -
Rao et al., 2004 [14] **** * * - -
Shimony et al., 2014 [15] **** * * - -
Newcastle-Ottawa quality assessment scale
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observational, comparison of likelihoods of the outcome
after adjusting for covariates would have been ideal, how-
ever, due to the limited number of studies that aimed to
find the effect of SES on the prescription of medications,
studies with unadjusted data have also been included in
the meta-analysis. Fourth, also because of the small num-
ber of studies found for this systematic review, the defini-
tions and types of SES (deprivation score, income and
education) and the level of SES (individual, neighbour-
hood and country) varied across the studies. Although
subgroup analysis for the different types of SES could not
be done, the results from the studies that reported the ef-
fect of two different types of SES on prescription of medi-
cations suggests that the different types of SES may not
affect the study results greatly. Fifth, the studies included
for this review may be limited due to our refined search
terms. Sixth, the power to test for asymmetry and hetero-
geneity was substantially low with only 2–4 studies for
each meta-analysis [31, 32].
Conclusion
Prescriptions of guideline-recommended secondary pre-
vention medications at discharge varied according to the
SES of patients. Patients from the lowest SES group were
less often prescribed beta blocker and statin, but more
often prescribed ACEi compared to those from the highest
SES group. Adherence to guidelines and policies needs to
be promoted to reduce the discrepancies between the low-
est and the highest SES groups.
Appendix 1
1. exp. Acute coronary syndrome/.
2. exp. myocardial infarction/.
3. exp. unstable angina/.
4. ACS.tw.
5. 1 or 2 or 3 or 4.
6. exp. patients/.
7. exp. hospital/.
8. 5 and 6 and 7.
9. Socioeconomic.tw.
10. socio?economic.tw.
11. SES.tw.
12. Socio economic.tw.
13. Employment.tw.
14. Education*.tw.
15. Educational status.tw.
16. Income*.tw.
17. Unemployment.tw.
18. Occupations.tw.
19. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18.
20. Aspirin.tw.
21. Antiplatelet.tw.
22. Clopidogrel.tw.
23. Ticagrelor.tw.
24. Prasugrel.tw.
25. Beta?blocker.tw.
26. Blood pressure lowering.tw.
27. BP-lowering.tw.
28. Statin.tw.
29. (Lipid adj3 lowering).tw.
30. ACE.tw.
31. ACEi.tw.
32. ACE-i.tw.
33. angiotensin converting enzyme inhibitor.tw.
34. arb.tw.
35. Angiotensin II receptor blockers.tw.
36. discharge*.tw.
37. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31 or 32 or 33 or 34 or 35.
38. 36 and 37.
39. 5 and 19 and 38
Table 3 Prescription of medication by socioeconomic groups for studies that reported more than two socioeconomic groups
Study No of SES groups Medication Group 1 (%) Group 2 (%) Group 3 (%) Group 4 (%) P-value
Barakat et al. 4 Aspirin 91 271 267 272 0.2
Beta blocker 136 119 103 122 >0.2
Foraker 3 Aspirin 83 79 80 NA
Beta blocker 62 72 75 NA
ACEi 56 47 46 NA
Kitzmillera 3 Lipid lowering medication 0.89 (0.79, 1.01) 0.98 (0.91, 1.07) Reference
Rao 3 Aspirin 69.7 69.6 68.6 >0.01
Beta blocker 33.3 38.5 42.7 <0.01
SES socioeconomic status, ACEi angiotensin co-enzyme inhibitor
Group 1 refers to the most disadvantaged SES group and Group 3/4 refers to the least disadvantaged SES group
aReported as prevalence ratio (95% confidence interval)
Appendix 2
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CHAPTER SIX 
The effect of socioeconomic disadvantage on in-hospital care and 
outcomes for ACS patients 
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PREFACE TO THE CHAPTER 
Further to Chapter 5, this chapter addresses Aim 2 of this thesis and explores the effect 
of SES on the care and clinical events during ACS admissions in Australian hospitals. 
CONCORDANCE registry data were used for this study. The case report forms and the 
ethics approval for CONCORDANCE are provided in Appendix 2. This chapter consists of 
a manuscript titled: Socioeconomic equity in the receipt of in-hospital care and outcomes 
in Australian acute coronary syndrome patients: the CONCORDANCE registry. 
 
Contrary to the findings from the systematic review of the receipt of individual 
medications in Chapter 5, this chapter suggests that the SES of patients with ACS has no 
impact on the receipt of a combination of the guideline-recommended medications at 
discharge and other care, including coronary angiogram, revascularisation and cardiac 
rehabilitation referral, in Australian public hospitals. However, patients in the lower SES 
groups are more likely to have in-hospital MACE than those in highest SES groups. 
Although this chapter provides reassuring evidence that equitable care is provided to 
patients regardless of their SES, it also calls for further research to help close the gap 
regarding the rate of MACE.  
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Background Socioeconomic status (SES) is a social determinant of both health and receipt of health care services, but its
impact is under-studied in acute coronary syndrome (ACS). The aim of this study was to examine the
influence of SES on in-hospital care, and clinical events for patients presenting with an ACS to public
hospitals in Australia.
Methods Data from 9064 ACS patient recordswere collected from 41 public hospitals nationwide from 2009 as part of
the Cooperative National Registry of Acute Coronary Syndrome Care (CONCORDANCE) registry. For this
analysis, we divided the cohort into four socioeconomic groups (based on postcode of usual residence) and
compared the in-hospital care provided and clinical outcomes before and after adjustment for both patient
clinical characteristics and hospital clustering.
Results Patients were divided into four SES groups (from the most to the least disadvantaged: 2042 (23%) vs. 2104
(23%) vs. 1994 (22%) vs. 2968 [23_TD$DIFF](32%)). Following adjustments for patient characteristics, there were no
differences in the odds of receiving coronary angiogram, revascularisation, prescription of recommended
medication, or referral to cardiac rehabilitation across the SES groups (p = 0.06, 0.69, 0.89 and 0.79, respec-
tively). After adjustment for clinical characteristics, no associations were observed for in-hospital and
cumulative death (p = 0.62 and p = 0.71, respectively).
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Introduction
Socioeconomically disadvantaged people may experience
significant health inequities in medical care and outcomes
after suffering an acute coronary syndrome (ACS). Acute
coronary syndrome is a high risk condition which includes
ST-elevation myocardial infarction (STEMI), non-ST-eleva-
tion myocardial infarction (NSTEMI) and unstable angina
(UA). In Australia, it not only has an estimated direct health
care system cost of $1.8 billion, but is also a factor in nearly
10,000 deaths [1]. Although the number of deaths due to ACS
is decreasing, the number of hospitalisation continues to
increase (79.5% for acute MI and 33.1% for UA between
1993–94 and 2007–08) [2].
Socioeconomic status (SES) impacts health in many ways.
Previous studies have found the negative correlation
between SES and various conditions including heart failure
(HF), chronic kidney disease, stroke and mental illness [3–6].
Similar findings have been reported in patients with ACS,
however, results vary. In the United Kingdom (UK), Canada
and France, SES was not found to affect the receipt of in-
hospital ACS care, and short-term or long-term mortality [7–
10]. In the United States (US), patients with lower SES were
less likely to receive care andmanagement andmore likely to
die compared to those with higher SES [11,12].
However, in Australia, conflicting results have been
reported [13–16]. This raised questions about the care that
Australian ACS patients receive. Therefore, our aim was to
examine the effect of SES on in-hospital care, and further,
clinical events for patients presenting with an ACS using a
contemporary dataset in Australia.
Methods
Study Design and Data
Data used for this study were from the Cooperative National
Registry of Acute Coronary Syndrome Care (CONCOR-
DANCE) registry. CONCORDANCE is an ongoing, prospec-
tive, observational study that provides continuous real-time
reporting on the clinical characteristics, management and
outcomes of patients admitted to Australian hospitals with
ACS. The first 10 patients aged 18 years or older, who pre-
sented to a hospital with symptoms of an ACS together with
significant electrocardiographic changes, elevated cardiac
enzyme levels, or newly documented coronary heart disease
per month were recruited since 2009 from 42 public hospitals
nationwide. The 42 hospitals are representative of regional
and metropolitan acute care facilities, with a range of clinical
and treatment characteristics, procedural services and hos-
pital systems. The study was approved by Sydney Local
Health District Concord Human Research Ethics Committee,
and an opt-out consent has been granted.
Data were collected frommedical records and entered into
a web-based electronic case report form, which includes
details of pre-hospital assessment and management, demo-
graphics, admission diagnosis, medical history, in-hospital
investigations and management, and in-hospital morbidity
and mortality. The presenting clinical characteristics to be
able to calculate the Global Registry of Acute Coronary
Events (GRACE) risk score, which is a score proved to have
a high capacity to predict mortality or myocardial infarction
(MI), were collected [17]. At 6-months post discharge, a
follow-up by telephone collects data about vital status, med-
ication compliance, participation in cardiac rehabilitation
and CVD risk reduction interventions.
Patient Stratification According to SES
and Outcomes
The Index of Relative Socio-economic Disadvantage (IRSD),
one of the census-based Socio-Economic Indexes for Areas
(SEIFA) classifications derived by Australian Bureau of Sta-
tistics, was used to attribute SES to each patient [18]. Patient’s
postcode of usual residence was matched with the IRSD
postcode. IRSD deciles, which is a nationwide distribution
of SES scores divided into 10 equal groups, were further
stratified into four groups, where Group 1 includes 20% of
the lowest SES areas and Group 4 includes 40% of the highest
SES areas.
The outcomes of interest encompassed in-hospital care and
clinical events. Outcomes for the in-hospital care were: the
documented receipt of in-hospital coronary angiogram,
revascularisation (percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG)), guide-
line-recommended discharge medication prescription (four
or five of aspirin, other oral antiplatelet therapy, statin/other
lipid-lowering therapy, beta blocker and angiotensin con-
verting enzyme inhibitor/angiotensin receptor blocker),
and cardiac rehabilitation referral. Outcomes for the clinical
events were: major adverse cardiovascular events (MACE;
MI, stroke or HF), all-cause in-hospital death and all-cause
cumulative death (from admission to 6-month follow-up).
However, the most disadvantaged group were 37% more likely to have a major adverse cardiovascular
event (MACE) than the least disadvantaged group (OR (95% CI): 1.37 (1.1, 1.71), p = 0.02) driven by
incidence of in hospital heart failure.
Conclusions Although there may be gaps in the delivery of care, this delivery of care does not differ by patient’s SES. It is
an encouraging affirmation that all patients inAustralian public hospitals receive equal in-hospital care, and
the likelihood of death is comparable between the SES groups.
Keywords Acute coronary syndrome  Socioeconomic status  In-Hospital care  Clinical events
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Statistical Analysis
Generally, hospital clustering effect exists as there is a posi-
tive covariance between patients in the same hospital due to
the similarities in treatment (similar management pathways)
and demographics (patients admitted to local hospitals in
specific geographic zones), and, therefore, patients within a
hospital lack independence [19]. Therefore, this hospital
clustering effect was adjusted for all the analyses. Patient
demographics, medical history, in-hospital management and
clinical events were compared between the four SES groups
using the Rao-Scott chi-square test for categorical variables
and univariable multilevel logistic regression model for con-
tinuous variables. Multiple adjusted multilevel logistic
regression models with random intercept were used for each
of the outcome to estimate the adjusted odds ratios (ORs) and
corresponding 95% confidence intervals (CIs) between the
SES groups. The cohort analysed and the independent var-
iables included in the model differed for each outcome. For
the receipt of coronary angiogram, all patients were included
in the model, and the independent variables included were
SES (four groups), age groups (<55 years, 55–64 years, 65–74
years and 75 years), gender, private insurance status, diag-
nosis (STEMI, NSTEMI or UA), history of comorbidities,
history of renal failure, history of CVD, smoking status (cur-
rent vs. not) and killip class (>1 vs. 1). For revascularisation,
the same independent variables were used in the model, but
the analysis was restricted to those who received in-hospital
coronary angiogram. For the receipt of guideline-recom-
mendedmedications, only the patients discharged alivewere
included in the analysis, and revascularisation and MACE
were included as independent variables in addition to the
Table 1 Demographic and medical history by SES groups.
Variable Level SES group 1
n = 2093 (23%)
n (%)
SES group 2
n = 2147 (23%)
n (%)
SES group 3
n = 2030 (22%)
n (%)
SES group 4
n = 2968 (32%)
n (%)
Overall
n = 9238
n (%)
p-Value
(trend)
IRSD score Median (IQI) 900 (863, 923) 961 (952, 973) 996 (987, 1006) 1053 (1034, 1068) 986 (945, 1029)
Patient Demographic
and Medical History
Age (years) Mean (SD) 63 (14) 66 (13) 65 (13) 65 (14) 65 (14) <0.001
Sex Male 1454 (70) 1475 (69) 1427 (70) 2189 (74) 6545 (71) 0.001
Private health insurance 282 (15) 528 (26) 473 (26) 963 (34) 2246 (26) <0.001
Diagnosis STEMI 665 (32) 622 (29) 603 (30) 982 (33) 2872 (31)
Non-STEMI 1055 (50) 1061 (49) 956 (47) 1471 (50) 4543 (49)
Unstable
Angina
373 (18) 464 (22) 471 (23) 515 (17) 1823 (20)
Killip class on presentation 1 1811 (87) 1907 (89) 1808 (89) 2637 (89) 8163 (88)
2 219 (11) 184 (9) 170 (8) 257 (9) 830 (9)
3 52 (3) 43 (2) 39 (2) 48 (2) 182 (2)
4 11 (0.5) 13 (0.6) 13 (0.6) 26 (0.9) 63 (0.7)
GRACE risk score (Fox) Median (IQI) 104 (82, 127) 106 (86, 131) 104 (83, 127) 106 (85, 127) 105 (84, 128) 0.46
Symptom onset to hospital
presentation time (hours)
STEMI:
Median (IQI)
1.9 (1.0, 4.7) 2.0 (1.0, 5.2) 1.8 (1.0, 4.4) 1.7 (1.1, 3.7) 1.8 (1.0, 4.4) 0.32
NSTEMI/UA:
Median (IQI)
2.8 (1.3, 9.0) 2.8 (1.3, 7.3) 2.8 (1.3, 7.4) 2.6 (1.3, 7.4) 2.7 (1.3, 7.7) 0.41
Previous Angiogram 701 (34) 757 (35) 721 (36) 1008 (34) 3187 (35) 0.47
Current Smoker 781 (38) 531 (25) 564 (28) 740 (25) 2616 (28) <0.001
History of Chronic
Renal Failure
241 (12) 172 (8) 186 (9) 203 (7) 802 (9) <0.001
History of CVDa 1075 (51) 1168 (54) 1067 (53) 1418 (48) 4728 (51) 0.20
History of comorbiditiesb 1567 (75) 1557 (73) 1460 (72) 2003 (68) 6587 (71) <0.001
Abbreviations: SD: standard deviation; IQI: interquartile intervals; STEMI: ST elevation myocardial infarction; CVD: cardiovascular disease; SES: socioeconomic
status; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft.
Group 1 refers to the most disadvantaged SES group, and Group 5 refers to the least disadvantaged SES group.
aHistory of CVD: prior myocardial infarction, prior atrial fibrillation, peripheral artery disease, prior PCI, prior CABG, prior stroke, prior chronic heart failure or
prior exertional angina.
bHistory of comorbidities: prior chronic renal failure, prior major bleeding, cardiac arrest at admission or dementia.
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independent variables listed above. For cardiac rehabilita-
tion, only the patients discharged alive were analysed, and
the independent variables included the covariates in the
model for the receipt of guideline-recommended medica-
tions, and in addition, the guideline-recommended medica-
tion variable itself. The three clinical outcomes were adjusted
usingmultiple adjustedmultilevel logistic regressionmodels
with random intercepts. All patients were included in ana-
lysing the clinical outcomes, and the independent variables
were: SES (four groups), age groups (<55 years, 55–64 years,
65–74 years and75 years), gender, private insurance status,
diagnosis (STEMI, NSTEMI or UA), history of comorbidities,
history of renal failure, history of CVD and smoking status
(current vs. not), revascularisation and killip class (>1 vs. 1).
The adjusted ORs and the corresponding 95% CIs for the SES
groups for each of the outcomes were plotted in forest plots.
Data were analysed using SAS 9.4 (SAS Institute Inc. Cary,
North Carolina, US).
Results
In total, 9238 ACS patients with SES available were included
in the analyses. The mean age of the total cohort was 65 years
(SD: 14 years), and 6545 (71%) were male (Table 1). Of the
9238 patients, 2093 (23%) were in Group 1 (the most disad-
vantaged), 2147 (23%) were in Group 2, 2030 (22%) were in
Group 3, and 2968 (32%) were in Group 4 (the least disad-
vantaged). Patients in lower SES groups were younger
(p < 0.001) (Table 1). The proportion of women decreased
(p = 0.001), but the proportion of patients with private health
insurance increased from themost to the least disadvantaged
group (p < 0.001). The median time from symptom onset to
hospital presentation were comparable between the SES
groups for STEMI and NSTEMI/UA patients (p = 0.32 and
0.41, respectively), but inverse trends in the rate of current
smoking (p < 0.001), chronic renal failure (p < 0.001), and
history of comorbidities (p < 0.001) were found across the
groups.
In-Hospital Care
Before adjustment, the receipt of coronary angiogram
decreased from Group 1 to Group 3, but increased in Group
4 (p = 0.01) (Table 2). No trend was found in the rates of
receipt of revascularisation, prescription of guideline-recom-
mended medications at discharge and cardiac rehabilitation
referral across the SES groups. After adjusting for the effect of
patient characteristics, no significant trend was found in the
likelihood of receiving coronary angiogram, revascularisa-
tion, prescription of guideline-recommended dischargemed-
ications and referral to cardiac rehabilitation between the SES
groups (Figure 1).
Clinical Events
In total, 1020 (11%) had in-hospital MACE (68% male), 331
(4%) died in hospital (66% male) and 566 (8%) died between
admission and 6-month follow-up (66% male). There was a
decreasing trend in the rate of in-hospital MACE from the
most to the least disadvantaged SES group (p < [24_TD$DIFF]0.001), how-
ever, no differences were found in the rate of in-hospital
death and cumulative death in the univariable comparison
Table 2 The receipt of in-hospital care and clinical events by SES groups.
Variable SES group 1
n = 2093 (23%)
n (%)
SES group 2
n = 2147 (23%)
n (%)
SES group 3
n = 2030 (22%)
n (%)
SES group 4
n = 2968 (32%)
n (%)
Overall
n = 9238
n (%)
p-Value
(trend)
In-Hospital Care
Coronary angiogram 1689 (81) 1709 (80) 1577 (78) 2446 (82) 7421 (80) 0.01
Revascularisation*,a 1112 (66) 1128 (66) 1052 (67) 1698 (69) 4990 (67) 0.32
4 or more of 5 medications** 1512 (75) 1499 (73) 1458 (74) 2222 (78) 6691 (75) 0.29
Cardiac Rehabilitation Referral** 1274 (63) 1397 (68) 1325 (68) 1872 (66) 5868 (66) 0.09
Clinical Events
MACEb 284 (14) 231 (11) 236 (12) 269 (9) 1020 (11) <0.001
Myocardial Infarction 61 (3) 67 (3) 57 (3) 61 (2) 246 (3) 0.35
Stroke 15 (0.7) 13 (0.6) 16 (0.8) 14 (0.5) 58 (0.6) 0.39
Heart Failure 218 (11) 169 (8) 178 (9) 212 (7) 777 (9) 0.001
In-Hospital Death 70 (3) 80 (4) 65 (3) 116 (4) 331 (4) 0.62
Cumulative [5_TD$DIFF] eath 122 (8) 140 (8) 117 (8) 187 (8) 566 (8) 0.71
Abbreviations: SES: socioeconomic status; MACE: major adverse cardiovascular events.
Group 1 refers to the most disadvantaged SES group, and Group 5 refers to the least disadvantaged SES group.
*Denominator: Patients undergone cardiac angiogram.
**Denominator: Patients who are alive.
aRevascularisation: percutaneous coronary intervention or coronary artery bypass graft.
bMACE: myocardial infarction, stroke or heart failure.
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(Table 2). After adjusting for patient demographic, clinical
characteristics and the receipt of cardiac procedures, the
significant trend remained in the odds of in-hospital MACE
across the SES groups; the odds ofMACEwas 37% greater for
Group 1 thanGroup 4 and 43% for Group 3 thanGroup 4 (OR
(95% CI): 1.37 (1.10, 1.71) and 1.43 (1.15, 1.79), respectively,
p = 0.02) (Figure 2). When MI, stroke and HF were assessed
independently, HF was the only cardiovascular event that
was associated with SES groups. The odds of HF were 36%
greater for Group 1 than Group 4 and 39% greater for Group
3 than Group 4 (1.36 (1.07, 1.74) and 1.39 (1.08, 1.79), respec-
tively, p = 0.02). In-hospital death and cumulative death
were not significantly correlated with SES (Figure 2).
Discussion
The results from this study suggest that ACS patients in the
lowest SES group receive comparable in-hospital care to
those in the highest SES group in Australian public hospitals.
On average, 80% of the ACS patients received coronary
angiogram, 67% received revascularisation, 75% received
the prescription of guideline-recommended medications at
discharge, and 66% received cardiac rehabilitation referral.
Although there may be gaps in the delivery of care, this
delivery of care does not differ by patient’s SES. Patient
demographic and clinical characteristics differed across the
SES groups. Although patients from lower SES areas were
generally younger, they were more likely to smoke, have a
history of CVD and comorbidities, which, together with
unmeasured clinical confounders, may have contributed to
the difference in the rate of MACE between the SES groups.
Importantly though, after accounting for the known differ-
ences in the patient characteristics at baseline and in-hospital
events, there was no evidence of disparities in care between
SES groups.
Despite the inverse relationship between the SES and the
likelihood of in-hospital MACE, these results provide an
Figure 1 Odds ratios and 95% confidence intervals between SES groups for in-hospital care adjusted for patient character-
istics and hospital clustering.
Abbreviations: CI: confidence interval.
Group 1 refers to the most disadvantaged and Group 4 refers to the least disadvantaged SES group.
Coronary angiogram and revascularisation are adjusted for age groups, gender, private insurance status, diagnosis, history
of comorbidities, history of renal failure, history of CVD, smoking status and killip class. Prescription of medications is
adjusted for age groups, gender, private insurance status, diagnosis, history of comorbidities, history of renal failure, history
of CVD, smoking status, killip class, revascularisation and major adverse cardiovascular event. Cardiac rehabilitation
referral is adjusted for age groups, gender, private insurance status, diagnosis, history of comorbidities, history of renal
failure, history of CVD, smoking status, killip class, revascularisation, major adverse cardiovascular event and prescription
of medications.
*Denominator: Patients undergone cardiac angiogram.
**
[3_TD$DIFF] enominator: Patients who are alive.
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encouraging affirmation of the equitable in-hospital care
provided to patients with ACS in the public healthcare sys-
tem. In Australia, government and non-government organ-
isations endeavour to set systems and guidelines in place to
minimise inequities in the management of ACS without
health inequities. Australian patients are fortunate to have
the free universal health care system, Medicare, which pro-
vides subsidies on prescription medications and public hos-
pital care [20]. Moreover, incentives are provided to
physicians and hospitals to encourage them to deliver the
optimal care. Examples include the fee-for-service for private
health insured patients and the activity-based fundingmodel
within the Australian public hospital system,where payment
is provided to physicians for the care delivered [21,22].
Studies from countries where a universal health care sys-
tem is available, including the UK, Canada and France report
similar findings to ours regarding the receipt of in-hospital
care. A Canadian and a UK study showed that the likelihood
of receiving aspirin and beta blocker at discharge, as well as
the recommended medications in hospital were comparable
across the SES groups [8,10]. There were no significant asso-
ciations between SES and the receipt of in-hospital coronary
angiogram and revascularisation [7,9,10]. Interestingly, stud-
ies from the US, where universal health care is not available,
have reported associations between SES and receipt of care.
A US study found that the lowest SES group were less likely
to be prescribed beta blocker (0.91 (0.86–0.97)) and more
likely to be prescribed ACE inhibitor (1.20 (1.10–1.30)),
[12]. Another US study has found that patients in the lowest
neighbourhood income quartile were 18% less likely to
receive angiogram (OR (95% CI): 0.82 (0.70, 0.96)) and 18%
less likely to receive any revascularisation (0.82 (0.73, 0.93))
compared to those in the highest neighbourhood income
quartile [11].
In Australia, studies have reported varied results regard-
ing the association between SES and receipt of care. A study
which analysed data from about 15–20 years ago reported
that patients in the lowest SES group were 25% less likely to
receive angiogram and 30% less likely to receive PCI than
those in the highest SES group, although there was no dif-
ference in receiving CABG [14]. In contrast, studies analysing
more recent data have found that patients with AMI had a
comparable likelihood of receiving coronary angiogram or
revascularisation [15]. Taken together, the results from the
past studies and our study suggest improved performance
by clinicians and hospitals over time to close the treatment
gap across SES groups in Australia.
Despite comparable delivery of evidence based care, we
found that the socioeconomic inequalities may exist for non-
fatal in-hospital MACE, which includedMI, stroke andHF in
the current analysis. A previous Australian report [23] found
that the rate ratio for hospitalisation due to cardiovascular
disease for the most disadvantaged group were 1.3 for the
least disadvantaged group for men, and 1.4 for women. The
hospitalisation rate due to coronary heart disease was 1.9
times higher for men and 2.4 times higher for women in the
Figure2 Odds ratios and 95% confidence intervals between SES groups for clinical events adjusted for patient characteristics
and hospital clustering.
Abbreviations: CI: confidence interval.
Group 1 refers to the most disadvantaged SES group, and Group 4 refers to the least disadvantaged SES group.
MACE: myocardial infarction, stroke or heart failure.
Each variable in the figure is adjusted for age groups, gender, private insurance status, diagnosis, history of comorbidities,
history of renal failure, history of CVD, smoking status, killip class and revascularisation.
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most disadvantaged group. It therefore appears that patients
from low SES are both more likely to be admitted to hospital
and have in-hospital events, particularly heart failure, fol-
lowing admission.
We did not find an association between SES and either in-
hospital death, or cumulative death from admission to 6-
month follow-up. These reassuring findings are supported
by other Australian studies which have not found a relation-
ship between death and SES [13,14,16]. Regardless of the
availability of universal health care system in countries of
previous studies, overseas studies found no significant dif-
ference in the rate of death in hospital, 30 days or 1 year since
admission across the SES groups for ACS patients [7–11].
However, a US study reported that among STEMI patients,
the odds of death were 17% greater for the most disadvan-
taged group compared to the least (OR (95% CI): 1.17 (1.11,
1.25)) [11].
This study has limitations. Firstly, it was based on obser-
vational data, where the baseline data were collected from
the medical records and the 6-month follow-up data were
self-reported (telephone or mail survey). Also, the IRSD
groups that we used to define SES are derived from the
average disadvantage of people living in an area under a
postcode. Although various factors such as income, lan-
guage, level of education, employment type and disability
have been incorporated to derive the socioeconomic ranks, it
is generalised and may not capture accurate SES of the
specific patients.
Conclusion
Acute coronary syndrome patients in Australian public hos-
pitals receive comparable in-hospital care across SES strata,
and the likelihood of death is comparable between the SES
groups. However, patients in the lowest SES group are more
likely to have non-fatal in-hospital CVD events, particularly
heart failure, than those in the highest SES group. Further
exploration is needed to determine the factors associated
with this disparity.
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CHAPTER SEVEN 
Variation in in-hospital care and outcomes between English speaking 
and non-English speaking ACS patients  
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PREFACE TO THE CHAPTER 
This chapter compares the provision of in-hospital care and outcomes between the 
limited English proficient (LEP) and English proficient (EP) patients with ACS in 
Australian hospitals. It addresses Aim 3 of this thesis, and SNAPSHOT ACS data were 
used to do this. The case report form and the ethics approval are provided in Appendix 
1. This chapter consists of an article titled: Is there inequity amongst patients with acute 
coronary syndrome who are proficient and not proficient in English language in terms of 
their in-hospital care: Analysis of the SNAPSHOT ACS Study.  
 
The language barrier between patients and clinicians may affect the in-hospital care and 
clinical outcomes, but with the growth of cultural and linguistic diversity in Australia, 
whether English proficiency influences the receipt of care and the likelihood of clinical 
events in Australian hospitals is unclear. Provision of equitable care to both LEP and EP 
patients with ACS was observed in Australian and New Zealand hospitals. The rate of 
guideline-recommended medication, coronary angiography, reperfusions and the 
lifestyle modification advice given to LEP and EP patients were comparable. This 
chapter provides an encouraging affirmation of the guidelines and policies in place to 
provide quality care for all. 
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Is There Inequity in Hospital Care Among
Patients With Acute Coronary Syndrome
Who Are Proficient and Not Proficient in
English Language?
Analysis of the SNAPSHOT ACS Study
Karice K. Hyun, MAppStats; Julie Redfern, PhD; Mark Woodward, PhD; Tom Briffa, PhD;
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Background: The provision of equitable acute coronary syndrome (ACS) care in Australia and New Zealand
requires an understanding of the sources of variation in the provision of this care. Objective: The aim of this study
was to compare the variation in care and outcomes between ACS patients with limited English proficiency (LEP)
and English proficiency (EP) admitted to Australian and NZ hospitals. Methods: Data were collected from 4387
suspected/confirmed ACS patients from 286 hospitals between May 14 and 27, 2012, who were followed for
18 months. We compared hospital care and outcomes according to the proficiency of English using logistic
regressions. Results: The 294 LEP patients were older (70.9 vs 66.3 years; P < .001) and had higher prevalence
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of hypertension (71.1% vs 62.8%; P = .004), diabetes (40.5% vs 24.3%; P < .001), and renal impairment
(16.3% vs 11.1%; P = .007) compared with the 4093 EP patients. Once in hospital, there was no difference in
receipt of percutaneous coronary intervention (57.0% vs 55.4%; P = .78) or coronary artery bypass graft surgery
(10.5% vs 11.5%; P = .98). After adjustment for medical history, there were no significant differences (P > .05)
between the 2 groups in the risk of major adverse cardiovascular events and/or all-cause death during the index
admission and from index admission to 18months. Conclusions: These results suggest that LEP patients admitted to
Australian or New Zealand hospitals with suspected ACS may not experience inequity in hospital care and outcomes.
KEY WORDS: acute coronary syndrome, in-hospital care, language barriers
An acute coronary syndrome event includes STelevation myocardial infarction, non-ST elevation
myocardial infarction, and unstable angina and repre-
sents a high-risk and potentially life-threatening pre-
sentation to the emergency department and beyond.
Hospitalization with acute coronary syndrome accounts
for significant morbidity and mortality in Australia
and New Zealand. In Australia, acute coronary syn-
drome resulted in 11 380 deaths in 2007 and 95 000
hospitalizations in 2008.1 Between 1993Y1994 and
2007Y2008, the number of acute coronary syndrome
hospitalizations has increased by 79.5% for acute
myocardial infarction and 33.1% for unstable angina.
National data on the total number of acute coronary
syndrome deaths were not available from New Zealand,
but 5339 deaths in 2012 were because of ischemic
heart disease and approximately 21 500 patients were
hospitalized because of acute coronary syndrome in
2007.2,3 With the population aging and the acute cor-
onary syndrome hospitalization rate increasing in both
jurisdictions, acute coronary syndrome represents a
growing social and economic burden.
The World Health Organization has reported health
inequities in ethnicity, socioeconomic status, gender,
education, and employment status.4 For patients whose
ethnicity is different from that of their treating doctors,
effective communication between clinician and patient
is required to ensure that the former are aligned with
the latter’s preferences. This has been shown to be im-
portant for diagnosis, quality of care, early and late
outcome, adherence to recommendations, and patient
satisfaction.5,6 Language barriers during a hospital ad-
mission have the potential to disrupt the bidirectional
flow of information, and this is particularly relevant in
societies where some patients’ languages spoken at
home differ from the primary languages spoken within
the society. Previous studies from Canada and the
United States have suggested that limited English
proficient (LEP) and English proficient (EP) patients
have disparities in comorbidities, in-hospital mortality,
length of stay, cardiac rehabilitation attendance, and
readmission rates.7,8
Australia and New Zealand are multicultural coun-
tries, where there are a growing number of LEP people.
In Australia, the number of LEP people has increased
by 93 959 (17%) from 2006 to 2011,9 and in New
Zealand, by 5595 (6%) from 2006 to 2013.10 Australia
and New Zealand recognize the growth of cultural and
linguistic diversity, as well as the implication that this
has for healthcare. Although policies and models have
been put in place to provide equitable healthcare for
LEP and EP patients,11,12 the evidence for its imple-
mentation is lacking. The aim of this article is to ex-
plore whether proficiency in English influences receipt
of guideline-advocated in-hospital care and outcomes
in Australia and New Zealand.
Methods
Data and Patient Cohort
Data for this study were collected as part of the
SNAPSHOT ACS audit. Full details of the SNAP-
SHOT ACS study and the main primary results for
each country have been previously published.13,14 In
brief, SNAPSHOT ACS was a prospective, observa-
tional study that captured data across Australia and
New Zealand. All Australian and New Zealand hos-
pitals receiving patients with suspected acute coronary
syndrome (including public and private, metropolitan,
and rural) were identified via public records and health
networks and invited to participate in the study. Pa-
tients at participating hospitals were eligible if they
were admitted overnight with a suspected or confirmed
acute coronary syndrome event between May 14 and
27, 2012. Patients were enrolled and followed for the
duration of the acute care episode, including all contig-
uous transfers between hospitals (counted as a single
episode of care). Patients surviving to hospital discharge
were followed up at 18 months. Ethics approval was
obtained from all participating sites, with a slightly dif-
ferent consent process in Australia and New Zealand
because of relevant local ethical procedures. In Australia,
approval was provided for opt-out and consent was ac-
quired from all participants. In New Zealand, a process
of national ethical review was undertaken and a consent
waiver was approved for New Zealand participants.
Data and Outcomes
All data were entered into a customized database per-
mitting secure, Web-based entry for each patient. Data
collected included demographics, details of clinical pre-
sentation, and transfers between hospitals. Presenting
characteristics included clinical variables enabling the
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calculation of the Global Registry of Acute Coronary
Events (GRACE) risk score.15 This score is proven to
have high capacity to predict mortality. In-hospital
care was observed, including utilization of guideline-
recommended therapies for inpatient invasive management/
revascularization; dietary/physical activity advice; screen-
ing for depression and discharge prescription of aspirin,
other oral antiplatelet therapies, statin, "-blocker, an-
giotensin converting enzyme inhibitor, and angiotensin
receptor blocker; referral for cardiac rehabilitation; and
smoking cessation advice. Within the case report form
for the study, patients’ primary language spoken at home
was recorded from the medical records. We were then
able to classify participants into the 2 groups of LEP or
EP, where those who were identified as having English as
their primary language spoken at home were classified as
EP and those who spoke a non-English language as their
primary language at home were classified as LEP. Al-
though the primary language spoken at home does not
provide an accurate level of proficiency in English, it has
been considered as an indicator of proficiency and found
to be a possible barrier to accessing healthcare.16,17
For the Australian cohort, mortality data at 18 months
after index admission were collected via data linkage
using the National Death Index. In addition, a survey
and/or telephone interview at approximately 18 months
after their index admission provided health service uti-
lization and risk factor profile within the 18-month
period. For LEP patients, a family member was asked
to interpret or translate to obtain the data. For the
New Zealand cohort, patients were not contacted for
the 18-month follow-up, but death and hospital
morbidity data were obtained by data linkage from
the Ministry of Health Register in New Zealand. The
outcomes explored were major adverse cardiovascular
events, all-cause death, and major adverse cardiovas-
cular events/all-cause death during hospitalization and
from admission to 18 month follow-up, independently.
In-hospital major adverse cardiovascular events included
new or recurrent myocardial infarction, worsening
congestive heart failure and stroke, all-cause death,
and major adverse cardiovascular events/all-cause
death. Detailed definitions of the events that com-
prised major adverse cardiovascular events have been
specified previously.13
Statistical Analysis
Patient demographics, medical history, in-hospital care,
and acute and late outcomes were stratified to com-
pare LEP and EP groups. The #2 statistic was used to
compare categorical variables, the independent t test
for means of continuous variables that were approx-
imately symmetric, and the Wilcoxon rank-sum test
for continuous variables that were skewed. A multiple-
adjusted regression model was used for length of
stay, and multiple-adjusted logistic regression models
were used for each of the outcomes to estimate the odds
ratios and corresponding 95% confidence intervals. For
length of stay, adjustments were made for gender,
GRACE risk score, previous cardiac diagnosis and pro-
cedures (diabetes, myocardial infarction, percutaneous
coronary intervention, coronary artery bypass graft,
atrial fibrillation, and stroke), presenting diagnosis (ST
elevation myocardial infarction, non-ST elevation myo-
cardial infarction, unstable angina, and other non-
confirmed cases of acute coronary syndrome), 4 or
more in-hospital evidence-based medications (aspirin,
oral antiplatelet therapy, "-blocker, angiotensin con-
verting enzyme inhibitor or angiotensin receptor blocker,
and statin or other lipid lowering drugs), percutaneous
coronary intervention and coronary artery bypass graft.
For in-hospital outcomes, the same covariates were ap-
plied, except that evidence-based medications and any
coronary revascularization procedure were excluded. For
outcomes to 18 months, additional variables in the mod-
els were 4 or more evidence-based medications given dur-
ing admission, percutaneous coronary intervention,
coronary artery bypass graft, and referral to rehabilitation.
As sensitivity analyses, the LEP patients were pro-
pensity matched to EP patients 1:2 and 1:5 using the
Greedy 8Y1 Digit Match to compare each in-hospital
and total outcomes. To compute propensity scores for
in-hospital and total outcomes, the covariates included
in the regression model were as identified for the in-
hospital outcome variable in the preceding paragraph.
Data were analyzed using SAS 9.3 for Windows (SAS
Institute Inc. Cary, North Carolina).
Results
Across Australia and New Zealand, 4387 patients were
enrolled in 286 hospitals within the 2-week enrolment
period. Excluding 321 in-hospital and posthospital
deaths collected from Australian hospitals and Na-
tional Death Index linkage, 3060 Australian survivors
were approached for follow-up. Of those, 1918
(62.7%) responded with data at 18 months after their
index admission. Hospital readmission and mortality
at 18 months were obtained through data linkage for
all 1006 New Zealand patients.
At baseline, 41 hospitals (14.3%) had 10% or more
of LEP patients enrolled in their sites. Of the 4387 pa-
tients, 294 (6.7%) were LEP patients, who were older
(70.9 vs 66.3 years;P < .001) and had a higher GRACE
risk score (113 vs 98;P < .001) than EP patients did but
had similar discharge diagnoses (Table). Patients with
LEP were more likely to have hypertension (71.1% vs
62.8%; P = .004), hyperlipidemia (61.6% vs 53.8%;
P = .001), diabetes (40.5% vs 24.3%; P < .001), and
renal failure (16.3% vs 11.1%; P = .007) and a lower
rate of family history of coronary heart disease (17.0%
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vs 33.7%; P < .001) than EP patients did. The median
symptom onset to presentation times for ST elevation
myocardial infarction patients was longer for LEP pa-
tients (3.2 vs 2.1 hours), but this difference was not
significant (P = .11). Of 294 LEP patients, 48 patients
(16.3%) died and 93 (31.6%) were followed up at 18
months after initial admission.
In-hospital Care
In-hospital treatment was comparable between LEP
and EP patients (Table). Time to reperfusion for ST
elevation myocardial infarction patients was longer,
although not significantly so (128 vs 87 minutes; P =
.74). There was no effect of EP on receipt of coronary
angiography (52.8% vs 57.1%;P = .29), percutaneous
TABLE Baseline Characteristics and In-hospital Management
Variables
Total
(n = 4387)
LEP (n = 294,
6.7%)
EP (n = 4093,
93.3%) P
Age, mean (SD) 66.6 (14.6) 70.9 (12.6) 66.3 (14.7) <.001
Sex male 2620 (59.7) 173 (58.8) 2447 (59.8) .75
Indigenousa 190 (4.3) 7 (2.4) 183 (4.5) .09
Medical history
Current smoker 799 (18.2) 41 (14.0) 758 (18.5) .05
Hypertension 2777 (63.3) 209 (71.1) 2568 (62.8) .004
Hyperlipidemia 2383 (54.3) 181 (61.6) 2202 (53.8) .001
Diabetes mellitus 1113 (25.4) 119 (40.5) 994 (24.3) <.001
MI 1191 (27.2) 85 (28.9) 1106 (27.0) .48
PCI 889 (20.3) 54 (18.4) 835 (20.4) .40
CABG 466 (10.6) 38 (12.9) 428 (10.5) .18
Family history of CHD 1429 (32.6) 50 (17.0) 1379 (33.7) <.001
AF 664 (15.1) 51 (17.4) 613 (15.0) .27
PVD 267 (6.1) 14 (4.8) 253 (6.2) .33
CVA 453 (10.3) 40 (13.6) 413 (10.1) .06
Renal impairment 502 (11.4) 48 (16.3) 454 (11.1) .007
Bleeding 107 (2.4) 7 (2.4) 100 (2.4) .95
Dementia 148 (3.4) 14 (4.8) 134 (3.3) .17
Impaired mobility 245 (5.6) 15 (5.1) 230 (5.6) .71
Morbid obesity 349 (8.0) 21 (7.1) 328 (8.0) .59
GRACE risk score, median (IQI) 98.8 (74.9Y124.2) 113.3 (87.7Y137.8) 97.7 (73.7Y123.2) <.001
In hospital
Symptom onset to presentation time, median (IQI), hb 2.2 (1.2Y5.5) 3.2 (1.6Y11.0) 2.1 (1.2Y5.3) .11
Time to reperfusion, median (IQI), minb 88 (50Y295) 128 (73Y170) 87 (50Y295) .74
Angiographyc 1338/2356 (56.8) 86/163 (52.8) 1252/2193 (57.1) .28
PCId 743/1338 (55.5) 49/86 (57.0) 694/1252 (55.4) .78
CABGd 141/1338 (10.5) 9/86 (10.5) 132/1252 (10.5) .98
Prescribed medication
Q2 meds during admissione 2194/2290 (95.8) 146/152 (96.1) 2048/2138 (95.8) .88
Q4 meds during admissione 1702/2290 (74.3) 115/152 (75.7) 1587 (74.2) .70
Q2 meds at dischargee 2114/2290 (92.3) 137/152 (90.1) 1977/2138 (92.5) .30
Q4 meds at dischargee 1485/2290 (64.9) 98/152 (64.5) 1387/2138 (64.9) .92
Discharge
In-hosp cardiac rehabf 1173 (27.3) 65/281 (23.1) 1108/4023 (27.5) .11
Smoking cessation advicef 763 (17.7) 50/281 (17.8) 713/4023 (17.7) .98
Screening for depressionf 322 (7.5) 10/281 (3.6) 312/4023 (7.8) .01
Dietary advicef 1073 (24.9) 69/281 (24.6) 1004/4023 (25.0) .88
Physical activity advicef 1271 (29.5) 74/281 (26.3) 1197/4023 (29.8) .22
Referral to outpatient cardiac rehabf 1275 (29.6) 70/281 (24.9) 1205/4023 (30.0) .07
Discharge diagnosis
STEMI 419 (9.6) 29 (9.9) 392 (9.5) .82
NSTEMI 1012 (23.1) 74 (25.2) 938 (22.9)
UA 925 (21.1) 60 (20.4) 865 (21.1)
Chest pain, not ischemic, and other 2031 (46.3) 131 (44.6) 1900 (46.4)
LOS, median (IQI), d 2.5 (1.1Y4.8) 3.1 (1.5Y5.9) 2.5 (1.1Y4.8) .001
Data are shown as n (%) unless otherwise specified.
Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; CABG, coronary artery bypass graft; CHD, chronic heart failure; CVA, cerebrovascular
accident; GRACE, Global Registry of Acute Coronary Events; IQI, interquartile interval; LOS, length of stay; MI, myocardial infarction; NSTEMI, non-ST
elevation MI; PCI, percutaneous coronary intervention; PVD, Peripheral vascular disease; STEMI, ST elevation MI; UA, unstable angina.
aData include Aboriginal, Torres Strait Islander and Maori.
Denominators are as follows: bSTEMI patients, cACS patients, dACS and received coronary angiogram, eACS patients survived through index admission,
fsurvived through index admission.
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coronary intervention (57.0% vs 55.4%; P = .78), and
coronary artery bypass graft (10.5% vs 10.5%; P =
.98), and the findings persist after adjusting for the
GRACE risk score. Similarly, the rates of receiving 4
or more of 5 evidence-based medications were similar
in hospital (75.7% vs 74.2%; P = .70) and at discharge
(64.5% vs 64.9%; P = .92), even after adjusting for
GRACE risk score. Furthermore, referral to cardiac
rehabilitation and receipt of smoking cessation, die-
tary, or physical activity advice were similar. However,
LEP patients were less likely to be screened for
depression than EP patients were (3.6% vs 7.8%; P =
.01). Even though the unadjusted median length of
stay was longer for LEP patients compared with EP
patients (3.1 vs 2.5 days; P = 0.001), once adjusted,
language barrier was no longer a predictor of longer
length of stay (P = .30).
Cardiovascular Events
Before adjustment, LEP patients had a higher rate of
in-hospital major adverse cardiovascular events (24.2%
vs 14.9%;P < .001), all-cause death (4.4% vs 1.7%; P =
.001), and major adverse cardiovascular events/all-cause
death (25.2% vs 15.4%; P < .001) compared with EP
patients. After adjustment, these differences were no
longer apparent (Figure). For the total cardiovascular
events, from index admission to the 18-month follow-
up, before adjustment, there was no difference in the
rate of major adverse cardiovascular events (22.5% vs
20.7%; P = .59); however, LEP patients had higher
all-cause death (16.3% vs 10.1%; P = .001) and total
major adverse cardiovascular events/all-cause death
(35.7% vs 26.4%; P = .001) compared with EP pa-
tients. These differences in outcomes did not persist
after adjustment for the higher baseline risk of the
LEP population (Figure).
Sensitivity Analyses
The results were confirmed by sensitivity analyses using
propensity score matching. After 1:2 propensity score
matching, 293 LEP patients were compared with 586
EP patients. We found that there was no significant
difference between LEP and EP patients for in-hospital
major adverse cardiovascular events (24.2% vs 20.3%;
P = .18), all-cause death (4.4% vs 2.2%; P = .07), and
major adverse cardiovascular events/death (25.3% vs
21.2%; P = .17). Furthermore, for combined events
from admission to the 18-month follow-up, after the
propensity score matching, the rates of events were
comparable for major adverse cardiovascular events
(31.1% vs 29.0%; P = .53), all-cause death (16.% vs
14.2%; P = .38), and major adverse cardiovascular
events/death (35.8% vs 34.3%; P = .65). Similarly, 1:5
propensity score matched analysis, where 293 LEP pa-
tients were matched to 1465 EP counterparts, showed
that the event rates in hospital (major adverse cardio-
vascular events: 24.2% vs 22.1%, P = .41; all-cause
death: 4.4% vs 3.3%, P = .32; and major adverse car-
diovascular events/death: 25.3% vs 23.0, P = 0.41)
and from admission to the 18-month follow-up (major
adverse cardiovascular events: 31.1% vs 30.0%, P =
.73; all-cause death: 16.4% vs 15.1%, P = .57; and
major adverse cardiovascular events/death: 35.8% vs
35.7%, P = .96) were comparable.
Discussion
In this analysis, we investigated the association of English
as a nonprimary language among acute coronary syn-
drome patients with in-hospital care and outcomes
using contemporary, comprehensive Australian and
New Zealand data. Our results suggest that LEP pa-
tients who presented to a hospital were significantly
older; were more likely to have a history of hyperten-
sion, hyperlipidemia, diabetes mellitus, familial coro-
nary heart disease, and chronic renal failure; and had a
higher GRACE risk score at presentation. Patients with
LEP tended to present later to hospital, and reperfusion
for patients with STelevation myocardial infarction was
delayed, although these differences were not statistically
significant. The language barrier was not associated
with inequities in in-hospital care, including receipt of
evidence-based medications and provision of percuta-
neous coronary intervention, coronary artery bypass
graft, lifestyle advice, and rehabilitation referral. Al-
though LEP patients had a longer length of stay and had
higher rates of major adverse cardiovascular events and
death during admission and from admission to follow-
up compared with EP patients, these differences did not
persist after adjustment for the baseline characteristics
and in-hospital therapies and procedures received by the
LEP patients.
Our findings are an encouraging affirmation of the
current Australasian hospital systems, which endeav-
ors to provide consistent in-hospital quality of care to
all patients. In Australia and New Zealand, there are
structured and standardized evidence-based clinical
FIGURE.Multiple-adjusted odds ratios and 95% confidence
intervals for in-hospital and total (cumulative in-hospital and
18-month follow-up) clinical events.
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guidelines and systems of care for the management of
acute coronary syndrome regardless of the patients’
culture and native language.18 There are not only
guidelines for managing acute coronary syndrome but
numerous guidelines and programs to provide access
and equity for culturally and linguistically diverse peo-
ple. These include the multicultural language services
guidelines19 and cultural competency in health guide-
line11 for Australia and the Health Practitioners Com-
petence Assurance Act 200312 and Operational Policy
Framework20 for New Zealand. Currently, hospitals
from both countries provide 24-hour translation and
interpretation services for more than 120 different lan-
guages and dialects,21,22 and the staff are trained to
develop cross-cultural competence23,24 to meet these
guidelines.
In contrast to our results, previous studies have
identified significant differences in receipt of in-
hospital care. A contemporary study from the United
States found that LEP patients with diverse medical
and surgical conditions were prescribed fewer medica-
tions at discharge compared with EP patients.25
Relative to other comparable high-income countries,
inequity is an acknowledged limitation of the US health-
care system.26 In comparison with the white American
population, other ethnic groups are more likely to be
uninsured,24 which may effect the care received by
LEP patients.
An earlier single-jurisdiction Australian study has
also found differing results to ours, which was that LEP
patients diagnosed with acute myocardial infarction
were more likely to receive percutaneous coronary in-
tervention than their EP counterparts were, although
the difference was not evident for unstable angina pa-
tients.25 Despite the contrasting results of in-hospital
care, the finding that language barrier was not associ-
ated with the length of stay is consistent with inter-
national literature.7,8,28,29
We found no difference in mortality during admis-
sion or from admission to 18-month follow-up based
on English language proficiency. Other studies have
drawn similar conclusions for patients with ischemic
heart disease28 and acute myocardial infarction29 and
general medical patients.8 A Canadian study has looked
at mortality for patients with acute myocardial infarc-
tion and unstable angina/chest pain separately.7 Inter-
estingly, this latter study found that LEP patients with
acute myocardial infarction had significantly lower
in-hospital mortality after adjustment for risk, where-
as LEP patients with unstable angina and chest pain
had no difference in in-hospital mortality compared
with EP patients.
Our study had several limitations. First, this was an
observational design that may have introduced report-
ing bias. As the data were transcribed from medical
records, the accuracy of the information recorded may
be less reliable. This includes classification of patients as
LEP and EP, which would require a thorough assess-
ment of literacy. Despite this, a strength of this study is
the nontrial design with opt-out (Australia) or consent
waiver (New Zealand), which is likely to have increased
the diversity of the sample compared with clinical trials
cohorts where written consent is required. Second, the
data were collected over a 2-week period and may not
be representative of admissions over a longer period.
Third, because of the lack of LEP patients, the effect of
the use of interpretation services or help from a kin
could not be analyzed separately. Fourth, the influence
of patient preference on in-hospital care could not be
tested as data on patient preference were not collected.
Finally, LEP patients comprise a heterogeneous popu-
lation from diverse geographic, cultural, and ethnic
backgrounds. It is possible that individual population
subgroups may experience disparities in care; larger co-
hort studies will be required to further investigate this.
Conclusion
In summary, LEP patients with acute coronary syn-
drome present older and with more comorbidities than
EP patients do. Language barrier is not associated with
inequities in the receipt of coronary angiography, evidence-
based medicines, and other secondary prevention strat-
egies. Patients with LEP have a higher rate of major
adverse cardiovascular events and all-cause death. After
accounting for patient demographics and comor-
bidities, there is no difference in mortality or major
adverse cardiovascular events between English and
nonYEnglish-speaking patients. These results suggest
that people admitted to an Australian or New Zealand
hospital with acute coronary syndrome and who have
LEP do not experience any major inequity in care,
acute, and late outcomes.
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CHAPTER EIGHT 
The household economic burden on survivors of ACS in the 18 months 
after index admission  
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PREFACE TO THE CHAPTER 
This chapter is composed of a published paper that addresses the Aim 4 of this thesis, 
titled: The household economic burden for acute coronary syndrome survivors in 
Australia. It investigates the disease-related out-of-pocket expenditure and household 
economic hardship experienced by survivors of ACS post-discharge in Australia that 
may contribute to the lack of adherence to the appropriate care at post-discharge. It 
used SNAPSHOT ACS data, and the case report forms and the ethics approval are 
provided in Appendix 1. 
 
Difficult financial status may limit adherence to secondary prevention, however, the 
disease-related economic burden that patients bear post-discharge as survivors of ACS 
in Australia is unknown. Even with a universal healthcare coverage, Medicare, in place, 
patients experienced considerable out-of-pocket expenditure and household economic 
hardship. Furthermore, patients with lower area-level SES were more likely to 
experience economic hardship than those with higher area-level SES. This chapter 
provides important evidence that supports the need for policy development to 
strengthen the coverage for out-of-pocket cost, lower the economic burden and close 
the gap between the SES groups so that all patients can access the secondary care they 
need. 
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The household economic burden for acute
coronary syndrome survivors in Australia
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Abstract
Background: Studies of chronic diseases are associated with a financial burden on households. We aimed to
determine if survivors of acute coronary syndrome (ACS) experience household economic burden and to quantify
any potential burden by examining level of economic hardship and factors associated with hardship.
Methods: Australian patients admitted to hospital with ACS during 2-week period in May 2012, enrolled in SNAPSHOT
ACS audit and who were alive at 18 months after index admission were followed-up via telephone/paper survey.
Regression models were used to explore factors related to out-of-pocket expenses and economic hardship.
Results: Of 1833 eligible patients at baseline, 180 died within 18 months, and 702 patients completed the survey. Mean
out-of-pocket expenditure (n = 614) in Australian dollars was A$258.06 (median: A$126.50) per month. The average
spending for medical services was A$120.18 (SD: A$310.35) and medications was A$66.25 (SD: A$80.78). In total, 350
(51 %) of patients reported experiencing economic hardship, 78 (12 %) were unable to pay for medical services and 81
(12 %) could not pay for medication. Younger age (18–59 vs ≥80 years (OR): 1.89), no private health insurance (OR: 2.04),
pensioner concession card (OR: 1.80), residing in more disadvantaged area (group 1 vs 5 (OR): 1.77), history of CVD
(OR: 1.47) and higher out-of-pocket expenses (group 4 vs 1 (OR): 4.57) were more likely to experience hardship.
Conclusion: Subgroups of ACS patients are experiencing considerable economic burden in Australia. These
findings provide important considerations for future policy development in terms of the cost of recommended
management for patients.
Keywords: Acute coronary syndrome, Household economic hardship, Out-of-pocket expenditure, Financial
burden
Background
Acute coronary syndrome (ACS) which includes acute
myocardial infarction (MI) and unstable angina (UA) has
a high incidence globally [1]. More than 2.5 million
hospitalizations are due to ACS worldwide [2]. In
Australia, the number of ACS hospitalizations has
increased 79 % from 1993 to 2008 for acute MI and
33 % for UA, resulting in 95,000 hospitalizations in 2008
[3]. The direct health care system costs associated with
ACS were estimated to be A$1.8 billion and total
economic cost of A$17.9 billion in 2009 [4]. As the
population ages, grows and the projections for ACS
hospitalizations rising, the economic burden, not only to
health systems but also to individuals and their house-
holds, will inevitably become more pronounced. To
better control the potentially substantial economic bur-
den, it is important to understand the current economic
wellbeing of the patients. However, this has not been
readily explored, especially in high income countries.
Recommended treatment for patients with ACS in-
cludes coronary revascularization, adherence to long-term
therapies such as: antiplatelet agent(s), beta-blocker,
angiotensin-converting enzyme inhibitor, statin and other
therapies as appropriate, cardiac rehabilitation services
and follow-up appointments with treating physicians [1].
Australian patients benefit from the national health insur-
ance system, Medicare. It can provide ‘bulk billing’, a
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payment option where a doctor accepts the Medicare
benefit as full payment and does not charge patients an
extra fee, co-payment system for medical services and
listed medications, and further benefits for those with high
out-of-pocket health costs (Medicare Safety Net) [5–8].
Despite this, only 72 % of patients continue prescribed
medications and 34 % complete cardiac rehabilitation pro-
gram after hospital discharge [9, 10]. The rate of bulk bill-
ing for a specialist appointment is also as low as 29 % [11].
Optimal ACS management involves long-term medical
therapies and attendance at programs and appointments
to prevent secondary events. Even with government
schemes to assist, treatment of ACS may impose an
economic burden on patients and contribute to a decrease
in the use of medications and health services in general.
Recent research in other chronic diseases in Australia
including stroke, chronic obstructive pulmonary disease
(COPD) and chronic kidney disease (CKD) indicates that
patients experience a significant household economic
impact related to their disease condition which has
negative consequences for patient outcomes in terms of
longer-term treatment adherence and quality of life
[12, 13]. There are various reasons for non-adherence
to treatment, such as poor understanding of their
disease state, ineffective communication between the
clinician and the patient, and financial reasons [14].
For ACS survivors, the impact of living with heart
disease on the economic well-being of the household
remains unclear. Therefore, the aim of this research
is to describe the out-of-pocket expenditure associ-
ated with ACS and investigate the consequent house-
hold economic burden.
Methods
Patient cohort
This study was a subgroup analysis of the Australian
SNAPSHOT ACS audit. Details relating to the method-
ology for the broader SNAPSHOT ACS study has been
published previously [15]. In brief, all hospitals receiving
patients with suspected ACS (including public and private,
metropolitan and rural) were identified from their medical
records and invited to participate. Patients were eligible to
participate in the study if they were admitted overnight
with a suspected/confirmed ACS event between May 14th
and 27th, 2012. Patients who survived to 18 months after
their index admission were followed-up. For the Australian
cohort, mortality data at 18 months after index admission
was collected via data linkage using the National Death
Index. For this sub-study, the household economic status
as a part of the 18-month follow-up was collected from
two Australian States, New South Wales (NSW) and
Queensland (QLD). Human Research Ethics Committee
(HREC) approvals were sought for each hospital, including
156 NSW and 122 QLD hospitals. During the 2-week
recruitment period, 91 NSW and 61 QLD hospitals
recruited suspected ACS patients. Ethics approval for opt-
out consent was obtained from all participating centers.
Data collection
Patients found to be alive at hospital discharge were
followed-up by phone/paper survey at approximately
18 months after their index admission. The question-
naire was adapted from a previous study [12]. Paper
surveys were posted to the entire cohort and data was
entered into a custom built database. Non-responders
were followed up by telephone and data was entered
directly into the database during the call. The phone
survey was conducted using a formal script that was the
same as the paper survey. In brief, the questionnaire
included information on demographic, education, em-
ployment, out-of-pocket expenditure and household
economic situation. The follow-up data were then linked
to the subset of baseline data from SNAPSHOT ACS.
The baseline data collected included demographics,
presenting clinical characteristics, receipt of evidence
based medication and coronary revascularization. The
patient risk at presentation was estimated using the
Global Registry of Acute Coronary Events (GRACE) risk
score, a score proved to have high capacity to predict
mortality [16]. The GRACE risk score was grouped into
three risk categories, consistent with the European
Society of Cardiology Guideline (low: ≤108, intermedi-
ate: 109–140, high >140) [17]. To determine the patient’s
socioeconomic status (SES), the postcode of each patient
was linked to the Index of Relative Socio-economic
Disadvantage (IRSD) score from the Australian Socio-
Economic Indexes for Areas (SEIFA) [18]. A low score
indicates that the area of residence has relatively greater
socioeconomic disadvantage. The IRSD tenths provided
by the Australian Bureau of Statistics were used to
define five groups for the current analyses.
Outcomes
The outcomes explored were out-of-pocket expenditure
on healthcare and household economic hardship (hard-
ship here after). The out-of-pocket expenditure was the
amount spent on managing the medical condition includ-
ing medical services, medications, ambulance/transport,
exercise/allied health, home and self-care assistance and
special foods, in the previous 3 months from the time of
18-month follow-up which was not covered by Medicare
or private health insurance. A period of 3 months was
used to observe the out-of-pocket expenditure as it was
considered to be a long enough time period to capture the
fluctuation of the expenditure for medical care and treat-
ment over time, but at the same time, a short enough time
for patients to recall the expenditures without too much
burden. This approach of 3-month recall has been
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employed in other studies [12, 13]. The expenditure was
then converted to monthly expenditure. The collection
and analyses of out-of-pocket expenditure were done in
Australian Dollars. Hardship was measured using a series
of questions about the household’s inability to pay living
or medical expense or the use of financial coping strat-
egies (e.g. drew on accumulated savings or sought finan-
cial assistance) in order to pay a living expense in the
previous 12 months, as defined in a previous study [12].
Variables related to income or socioeconomic status was
not used to define hardship as household economic
hardship can potentially affect individuals of all socioeco-
nomic status. Patients were categorized into the hardship
group if they reported to have difficulties paying at least
one expense or used any one or more of the financial
coping strategies.
Statistical analysis
Unadjusted analyses were performed between the patient
specific characteristics and the two outcomes: the
amount of expenditure and hardship. To compare cat-
egorical variables Chi-squared test was used, to compare
means between two groups, independent t-test was used,
and to compare a continuous variable with a skewed dis-
tribution and a categorical variable Wilcoxon rank-sum
test (for two groups) and Kruskal-Wallis test (for three
groups) were used. The zero-inflated negative binomial
model was used to derive the relative rates (RRs), the
corresponding 95 % confidence intervals (CIs) and the
p-values for the factors associated with the amount of
out-of-pocket expenditure. A multiple-adjusted logistic
regression model was used to predict factors associated
with hardship. The odds ratios (ORs), the corresponding
95 % CIs were estimated and the p-values derived.
Candidate variables for both models comprised of those
which were statistically significant at α = 0.2 on univari-
able comparisons. Variables included in the negative
binomial regression model predicting the out-of-pocket
expenditure were: age (18–59, 60–69, 70–79 and
≥80 years), revascularization from baseline, and private
health insurance status, employment status and pen-
sioner concession card at follow-up. Variables included
in the logistic regression model to predict hardship: age
(categorized as above), SES (IRSD in five groups),
GRACE risk categories, smoking status, hypertension
and prior cardiovascular disease (CVD) from baseline,
and private insurance, employment status, pensioner
concession card and out-of-pocket spending (in four
groups) at follow-up. Other demographic and clinical
characteristics were also explored, however, were not
included in the models as they did not meet the level of
significance in the univariate analyses. Data were
analyzed using SAS 9.4 (SAS Institute Inc. Cary, North
Carolina, United States).
Results
Of 3381 Australian patients from 251 participating
hospitals who participated in SNAPSHOT ACS, 1833
had ACS and were admitted to one of the 152 NSW/
QLD hospitals and were therefore included in this
present analysis. Excluding 180 (10 %) patients who died
in hospital and after discharge, 1653 (90 %) NSW/QLD
patients were contacted for follow-up at 18 months. Of
those, 702 (42 %) responded and agreed to complete the
survey relating to household economic status. Patients
who have completed the survey had the mean age of
65 years (SD (standard deviation): 13), 431 (61 %) were
male, and 263 (37 %) had private health insurance at
baseline. The median GRACE risk score for these
patients was 94 (IQI (inter-quartile interval): 74–118),
339 (48 %) patients had prior cardiovascular disease, 156
(53 %) had revascularization and 98 (14 %) had an
in-hospital event.
Out-of-pocket expenditure
In total, 92 % (n = 614) of patients reported that they
had out-of-pocket expenditure. The mean out-of-pocket
expenditure in the 3-month period prior to the
18-month follow-up was A$258.06 (SD: A$405.38) per
month (Table 1). Of those with out-of-pocket expenditure,
90 % spent on medication, 51 % on medical services
(general practitioner, physician specialist, hospitalization
and medical test) and 26 % on ambulance/transport. The
mean spending for medical services was A$120.18 (SD:
A$310.35), medication was A$66.25 (SD: A$80.78), ambu-
lance/transport was A$30.95 (SD: A$130.53) and exercise/
allied health was A$15 (SD: A$55).
Factors associated with out-of-pocket expenditure
Patient factors associated with the amount of out-of-
pocket expenditure were predicted. After adjustment,
younger patients (18–59 vs. ≥80 years (RR (95 % CI)):
1.80 (1.16, 2.77); 60–69 vs. ≥80 years: 1.63 (1.18, 2.25);
and 70–79 vs. ≥80 years: 1.75 (1.29, 2.38); p = 0.005) with
private health insurance ((RR (95 % CI)): 1.57 (1.30, 1.91);
p < .0001) were more likely to have higher expenses.
Household economic hardship
In total, 350 (51 %) respondents reported that they had
experienced hardship. That included, 78 (12 %) reporting
they were unable to pay for medical consultations/tests,
81 (12 %) for medications, 109 (17 %) for dental appoint-
ments, 77 (12 %) for rent or mortgage, 39 (6 %) for
meals and 101 (15 %) for utility bills on time. In
addition, 221 (34 %) drew on accumulated savings, 61
(9 %) sought financial assistance from welfare/community
organization and 71 (11 %) sought financial assistance
from friends/family.
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Factors associated with hardship
The characteristics of patients with hardship at
18 months are shown in Table 2. Younger patients (OR
for 18–59 vs. ≥80 years: 1.89; 60–69 vs. ≥80 years: 1.64;
70–79 vs. ≥80 years: 0.69), without private health insur-
ance (OR: 2.04), with a pensioner concession card (OR:
1.80), residing in a more disadvantaged area (OR for
group 1 vs. 5: 1.77; group 2 vs. 5: 2.30; group 3 vs. 5:
1.31; group 4 vs. 5: 0.92), had history of CVD (OR: 1.47)
and with higher out-of-pocket expenditure (OR for
group 2 vs. 1: 1.61; group 3 vs. 1: 2.68; and group 4 vs. 1:
4.57) had greater likelihood of experiencing hardship
(Table 3).
Discussion
This is one of the first known studies to explore the
household economic burden for Australians living with
heart disease. Results indicate that 50 % of ACS survi-
vors experience substantial household economic burden
associated with their illness. On average patients with
ACS were spending A$258 per month on health care re-
lated out-of-pocket costs. In total, half of the responders
to the survey reportedly experienced hardship in the last
12 months prior to the follow-up. Patients who were
more likely to have higher out-of-pocket expenditure
were those who were older and those with private health
insurance. Similar to other studies, hardship was signifi-
cantly associated with both younger and advanced age,
no private health insurance, pensioner concession card,
residence of a more disadvantaged area, history of CVD
and greater out-of-pocket expenses [19, 20].
Our findings show a substantial monthly out-of-
pocket expense following an ACS event, which was
greater than the average estimated out-of-pocket health
spending in Australia in 2010–11 of A$90 per month,
per person [21], the UK in 2013 of $196 per month, per
person [22], and the US in 2011 of $101 for 65 years or
older patients per month, per person [23]. We also
found that a relatively large proportion of patients in our
cohort were unable to pay for medical consultations/
tests (12 %) and prescription or non-prescription medi-
cations (12 %). Similar findings have been reported for
other chronic disease areas [12, 13, 24]. For patients with
COPD, 25 % reported that they were unable to pay for
medical or dental consultations and tests and 18 % for
medications, and for CKD patients, 14 % could not for
medical appointments and 19 % for medications [12, 13].
The findings suggest that in spite of patients reporting
high levels of expenditure on ongoing treatment, there are
many patients who report instances where they have
foregone treatment due to cost. The policy argument
strengthening coverage for out-of-pocket costs is therefore
justified as these costs reinforce economic disadvantages
in patients with this condition and in addition, represent a
significant barrier to optimal management of ACS.
National and international guidelines continue to
emphasize the importance of evidence-based medica-
tions, along with lifestyle advice and participation in car-
diac rehabilitation program for secondary prevention
[25]. It is well known that an opposing relationship ex-
ists between non-adherence to medications and associ-
ated health care cost [26]. It was found that missing
doctors’ appointments and sub-optimal communication
between clinicians and patient can also lead to non-
adherence to medication [27]. Whilst Medicare provides
extensive subsidies on prescription medicines and non–
hospital medical services and free public hospital care
there is a growing recognition that the burden of out-of-
pocket costs is significant, particularly for individuals
with long term and chronic conditions [28]. The main
drivers of these costs are likely to be the need for on-
going multiple medicines and follow-up treatment for
people with ACS, and high gap payments (the difference
provided by government and the full cost which is cov-
ered out-of-pocket) particularly for medical (or phys-
ician) specialist consultations.
Table 1 Out-of-pocket expenditure (per month)
Items Mean A$ (SD) for patients
with any OOP expenditure
on at least one of the items
Median A$ (IQI) for patients
with any OOP expenditure
on at least one of the items
n (%) patients with
any OOP expenditure
on the specific item
Median A$ (IQI) for patients
with any OOP expenditure
on the specific item
Medical service 120.18 (310.35) 10.33 (0.00, 100.00) 277 (51) 100.00 (46.67, 258.33)
Medications 66.25 (80.78) 44.67 (26.67, 73.00) 487 (90) 50.00 (33.33, 80.00)
Ambulance/Transport costs 30.95 (130.53) 0.00 (0.00, 8.33) 142 (26) 40.00 (18.67, 133.33)
Exercise/allied health 16.68 (66.28) 0.00 (0.00, 0.00) 78 (14) 81.67 (40.00, 133.33)
Home and self-care assistance 14.14 (81.90) 0.00 (0.00, 0.00) 50 (9) 84.00 (40.00, 144.00)
Special foods 5.66 (52.95) 0.00 (0.00, 0.00) 19 (4) 66.67 (33.33, 133.33)
Other 4.20 (58.23) 0.00 (0.00, 0.00) 10 (2) 58.33 (30.00, 120.00)
Total expenditure 258.06 (405.38) 126.50 (50.00, 280.00) 540 (100) 126.50 (50.00, 280.00)
Out-of-pocket expenditures are in Australian Dollars
SD standard deviation, IQI inter-quartile interval, OOP out-of-pocket
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This study has limitations. As an observational design
was used, reporting bias may have been introduced. Also,
the response rate to the follow-up study was relatively
low; however, assessment of the patient characteristics at
baseline and follow-up were similar between NSW/QLD
participants and those who were lost to follow-up as well
as the rest of the Australian patients. Further, compared
to the previous studies that collected similarly detailed
and personal data, aiming to find the household economic
hardship in other chronic areas, 702 would be considered
sizable and well powered to detect important predictors of
the household economic hardship such as age, conces-
sional status, and health insurance status [12, 13]. Also,
the SNAPSHOT ACS study collected data on a represen-
tative and diverse cohort over a 2-week period from more
than 200 hospitals across Australia using the opt out
methods of consent. Therefore, although the sample size
seems modest, the results are generalizable. As patients
were asked to provide out-of-pocket expenditure over a
3-month period, it is likely that it was underestimated and
be subjected to recall bias. The out-of-pocket expenditure
may not have been related to ACS management only, but
also for other major comorbidities including diabetes,
heart failure, chronic renal failure and major bleeding.
However, as ample number of ACS patients manage
comorbidities, our estimates reflect the expenditures in
reality. Also, when predicting the factors associated with
household economic hardship, variables such as prior
cardiovascular diseases and out-of-pocket expenditure,
which takes into account the costs of comorbidities, were
included as independent variables to adjust for comorbidi-
ties. In addition, data was collected via self-report and
findings need to be considered accordingly.
Conclusion
In this cohort, we examined the out-of-pocket expenses
and household economic situation. The results indicate
Table 2 Baseline characteristics and in-hospital management
for household economic hardship
Hardship
(n = 350, 51 %)
No-hardship
(n = 331, 49 %)
P-value
Age, mean (SD) 63 (14) 67 (12) 0.0001
Age
18–59 years 138 (39) 93 (28) 0.0006
60–69 years 96 (27) 81 (24)
70–79 years 71 (20) 108 (33)
80+ years 45 (13) 49 (15)
Male 224 (64) 197 (60) 0.2287
No private insurance 224 (67) 162 (49) <.0001
Work status at 18 months
Employed 79 (24) 90 (28) <.0001
Unemployed 61 (19) 18 (6)
Retired 186 (57) 213 (66)
Education
No education or primary
school only
49 (15) 47 (15) 0.9233
Secondary school only 152 (46) 152 (48)
TAFE diploma or certificate 74 (22) 65 (20)
University degree 55 (17) 56 (18)
Pensioner concession card 222 (67) 195 (59) 0.0425
IRSD (5 groups)
1 (most disadvantaged) 72 (21) 48 (15) 0.0028
2 104 (30) 72 (22)
3 80 (23) 83 (25)
4 57 (16) 81 (24)
5 (least disadvantaged) 35 (10) 47 (14)
Medical history
GRACE risk score
(risk categories)
Low 237 (68) 203 (61) 0. 0528
Intermediate 91 (26) 94 (28)
High 20 (6) 34 (10)
Current smoker 74 (21) 36 (11) 0.0003
Hypertension 225 (64) 197 (60) 0.2001
Hyperlipidemia 202 (58) 186 (56) 0.6887
Diabetes 93 (27) 77 (23) 0.3187
Prior CVDa 180 (51) 148 (45) 0.0796
Other Comorbiditiesb 63 (18) 49 (15) 0.2607
Diagnosis
STEMI 28 (8) 38 (11) 0.4650
NSTEMI 62 (18) 60 (18)
UA 91 (26) 84 (25)
Other 169 (48) 149 (45)
Table 2 Baseline characteristics and in-hospital management
for household economic hardship (Continued)
In-hospital management
Cardiac catheterization 140 (40) 142 (43) 0.4425
Revascularizationc 74/140 (53) 78/142 (55) 0.7270
4 or more EBM at discharge 164 (47) 149 (45) 0.6297
In-hospital events
In hospital eventsd 52 (15) 44 (13) 0.5577
Data are shown as frequency and proportion (%) unless otherwise specified
SD standard deviation, IRSD index of relative socio-economic disadvantage,
GRACE global registry of acute coronary events, IQI inter-quartile interval, CVD
cardiovascular disease, PCI percutaneous coronary intervention, CABG coronary
artery bypass graft, STEMI ST elevation myocardial infarction, NSTEMI non-ST
elevation myocardial infarction, UA unstable angina, EBM evidence
based medications
aPrior CVD: prior myocardial infarction, prior peripheral vascular disease, prior
stroke, prior PCI, prior CABG or prior atrial fibrillation
bOther Comorbidities: prior renal failure, prior major bleeding, prior active
cancer, prior dementia or prior impaired mobility
cRevascularization: PCI or CABG
dIn hospital events: myocardial infarction, stroke, heart failure, renal failure,
major bleeding or cardiac arrest
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that along with the high risk medical condition, ACS
brings excess out-of-pocket expenditure compared to
the national average expenditure. Further, a sizable sub-
set of ACS survivors experiences a substantial household
economic burden and that half of the cohort experi-
enced at least once incidence of hardship in the previous
12 months. These findings suggest that out-of-pocket
costs pose a significant barrier to optimal management
of patients with ACS and more broadly, contribute to
exacerbating economic disadvantage amongst household
with individuals with chronic disease.
Appendix
Participating hospitals
New South Wales
Hospital; Armidale Rural Referral Hospital; Ballina
District Hospital; Balmain Hospital; Balranald District
Hospital; Bankstown Lidcombe Hospital; Baradine MPS;
Barham Health Service; Barraba MPS; Bateman’s Bay
District Hospital; Bathurst Health Service; Batlow
Adelong MPS; Bega Hospital; Bellingen River District
Hospital; Belmont Hospital; Berrigan Health Service;
Bingara MPS; Blayney District Hospital; Boggabri MPS;
Bombala MPS; Boorowa Health Service; Bourke District
Hospital; Bowral Hospital; Braidwood MPS; Brewarrina
MPS; Broken Hill Base Hospital; Bulahdelah Community
Hospital; Byron District Hospital; Calvary Health Care
Riverina; Calvary Mater Newcastle; Campbelltown Hospital;
Canterbury Hospital; Casino & District Memorial Hospital;
Cessnock District Hospital; Cobar Health Service; Coffs
Harbour Health Campus; Collarenebri Health Service;
Concord Repatriation General Hospital; Condobolin
District Hospital; Coolah MPS; Coolamon MPS; Cooma
Hospital; Coonamble Health Service; Cootamundra
Hospital; Corowa Health Service; Cowra District Hospital;
Crookwell District Hospital; Culcairn Health Service;
Delegate MPS; Deniliquin Hospital; Denman MPS;
Dorrigo MPS; Dubbo Base Hospital; Dunedoo MPS;
Dungog Community Hospital; Fairfield Hospital; Finley
Hospital; Forbes District Hospital; Gilgandra MPS; Glen
Innes Health Service; Gloucester District Health Service;
Goodooga Hospital; Gosford Hospital; Goulburn Base
Hospital; Grafton Base Hospital; Grenfell MPS; Griffith
Base Hospital; Gulargambone MPS; Gulgong Health
Service; Gunnedah District Health Service; Hay Hospital;
Henty MPS; Hillston Hospital; Inverell Hospital; John
Hunter Hospital; Junee MPS; Kempsey Health Campus;
Kurri Kurri Hospital; Kyogle Hospital; Lake Macquarie
Private Hospital; Leeton Health Service; Lismore Base
Hospital; Liverpool Hospital; Lockhart Health Facility;
Macksville Health Campus; Maclean Hospital; Maitland
Hospital; Manilla MPS; Manly Hospital; Manning Rural
Table 3 Multiple-adjusted odds ratios and 95 % confidence intervals for household economic hardship vs. no-hardship
Hardship vs. no-hardship Odds ratio (95 % confidence interval) P-value
Age 18–59 years vs. 80+ years 1.89 (0.77, 4.63) 0.0130
60–69 years vs. 80+ years 1.64 (0.81, 3.34)
70–79 years vs. 80+ years 0.69 (0.38, 1.27)
No private insurance vs. private insurance 2.04 (1.37, 3.03) 0.0005
Employment status Unemployed vs. employed 2.06 (0.97, 4.39) 0.1087
Retired vs. employed 1.01 (0.51, 1.99)
Pensioner Concession card 1.80 (1.03, 3.18) 0.0406
IRSDa Group 1 vs. 5 1.77 (0.91, 3.45) 0.0043
Group 2 vs. 5 2.30 (1.23, 4.30)
Group 3 vs. 5 1.31 (0.70, 2.45)
Group 4 vs. 5 0.92 (0.48, 1.75)
GRACE risk category Intermediate vs. low 1.24 (0.76, 2.01) 0.0940
High vs. low 0.55 (0.25, 1.24)
Current smoker vs. ex-smoker 1.67 (0.98, 2.82) 0.0576
Hypertension vs. not 1.21 (0.83, 1.76) 0.3144
Prior CVD vs. not 1.47 (1.00, 2.14) 0.0477
Out-of-pocket expenditureb Group 2 vs. 1 1.61 (0.98, 2.64) <.0001
Group 3 vs. 1 2.68 (1.62, 4.43)
Group 4 vs. 1 4.57 (2.71, 7.70)
IRSD index of relative socio-economic disadvantage, GRACE global registry of acute coronary events, CVD cardiovascular disease
aGroup 1 is the most disadvantaged and Group 5 is the least disadvantaged
bGroup 1 had lowest out-of-pocket expenditure and Group 4 had highest expenditure
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Referral Hospital (Taree); Menindee Health Service;
Merriwa MPS; Milton-Ulladulla Hospital; Moree District
Health Service; Moruya District Hospital; Mudgee Health
Service; Mullumbimby Hospital; Murrumburah-Harden
Health Service; Muswellbrook District Health Service;
Narrabri District Health Service; Narrandera Health
Service; Narromine Health Service; Newcastle Private
Hospital; Nyngan MPS; Tomaree Community Hospital
(Nelson Bay); North Shore Private Hospital; Oberon
Health Service; Orange Health Service; Pambula District
Hospital; Parkes Health Service; Peak Hill Health Service;
Port Macquarie Base Hospital; Prince of Wales Hospital;
Prince of Wales Private Hospital; Queanbeyan Hospital;
Quirindi Community Hospital; Royal North Shore
Hospital; Royal Prince Alfred Hospital; Ryde Hospital;
Scott Memorial Hospital (Scone); Shellharbour Hospital;
Shoalhaven District Memorial Hospital; Singleton District
Hospital; St George Hospital; St George Private Hospital;
Strathfield Private Hospital; Sutherland Heart Clinic;
Tamworth Rural Referral Hospital; Temora Hospital;
Tenterfield Community Hospital; Tibooburra District
Hospital; Tocumwal Hospital; Tottenham MPS; Trangie
MPS; Trundle MPS; Tullamore MPS; Tumbarumba MPS;
Tumut Health Service; Urana MPS; Urbenville Health
Service; Vegetable Creek Hospital (Emmaville); Wagga
Wagga Base Hospital; Walcha MPS; Walgett Health
Service; Warialda MPS; Wee Waa Community Hospital;
Wellington Health Service; Werris Creek Health
Service; Westmead Private Hospital; Wilcannia MPS;
Wilson Community Hospital (Murrurundi); Wollongong
Hospital; Wyalong Hospital; Wyong Hospital; Yass
District Hospital; Young District Hospital.
Queensland
Allamanda Private; Alpha Hospital; Atherton Hospital;
Augathella Hospital; Ayr Hospital; Babinda Hospital;
Bamaga Hospital; Baralaba Hospital; Barcaldine Hospital;
Beaudesert Hospital; Biggenden Hospital; Biloela Hospital;
Blackall Hospital; Blackwater Hospital; Boonah Hospital;
Bowen Hospital; Bundaberg Friendly; Bundaberg Hospital;
Caboolture Hospital; Cairns Base Hospital; Cairns Private;
Caloundra Hospital; Capricorn Coast Hospital; Charleville
Hospital; Charters Towers Hospital; Cherbourg Hospital;
Childers Hospital; Chinchilla Hospital; Clermont Hospital;
Collinsville Hospital; Cooktown Hospital; Cloncurry
Hospital; Dalby Hospital; Dirranbandi Hospital; Doo
madgee Hospital; Eidsvold Hospital; Emerald Hospital;
Esk Hospital; Dysart Hospital; Gatton Hospital; Gayndah
Hospital; Gin Gin Hospital; Gladstone Hospital; Gold
Coast Hospital; Goondiwindi Hospital; Greenslopes
Private; Gympie Hospital; Hervey Bay Hospital; Hillcrest
Private Hospital; Hughenden Hospital; Ingham Hospital;
Inglewood Hospital; Innisfail Hospital; Ipswich Hospital;
John Flynn; Jandowae Hospital; Kilcoy Hospital; Joyce
Palmer Hospital; Julia Creek Hospital; Laidley Hospital;
Logan Hospital; Longreach Hospital; Mackay Base Hospital;
Maleny Hospital; Mareeba Hospital; Maryborough Hospital;
Mater Adult Public Hospital; Mater Private Brisbane; Mater
Private Mackay; Mater Private Rockhampton; Mater Private
Townsville; Miles Hospital; Millmerran Hospital; Mitchell
Hospital; Monto Hospital; Moranbah Hospital; Mornington
Island Hospital; Mossman Hospital; Mount Isa Hospital;
Mount Morgan Hospital; Moura Hospital; Mundubbera
Hospital; Mungindi Hospital; Murgon Hospital; Nambour
Hospital; Nambour Selengor; Nanango Hospital; Norm
anton Hospital; Princess Alexandra Hospital; Proserpine
Hospital; Queen Elizabeth II Jubilee Hospital; Quilpie
Hospital; Redcliffe Hospital; Redland Hospital; Richmond
Hospital; Rockhampton Base Hospital; Roma Hospital;
Royal Brisbane & Women’s Hospital; Sarina Hospital;
St Andrew’s Private Toowoomba; St Andrew’s War
Memorial, Brisbane; St George Hospital; St Vincent’s
Hospital; Springsure Hospital; Stanthorpe Hospital;
Sunshine Coast Private Hospital; Surat Hospital; Tara
Hospital; Texas Hospital; Theodore Hospital; The Prince
Charles Hospital; Thursday Island Hospital; Toowoomba
Hospital; Townsville Hospital; Tully Hospital; Warwick
Hospital; Weipa Hospital; Winton Hospital; Wesley
Hospital; Woorabinda Hospital; Wynnum Hospital;
Yarrabah Hospital.
Abbreviations
ACS: Acute coronary syndrome; CI: Confidence interval; CKD: Chronic kidney
disease; COPD: Chronic obstructive pulmonary disease; CVD: Cardiovascular
disease; GRACE: Global registry of acute coronary events; IQI: Inter-quartile
interval; IRSD: Index of relative socio-economic disadvantage; MI: Myocardial
infarction; NSW: New South Wales; OR: Odds ratio; QLD: Queensland;
RR: Relative rate; SD: Standard deviation; SEIFA: Socio-economic indexes for
areas; SES: Socioeconomic status; UA: Unstable angina
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CHAPTER NINE 
Discussion and conclusions 
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The overall aim of this thesis was to explore whether health inequities regarding care 
and clinical outcomes exist in patients with CVD in Australian primary healthcare and 
hospital system, and to determine the effect of disease on their household economic 
hardship post-discharge. This chapter will provide a summary of the main findings and 
discussion of the results in terms of the primary care, in-hospital and post-discharge 
environments in Australia. In addition, this chapter will discuss the clinical implications 
and future research and limitations.  
 
MAIN FINDINGS AND DISCUSSION 
This program of research identified varying impacts of inequities such as gender, SES 
and language spoken on the management of CVD.  The gender difference in the receipt 
of CVD risk assessment and prescription of guideline-recommended medications in 
Australian primary care was examined. Although the systematic review and meta-
analysis of international studies (Chapter 3) presented no significant difference in the 
assessment of CVD risk scores and individual CVD risk factors between women and 
men, there was substantial heterogeneity between the studies and only a limited 
number of studies explored CVD risk assessment by gender. This lack of gender 
comparison and analysis is concerning and an important area for future research. In 
Chapter 4, the analysis of Australian primary healthcare data found that women were 
less likely to be assessed for the CVD risk than men (1). Further, significant gender 
disparity in the management of the CVD risk factors for those who were in the CVD/high 
CVD risk group was observed. Although women in the CVD/high CVD risk group 
appeared to receive the guideline-recommended medication prescriptions more often 
than their male counterparts, younger women (35-54 years) were less likely and older 
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women (≥65 years) were more likely to be prescribed appropriate medications than 
their male counterparts. 
 
The systematic review presented in Chapter 3 showed varied results in terms of the 
receipt of CVD risk screening and prescription of guideline-recommended medications. 
Also, Delpech et al. have reported the odds of screening in women to be 36% lower than 
men in French primary healthcare, and the gender discrepancies were greater in 
patients who were under the care of male doctors than female (2). A New Zealand study 
in the general population, reported no gender difference in the receipt of CVD risk 
assessment, whereas, Gu et al. found that, of the Pacific Islanders in New Zealand, 
women were more often assessed than men (65% vs. 56%), possibly influenced by their 
culture (3, 4). Further, Lang et al. found comparable risk assessment rate between 
women and men in the UK primary healthcare (5). Regarding prescription of 
medication in primary healthcare, similarly to the findings from Chapter 4, Zhao et al., 
Stafford et al., Hippisley-Cox et al., Mathur et al., O’Keeffe et al. and Schmittdiel et al. 
reported that in patients with CHD, women had lower odds of being prescribed aspirin, 
beta blocker, ACE/ARB and/or lipid-lowering medications than men (6-11). Moreover, a 
recent study has found that though the CVD risk score recording rate was higher in 
women (61 vs. 52 scores/1000 patient-years), the statin initiation rate was lower than 
men (21 vs. 26 initiations/1000 patient-years) in the UK (12). However, Sayer and Britt 
and Sheppard et al. found opposing results of women more often being prescribed 
statin and antihypertensive medications than men (13, 14). Despite the varied results 
from previous studies, it is evident that gender discrepancies, whether it be women or 
men who receive less care, in primary healthcare still exist in Australia.  
156 
 
 
Considerable efforts are being made to close this gender gap. There are guidelines for 
CVD prevention and management, as well as initiatives and educational campaigns such 
as Go Red for Women by the American Heart Association, Women’s Room by the British 
Heart Foundation and Women at Heart by the European Society of Cardiology (15-17). 
In Australia, specifically, guidelines from the National Vascular Disease Prevention 
Alliance and campaigns for women’s cardiovascular health such as Making the Invisible 
Visible by the National Heart Foundation are available (18, 19). Despite these efforts 
made to promote women’s CVD health, significant gaps between Australian women and 
men in the rate of CVD risk assessment and the prescription of guideline-recommended 
medications in primary healthcare were observed.  
 
This thesis also investigated the provision of equitable care in Australian hospitals 
across SES subgroups and levels of English proficiency. Through a systematic review 
and meta-analysis of international studies (Chapter 5), the disparity between SES 
(individual or area-level) groups was found in the receipt of individual guideline-
recommended discharge medication prescriptions in patients with ACS (20). Whereas, 
in Australian hospitals, the receipt of four or more of the five ACS discharge medication 
prescriptions was comparable across the area-level SES groups (Chapter 6) (21). 
Moreover, the likelihood of the receipt of coronary angiogram, revascularisation and the 
referral to cardiac rehabilitation were comparable. Such equitable care was also 
provided to LEP and EP patients with ACS as shown in Chapter 7 (22). The language 
barrier did not affect the receipt of recommended medications, PCI, CABG, lifestyle 
advice, cardiac rehabilitation referral and the length of stay. Further, there was no 
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difference in the odds of death and MACE in hospital between the LEP and EP patients. 
Across the area-level SES groups, the likelihood of death was comparable, however, an 
inverse relationship was observed between the likelihood of MACE and SES.  
 
The equitability of care between the SES groups was associated with the availability of 
universal health coverage. As provision of equitable delivery of in-hospital care was 
found in Australia in Chapter 6, where patients have access to Medicare, a systematic 
review by Schroder et al. which assessed the effect of SES on the access to prevention 
and treatment, including coronary angiography, revascularisation, prescription of 
medication and coronary rehabilitation referral for CHD also found that access to 
treatment was less often associated with SES in the studies conducted in countries with 
universal healthcare coverage (23). Whilst most of the studies from countries without 
universal healthcare coverage reported socioeconomic discrepancies in access to 
treatment. However, studies by Coory et al. and Korda et al. argue that socioeconomic 
inequities still exist for patients with ACS even in Australian hospitals in the receipt of 
coronary angiogram and/or revascularisation depending on whether patients are in 
public or private sector and the severity of disease risk (24, 25). 
 
Studies that explored the effect of language proficiency on the provision of in-hospital 
care were limited. Similarly to the results found in Chapter 7, in patients with ACS or 
stroke, the receipt of guideline-recommended medications was comparable between 
those who were proficient in primary language spoken and those who were not (26-28). 
Whereas, the rate of coronary angiography and PCI were lower and the odds of in-
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hospital death was greater in patients with a language barrier in Saudi Arabia (26). 
Likewise, lower rates of cardiac angiogram, PCI and rehabilitation referral, as well as, 
greater odds of in-hospital death were observed in patients with English as their second 
language compared to those with English as their first language in Australia (27).  
 
The finding of the provision of equitable ACS care provided to subgroups that were 
presumed to receive inequitable care and have worse outcomes in Australian hospitals 
is rewarding and encouraging for the Australian healthcare professionals and the 
system. Investments were made to equip Australian hospitals with infrastructure. In 
2012, intermediate to high-quality infrastructure, which includes diagnostic and cardiac 
intervention resources were available to over two-thirds of Australian hospitals (29). 
Also, extensive efforts have been made to review and produce up-to-date national ACS 
guidelines, which are in place to provide equitable treatment and care for all patients 
regardless of their social subgroups, hospital-specific clinical pathways that are used to 
provide consistent, tailored optimal care, and trainings and seminars to improve the 
quality of care provided to patients. For subgroups, such as those in the cultural and 
linguistical minorities, that require additional assistance, additional guidelines, 
including the Multicultural Language Services Guidelines and the Cultural Competency 
in Health Guideline, and services, such as 24-hour translation and interpretation 
services, are available to accommodate them to receive the recommended care (30-32). 
Having these guidelines, systems and infrastructure in place may have contributed to 
the equitable care provided to patients with various SES or proficiency of English who 
have been admitted due to ACS.  
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This thesis also examined the access to secondary prevention after surviving an acute 
CVD event or ACS. Possible discrepancies in the access to secondary prevention were 
found between genders in Chapter 4, within the primary care setting, and area-level SES 
groups in Australia in Chapter 8, within the hospital setting (1, 33). The finding of the 
gender difference in the prescription of guideline-recommended medications in 
patients with CVD or at high-risk of CVD in primary healthcare, arguably, suggests that 
inequitable secondary prevention care was provided for women and men since 50% of 
the patients with the diagnosis of CVD would have required the medications as a 
secondary prevention measure (1). Also, the access to the secondary prevention and the 
allied health services post discharge may have been limited to patients with ACS in 
lower area-level SES groups as the odds of experiencing household economic hardship 
post discharge were greater in patients in lower SES groups compared to those in the 
highest SES group (33).  
 
Gender and SES differences in access to secondary prevention were also observed in 
previous studies. An Australian study by Hyun et al. found that, at 6-months post-
discharge, the odds of women who were previously admitted due to ACS taking >75% of 
secondary prevention medications were 14% lower than men, though women had more 
comorbidities (34). Furthermore, women had greater odds of post-discharge MACE 
than men by 35%. However, Lahoz et al. and Nilsson et al. observed no gender 
difference in the prescription of secondary prevention medications following CHD in 
Spain and Sweden, respectively (35, 36). Area-level SES was another factor found in this 
thesis that was likely to affect the access to secondary prevention due to household 
economic hardship. Studies by WHO, Bansilal et al., Milan et al. and Dhaliwal et al. have 
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confirmed this association (37-40). Milan et al. and Dhaliwal et al. reported that, even 
with universal health coverage available, out-of-pocket costs and financial burden 
adversely affected the adherence to secondary prevention, such that patients were not 
able to attend cardiac rehabilitation, forced to discontinue medications or prioritise the 
secondary prevention care to adhere to as they could not access all (39, 40). 
 
In order to research and develop strategies to provide effective evidence-based 
secondary prevention care to all and reduce CVD mortality, government and research 
organisations and associations for the healthcare professionals, including the Australian 
Commission for Safety and Quality in Health Care, Cardiac Society of Australia and New 
Zealand, National Heart Foundation and the George Institute for Global Health, are 
collaborating under the Secondary Prevention Alliance (41). The alliance continues to 
promote awareness of the disease and improve the delivery of equitable secondary 
prevention to Australians in partnership with various levels of the healthcare system 
and the government. Also, Medicare, a universal healthcare coverage, is available to all 
Australians. It provides no payment or co-payment medical services and cost-subsidised 
medications through the Medicare Benefits Schedule and Pharmaceutical Benefits 
Scheme, respectively, to provide patients in any financial circumstance the assistance to 
adhere to the guideline-recommended prevention of disease by having equitable access 
to healthcare services. In spite of these initiatives, Medicare and the guidelines available 
to provide optimal care for all after discharge, gaps in secondary prevention still exist. 
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CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
This thesis provides an overview of CVD care provided in the Australian healthcare 
system to subgroups where health inequities might occur, with the goal of providing 
important information on the current status of the delivery of care and bring about 
effective strategies to provide more equitable and improved care, where required. In 
Chapters 6 and 7, the equitable in-hospital ACS management provided to patients 
regardless of their SES and English proficiency is a rewarding finding for the clinicians 
who strive to provide quality care for all patients who are admitted to an Australian 
hospital. Continuous effort into reviewing and updating the evidence-based guidelines 
and following the guidelines and other resources such as the Clinical Care Standards by 
the Australian Commission on Safety and Quality in Healthcare to maintain this 
standard of care is needed (42, 43). It is also important to investigate and ensure that 
the equitable quality care is being provided not only to patients with ACS but to those 
with all types of CVD, including stroke and heart failure.  
 
In Chapter 4, gender discrepancies were found in CVD risk assessment and prescription 
of medication in Australian primary healthcare. This supports the need for quality 
improvement strategies, including academic detailing and the use of electronic decision 
support tools, to better implement the evidence-based guidelines and close the gaps 
identified. Academic detailing is continued structured training and technical assistance 
delivered to primary healthcare professionals to help change clinical behaviours to 
provide better and equitable care and educate patients (44-47). Academic detailing can 
improve care and enhance patient-physician communication, which in turn encourages 
patients to be proactive in risk assessment and self-management of CVD (47). This can 
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be used to correct the misconception that CVD is a ‘man’s disease’ and educate 
physicians and patients of the severity of the burden of CVD in women as well as men to 
be able to close the gender gap in the assessment and management of the disease.  
 
Based on the evidence found in this thesis, further research and strategies are required 
to provide equitable access to secondary prevention for all. With the advancement of 
technology, electronic decision support tools have been developed to provide primary 
healthcare physicians with computerised alerts and suggestions based on guidelines 
and the patient’s electronic medical record, which has been proven to improve 
physicians’ performance on risk assessment, prevention of disease, diagnosis, disease 
management and medication prescription (48-50). Also, e-health and m-health are 
developing fast with validated web and/or mobile phone-based applications and auto-
generated text messages that help patients monitor their own risk and adhere to 
secondary prevention (51-53). As the use of these quality improvement strategies 
become more prevalent in Australian primary healthcare system for both primary and 
secondary prevention of CVD, it should be possible to ensure that all patients receive 
equitable and improved care. Additionally, further research to find whether these 
strategies can close the gaps in primary and secondary prevention is needed.  
 
The study included in Chapter 8 that assessed the out-of-pocket costs and household 
economic hardship after an ACS event was unique in ACS or CVD research, as it 
quantified the economic burden experienced by patients and examined the factors 
associated with the hardship. It provides a foundation to explore further into disease-
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related out-of-pocket costs and hardship experienced by patients nationwide, as well as, 
valuable evidence to support an improved policy that can help patients at all levels of 
SES access optimal secondary prevention care.  
 
LIMITATIONS 
Limitations exist in this thesis. Firstly, observational data were used for the studies, 
which may be subject to reporting bias and data entry errors. However, this type of data 
is most appropriate to capture real-life healthcare services provided to patients in 
various subgroups including by gender, SES and English proficiency. Second, the 
systematic reviews were based on a small number of studies. Although authors of the 
study articles were contacted for further information when required, they rarely 
responded. Also, the reviews included unadjusted observational data for the studies 
that did not have the same aim as the review itself. Third, the studies found in the 
systematic reviews in Chapters 3 and 5 were heterogeneous, possibly due to the small 
number of studies found, so it may affect the true effect size. Fourth, this work only 
looked at three aspects of potential inequalities. Whether similar findings would have 
been found for other subgroups that were not investigated in this thesis is unknown and 
further research is needed. However, the strength of this thesis is that it captures the 
wide sense of the equitable or inequitable care provided in different levels of the 
system. Fifth, in Chapter 6, follow-up period of 6 months may not have been long 
enough and the statistical power might have been insufficient to find the differences in 
deaths between the SES groups. Sixth, the association between SES and household 
economic hardship was estimated on a small sample of responders in New South Wales 
and Queensland, so further research with wider sample is needed. The response rate for 
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the household economic burden survey reported in Chapter 8 was low, however, the 
patient characteristics were similar between the responders and non-responders, and 
therefore, the findings can be generalised. Also, patients were considered to have 
experienced household economic hardship if they experienced any financial stress or 
inability to pay expenses but the types of financial stress and the expenses that could 
not be paid were not weighted, therefore the measurement of household economic 
hardship may have been overestimated. Additionally, the limitations of the specific 
studies in the thesis have been raised in each chapter. 
 
CONCLUSIONS 
Equitable in-hospital care and management were delivered across the SES groups and 
the level of English proficiency, providing encouraging affirmation of the systems in 
place to provide quality care in Australian hospital. However, gender discrepancies 
were found in access to the primary and secondary prevention of CVD. Also, patients 
with low SES were more likely to experience household economic hardship, which may 
discourage patients to access secondary prevention due to financial reasons. Further 
research is required to determine whether any other subgroups experience health 
inequities in various levels of the healthcare system and if so, the cause of the disparity. 
Effective and sustainable strategies are also required to provide equitable CVD 
prevention and care for all at every level of the system.  
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